ANNUAL REPORT 2025


BEACON®
Pharmaceuticals PLC
Light for life



আমাদের নিঃশ্বাস নেওয়ার জন্যে দ্বিতীয় কোন গ্রহ নাই

BEACON®

Light for life



Corporate Office

BEACON Business Centre
9/B/2, Toyenbee Circular Road
Motijheel, Dhaka-1223, Bangladesh

LETTER OF
TRANSMITTAL

27 November 2025

All the Shareholders of Beacon Pharmaceuticals PLC

Bangladesh Securities and Exchange Commission (BSEC)

Dhaka Stock Exchange PLC (DSE)

Chittagong Stock Exchange PLC (CSE)

Registrar of Joint Stock Companies & Firms (RJSCF)

Subject: Annual Report of Beacon Pharmaceuticals PLC for the year ended 30 June 2025.

Dear Sir(s),

Greetings From Beacon Pharmaceuticals PLC.

We are pleased to present before you the Annual Report of Beacon Pharmaceuticals PLC for the year ended 30 June 2025 together with the Audited Financial Statements, Report of the Board of Directors and Auditor's Report thereon for your information and reference.

The Proxy FORM with Attendance Slip is attached at the end of the Annual Report for your use. In case of appointing a proxy, please complete the Proxy FORM and submit it to our corporate office at least 72 hours before the scheduled meeting time. This will be our utmost pleasure to welcome you to the 24th AGM of the Company.

Truly yours,



Md. Sahabuddin FCS
Company Secretary

TABLE OF CONTENTS

01 COMPANY OVERVIEW 6-35

1	Brief about the company	07
2	Our journey	08-09
3	Corporate directory	10-11
4	Our vision, mission and core values	12
5	Product portfolio	14-27
6	Financial calendar	28
7	Chairman's message	30-31
8	Managing Director's message	32-35

02 PERFORMANCE REVIEW 37-50

1	Performance highlights 2024-2025	38-41
2	Key ratio	42-45
3	Five years' highlights	46-49
4	Value added statement and distribution(VAS)	50

03 OPERATIONS 52-62

1	Manufacturing	53-59
2	New products launched FY 2024-2025	60-61
3	Global footprint	62

04 BOARD OF DIRECTORS PROFILE 65-75

1	Profile of board members	66-69
2	Profile of Executive Director	70
3	Profile of CFO, CS & HIA	71-72
4	Leading from the Front	74-75

05 ROADMAP TO SUSTAINABILITY 77-109

1	Sustainability reporting	77-103
2	Corporate social responsibility	105-109

TABLE OF CONTENTS

06 BUSINESS AND VALUE CHAIN MODEL ANALYSIS 111-117

1	Business model	112-114
2	Value chain model	115-117

07 INTEGRATED REPORTING 119-141

1	Integrated reporting with SDG impact	119-141

08 GOVERNANCE AND STATUTORY REPORTS 143-180

1	Directors' report	144-149
2	Declaration by the MD & the CFO to the board	150
3	Corporate governance compliance certificate	151
4	Corporate governance compliance status	152-168
5	Directors' attendance	169
6	Pattern of shareholding	169
7	Industry outlook and future prospects	170-171
8	Audit committee report	172-174
9	Nomination and remuneration committee report	175-177
10	Corporate governance structure	178-179
11	BAPLC certificate	180

09 STATUTORY AUDITOR'S REPORT AND AUDITED FINANCIAL STATEMENTS 181-220

1	Independent auditor's report	182-187
2	Statement of financial position	188
3	Statement of profit or loss and other comprehensive income	189
4	Statement of changes in equity	190
5	Statement of cash flows	191
6	Notes to the financial statements	192-220

10 AGM AND OTHER INFORMATION 222-225

1	Notice of 24th AGM	222
2	Photos of 23rd AGM	223
3	Proxy Form	225

COMPANY OVERVIEW



BRIEF ABOUT
THE COMPANY

Beacon Pharmaceuticals PLC is a renowned pharmaceutical company in Bangladesh, widely recognized for its innovative treatment approaches aimed at improving the quality of life. Established in 2001 and transformed into a Public Limited Company in 2010, Beacon has continuously invested in research and development to deliver advanced pharmaceutical solutions to the people of Bangladesh and beyond, ensuring the satisfaction of all stakeholders.

The company manufactures a wide range of therapeutic products, including anti-cancer, cardiovascular, gastrointestinal, antibiotics, anti-coagulants, protein supplements, muscle relaxants, antihistamines, analgesics, NSAIDs, and more. Through these diversified and innovative product offerings, Beacon has positioned itself as a unique and fast-growing leader in the pharmaceutical industry of Bangladesh.

Beacon's state-of-the-art manufacturing facility is located in Bhaluka, Mymensingh, covering 30 acres of land. Designed by European experts, the industrial complex stands as one of the finest in the country. The facility has been built to comply with major international regulatory standards, including WHO-CGMP, US FDA, UK MHRA, TGA, and other global requirements.

Beacon Pharmaceuticals PLC

PIONEERING BREAKTHROUGHS IN HEALTHCARE

"Redefining Health, Innovating Care, Inspiring Lives"

2001
Incorporated as a Private Limited Company

2006
Launched Commercial Operations

2008
Transitioned to a Public Limited Company


2016
Expanded Globally with B2B and B2C Services

2017
Formed Technology Transfer Partnership with Herber Biotech, Cuba

2018
Partnered with Daiwa Pharmaceuticals Co., Ltd. of Japan

2020
Released Cephalosporin Products and COVID-19 Treatments Favipira & Pandovir

2021
Syrian Government Inspection of Beacon Plant, Expressing High Satisfaction


2009
Pioneered Anti-Cancer Drug Production in Bangladesh
2010
Successfully Launched Initial Public Offering (IPO)
IPO
2011
Introduced Bio-Tech Products and Cardiovascular Solutions in Bangladesh
2012
Initiated Export of Life-Saving Anti-Cancer Medications
2015
Introduced Hepatitis-C Treatments for the First Time in Bangladesh
2022
Launched Empagliflozin-Linagliptin Combination for Diabetes and Raised Nationwide Awareness on Thalassemia
2023
Introduced Thalimide and Daprosis for Anemia Management in CKD and Thalassemia Care
2024
Topical Market Breakthrough & Rise with SAP S/4HANA Integration in private cloud
SAP

CORPORATE DIRECTORY

Board of Directors	
Nurun Nahar Karim	Chairman
Mohammad Ebadul Karim	Managing Director
Mohammad Niazul Karim	Director
Ulfat Karim	Director and Chief Operating Officer
Rezanur Chowdhury FCA	Independent Director
Prof. A B M Faroque	Independent Director
Mohammed Ariful Hoque FCA	Independent Director
Prof. Dr. Shamem Ara Mili	Independent Director

Audit Committee	
Mohammed Ariful Hoque FCA	Chairman
Rezanur Chowdhury FCA	Member
Prof. A B M Faroque	Member
Prof. Dr. Shamem Ara Mili	Member
Mohammad Niazul Karim	Member

Nomination & Remuneration Committee	
Prof. A B M Faroque	Chairman
Rezanur Chowdhury FCA	Member
Mohammed Ariful Hoque FCA	Member
Prof. Dr. Shamem Ara Mili	Member
Mohammad Niazul Karim	Member

Management Executive Committee	
Mohammad Ebadul Karim	Managing Director
Mohammad Niazul Karim	Director
Risana Karim	Executive Director
Ulfat Karim	Director and Chief Operating Officer
Monjurul Alam	Director, Business Development
Md. Jalal Uddin FCA	Chief Financial Officer and Head of IT
S. M. Mahmudul Haque	Executive Vice President, Marketing & Sales
Md. Anisur Rahman Khan	Executive Vice President, Estate and Public Relations
Shams Minhaz Monzur	Executive Vice President, Project Management
S M Foysal Habib	Senior Vice President, Marketing & Sales
Md. Rezaul Karim	Senior Vice President, Marketing & Sales
Bappa Sarker	Senior Vice President, Marketing & Sales
Md. Hafiz Imtiaj	Head of Human Resources
Syeda Shahanawas Shilpi	Vice President, Supply Chain Management
Md. Sahabuddin FCS	Company Secretary
Rahamat Ara Huda FCA, FCMA	Head of Internal Audit

CORPORATE DIRECTORY

Statutory Positions

Md. Jalal Uddin FCA	Chief Financial Officer and Head of IT
Md. Sahabuddin FCS	Company Secretary
Rahamat Ara Huda FCA, FCMA	Head of Internal Audit

Statutory Auditors

Habib Sarwar Bhuiyan & Co.
Eastern Commercial Complex, 73 Kakrail, 7th floor, Dhaka-1000

Corporate Governance Compliance Auditor

MNA Associates
Chartered Secretaries and Consultants
Tropical Molla Tower L-3, Sha-15/1-4, Pragati Sarani, Middle Badda, Dhaka.

Listing

Dhaka Stock Exchange PLC

Chittagong Stock Exchange PLC

Registered Office

Beacon Pharmaceuticals PLC
Kathali, Bhaluka, Mymensingh, Bangladesh.

Corporate office

Beacon Business Centre
9/B/2, Toyenbee Circular Road, Motijheel, Dhaka-1223
Tel: +88-02-41054005-10
E-mail: info@beaconpharma.com.bd, Website: www.beaconpharma.com

Factory

Kathali, Bhaluka, Mymensingh, Bangladesh.

Bankers List

Janata Bank PLC	Mutual Trust Bank PLC
Rupali Bank PLC	Bank Asia PLC
Sonali Bank PLC	Jamuna Bank PLC
Agrani Bank PLC	United Commercial Bank PLC
Commercial Bank of Ceylon PLC	Shimanto Bank PLC
Eastern Bank PLC	Dutch Bangla Bank PLC
Shahjalal Islami Bank PLC	First Security Islami Bank PLC
Standard Chartered Bank	IPDC PLC
Prime Bank PLC	

BEACON®
Light for life



Our Vision

To be regarded and recognized as one of the most value-driven pharmaceutical companies in the World.

Our Mission

To improve the quality of human life by providing innovative pharmaceutical products developed through continuous research and development ensuring stakeholder's satisfaction.

Core Values

- Committed to quality in all our activities
- Trustworthy relationship with customer
- Respect to other
- Believe in winning
- Encourage innovative ideas
- Corporate Social Responsibility
- Work as a team

Gaviflux

Sodium Alginate USP, Sodium Bicarbonate USP & Calcium Carbonate BP

Faster Action, Faster Relief
from Heartburn & Acid Reflux

To manufacture Gaviflux, Raw Materials used from European Country, Norway

From Norway
European
Grade Raw Material



Advantages-

- Forms a strong Physical barrier/Raft
- Lasts upto 4 Hours
- Provides rapid onset of action within 1 minute
- Ensures better relief from GERD than conventional alginate


Also Available as



BEACON®
Pharmaceuticals PLC

PRODUCT

PORTFOLIO



BEACON PRODUCTS

Beacon Pharmaceuticals PLC currently manufactures over 533 generics, available in more than 700 presentations, covering a diverse range of 45 therapeutic classes through 274 leading brands in 15 dosage forms.

The company's extensive product portfolio spans major therapeutic segments including Oncology, Hematology, Hepatology, Nephrology, Antibiotics, Analgesics, Anti-Diabetics, Respiratory, Cardiovascular, Dermatology, Gastrointestinal, Infectious Diseases, Immunology, Rheumatology, Pediatrics, and Nutritional Supplements, among others.

Beacon enjoys market leadership across several key brands in Bangladesh's pharmaceutical landscape, such as Pemro, Nivomab, Xelpac Premium, Docexan, Xaloplat Aqua, Gemoxen Aqua, ETP, FXR, Renesis, Mezest, Eposis, Tirza, Xelmet, Xerova, Sinjard, Ovocal, Haxinor, Tetrazin, Lubilux, Paloxi, Olonex, Gaviflux, Mirogab, Flexibac and Bukof, among many others.

Armed with cutting-edge technology and specialized expertise in Oncology, Biotech, and Cephalosporin segments, Beacon has established itself as a trusted name in advanced pharmaceutical manufacturing. The company operates one of the most modern cancer treatment facilities in Bangladesh, offering innovative therapies including immunotherapy for a wide range of cancer indications.

Beacon Pharmaceuticals PLC remains steadfast in its commitment to enhancing access to innovative, affordable, and high-quality medicines. The company's expanding and differentiated product portfolio—comprising high-value and difficult-to-copy molecules—continues to act as a key growth driver, reinforcing Beacon's status as a brand leader in multiple therapeutic categories across Bangladesh.

Therapeutic Class	Brand Name	Dosage Type	Generic Name with Strength
Anesthetic	Buva	Injection	Bupivacaine Hydrochloride in 8% Dextrose 0.5%+8%
	Lidocaine	Injection	Lidocaine 20MG
	Lidocaine	Injection	Lidocaine 35MG
Anti Cholinergic	Hexinor	Syrup	Trihexyphenidyl Hydrochloride 2MG/5ML
	Hexinor	Tablet	Trihexyphendiyl HCl 1MG
	Hexinor	Tablet	Trihexyphendiyl HCl 2MG
	Hexinor	Tablet	Trihexyphendiyl HCl 5MG
	Pradox	Injection	Pralidoxime Chloride 1000MG
Anti Cough	Bukof	Syrup	Butamirate Citrate 15ML
	Bukof	Syrup	Butamirate Citrate 7.5MG/5ML
	Bukof	Tablet	Butamirate Citrate 50MG
	Caughex	Tablet	Gefapixant Citrate 45MG
	Daykof	Syrup	Guaifenesin + Levomenthol + Diphenhydramine 100ML
	DGM	Syrup	Dextromethorphan + Guaiphenesin + Menthol 100ML
	Dorakid	Syrup	Multivitamin 100ML
	Mufree	Syrup	Guaifenesin 100MG/5ML
	Nytkof	Syrup	Dextromethorphan + Pseudoephedrine + Triprolidine 100ML
	Safoxol	Capsule	Ambroxol Hydrochloride 75MG
	Safoxol	Syrup	Ambroxol Hydrochloride 15MG/5ML
Anti Histamines	Alertadin	Tablet	Desloratadine 5MG
	Bilanex	Syrup	Bilastine INN 12.5 MG/5 ML
	Bilanex	Tablet	Bilastine 20MG
	Kiti	Syrup	Ketotifen Fumarate 1MG/5ML
	Kiti	Tablet	Ketotifen Fumarate 1GM
	Olonex	Tablet	Olopatadine Hydrochloride 5MG
	Perfex	Suspension	Fexofenadine Hydrochloride 50ML
	Perfex	Tablet	Fexofenadine 120 MG
	Perfex	Tablet	Fexofenadine 180 MG
	Perfex	Tablet	Fexofenadine 60MG
	Rupadin	Syrup	Rupatadine Fumarate 5MG/5ML
	Rupadin	Tablet	Rupatadine Fumarate 10MG
Anti Ulcerants	Dexoprex	Capsule	Dexlansoprazole 30MG
	Dexoprex	Capsule	Dexlansoprazole 60MG
	Esoprex	Capsule	ESOMEPRAZOLE MAGNESIUM 20MG
	Esoprex	Capsule	ESOMEPRAZOLE MAGNESIUM 40MG
	Esoprex	Injection	Esomeprazole 40MG
	Esoprex	Tablet	ESOMEPRAZOLE MAGNESIUM 20MG
	Esoprex	Tablet	ESOMEPRAZOLE MAGNESIUM 40MG
	Gaviflux	Suspension	Sodium Alginate + Sodium Bicarbonate + Calcium Carbonate (500 mg+213 mg+325 mg)/10 ml 200MG
	Gaviflux	Suspension	Sodium Alginate+Sodium Bicarbonate+Calcium Carbonate 200MG
	Gaviflux	Tablet	Sodium Alginate+ Sodium Bicarbonate+Calcium Carbonate
	Rabepes	Capsule	Rabeprazole 20MG

Therapeutic Class	Brand Name	Dosage Type	Generic Name with Strength
Anti Ulcerants	Rabepes	Tablet	Rabeprazole 10MG
	Rabepes	Tablet	Rabeprazole 20MG
	Ulsil	Suspension	Sucralfate 1MG/5ML
	Vonopa	Tablet	Vonoprazan 10MG
	Vonopa	Tablet	Vonoprazan 20MG
	Xelopes	Capsule	Omeprazole 20MG
	Xelopes	Capsule	Omeprazole 40MG
	Xelopes	Injection	Omeprazole 40MG
Anti Viral	Favipira	Tablet	Favipiravir INN 200MG
	Pandovir	Injection	Remdisivir 100MG
	Xovir	Cream	Acyclovir USP 5%
	Xovir	Injection	Acyclovir 250MG
	Xovir	Injection	Acyclovir 500MG
	Xovir	Suspension	Acyclovir 200MG/5 ML
	Xovir	Tablet	Acyclovir 200MG
	Xovir	Tablet	Acyclovir 400MG
Antibiotics	Bactover	Ointment	Bactover 2% BP 2%
	Cozid	Injection	Ceftazidamide Pentahydrate 1GM
	Cozid	Injection	Ceftazidamide Pentahydrate 250MG
	Cozid	Injection	Ceftazidamide Pentahydrate 500MG
	Eramox	Infusion	Moxifloxacin Hydrochloride 250ML
	Eramox	Tablet	Moxifloxacin Hydrochloride 400MG
	Kidcef	PFS	Cefpodoxime Proxetil 40MG/5ML
	Merocon	Injection	Meropenem 1GM
	Merocon	Injection	Meropenem 500MG
	Quixin	Tablet	Levofloxacin 500MG
	Simpli-3	Injection	Azithromycin 500MG
	Simpli-3	PFS	Azithromycin 200 MG/5 ML
	Simpli-3	Tablet	Azithromycin 500MG
	Starcef	Capsule	Cefixime 200MG
	Starcef	Capsule	Cefixime 400MG
	Starcef	PFS	Cefixime 100MG/5ML
	Starcef	PFS	Cefixime 200 MG/5 ML
	Traxef	Injection	Ceftriaxone 1GM
	Traxef	Injection	Ceftriaxone 250MG
	Traxef	Injection	Ceftriaxone 2GM
	Traxef	Injection	Ceftriaxone 500MG
	Xbac	Suspension	Ciprofloxacin 100MG/5ML
	Xbac	Tablet	Ciprofloxacin 500MG
	Xbac	Tablet	Ciprofloxacin 750MG
	Zerotil	Injection	Cefuroxime Axetil 1.5 G
	Zerotil	Injection	Cefuroxime Axetil 750MG

Therapeutic Class	Brand Name	Dosage Type	Generic Name with Strength
Antibiotics	Zerotil	PFS	Cefuroxime Axetil + Clavulanic acid 125 MG/ 5ML
	Zerotil	PFS	Cefuroxime Axetil + Clavulanic acid 125MG+31.25MG
	Zerotil	Tablet	Cefuroxime Axetil + Clavulanic acid 250MG+62.5MG
	Zerotil	Tablet	Cefuroxime Axetil + Clavulanic acid 500MG+125MG
	Zerotil	Tablet	Cefuroxime Axetil 250MG
	Zerotil	Tablet	Cefuroxime Axetil 500MG
Anticoagulant	Fibanix	Infusion	Tirofiban Hydrochloride INN. 12.5MG/250ML
	Heparon	Injection	Heparin Sodium 25000 IU
	Rivosis	Tablet	Rivaroxaban 10MG
Antiemetic	Ramos	Tablet	Ramosetron Hydrochloride INN 5MCG
	Ramos	Tablet	"Ramosetron Hydrochloride INN 2.5MCG"
Antiemetics	Aproxi	Capsule	Aprepitant 80MG+125MG
	Paloxi	Injection	Palonosetron 0.075 MG
	Paloxi	Injection	Palonosetron Hydrochloride 0.25 MG
	Paloxi	Tablet	Palonosetron 0.5MG
Antifungals	Aniducon	Injection	Anidulafungin INN 100MG
	Candisore	Gel	Miconazole Nitrate 2% w/w 2%
	Clotrizen	Cream	Clotrimazole 1% USP 1%
	Itrazen	Capsule	Itraconazole 200MG
	Itrazen	Capsule	Itraconazole USP 65MG
	Itrazen	Tablet	Itraconazole 100MG
	Lucza	Capsule	Fluconazole 150MG
	Lucza	Capsule	Fluconazole 50MG
	Lulima	Cream	Luliconazole 1% INN 1%
	Terbicon	Cream	Terbinafine 1% USP 1%
	Terbicon	Tablet	Terbinafine Hydrochloride 250MG
	Tericin	Injection	Amphotericin B 50MG
	Viera	PFS	Voriconazole 40 ML
	Viera	Tablet	Voriconazole 200MG
	Viera	Tablet	Voriconazole 50MG
Anti-Migrain	Fizi	Tablet	Flunarizine 10MG
	Fizi	Tablet	Flunarizine 5MG
	Migratol	Tablet	Tolfenamic acid 200MG
Antirheumatoid	Barinez	Tablet	Baricitinib 2MG
	Igura	Tablet	Iguratimod INN Micr. 25MG
	Jaktor	Tablet	Tofacitinib 11 MG
	Jaktor	Tablet	Tofacitinib 5MG
	Tenoflex	Tablet	Tenoxicam 20MG
Cardiac Portfolio	Belsar	Tablet	Amlodipine + Olmesartan Medoxomil 5/20MG
	Belsar	Tablet	Amlodipine + Olmesartan Medoxomil 5/40MG
	Belsar	Tablet	Olmesartan Medoxomil 10MG
	Belsar	Tablet	Olmesartan Medoxomil 20MG

Therapeutic Class	Brand Name	Dosage Type	Generic Name with Strength
Cardiac Portfolio	Belsar	Tablet	Olmesartan Medoxomil 40MG
	Cardisan	Tablet	Losartan Potassium 100MG
	Cardisan	Tablet	Losartan Potassium 25 MG
	Cardisan	Tablet	Losartan Potassium 50MG
	Cardisan	Tablet	Losartan Potassium+ Hydrochlorthiazide 50MG + 12.5MG
	Eparin	Injection	Enoxaparin Sodium 40MG
	Eparin	Injection	Enoxaparin Sodium 60MG
	Eptase	Injection	Streptokinase 1500000IU
	Frilinta	Tablet	Ticagrelor 90MG
	Lovask	Tablet	Amlodipine Besilate + Atenolol 5MG+50MG
	Lovask	Tablet	Amlodipine Besilate 5MG
	Nebinex	Tablet	Nebivolol Hydrochloride BP 2.5MG
	Nebinex	Tablet	Nebivolol Hydrochloride BP 5MG
	Resva	Tablet	Rosuvastatin 10MG
	Resva	Tablet	Rosuvastatin 20MG
	Resva	Tablet	Rosuvastatin 5MG
	Savesto	Tablet	Sacubitril-Valsartan SHPH. INN 100MG
	Savesto	Tablet	Sacubitril-Valsartan SHPH. INN 50MG
	Selbis	Tablet	Bisoprolol 1.25 MG
	Selbis	Tablet	Bisoprolol 2.5 MG
	Selbis	Tablet	Bisoprolol 5MG
	Teslar	Tablet	Telmisartan 20MG
	Teslar	Tablet	Telmisartan 40MG
	Teslar	Tablet	Telmisartan 80MG
	Xerova	Tablet	Atorvastatin + Ezetimibe 10/10 MG
	Xerova	Tablet	Atorvastatin + Ezetimibe 20/10 MG
	Xerova	Tablet	Atorvastatin 20MG
	Xerova	Tablet	Atorvastatin Calcium 10MG
	Xerova	Tablet	Atorvastatin Calcium 40MG
	Xerova	Tablet	Atorvastatin Calcium Trihydrate BP 20MG
Chest	Belsar	Tablet	Olmesartan Medoxomil (Micronised) +Hydrochlorothiazide 20/12.5MG
	Belsar	Tablet	Olmesartan Medoxomil (Micronised) +Hydrochlorothiazide 40/12.5MG
	Camzoy	Capsule	Mavacamten (Micronized) 2.5MG
	Camzoy	Capsule	Mavacamten (Micronized) 5MG
	Doxoven	Syrup	Doxophylline 100MG/5ML
	Doxoven	Tablet	Doxophylline 200MG
	Doxoven	Tablet	Doxophylline 400MG
	Montinex	Tablet	Montelukast Sodium 10MG
	Montinex	Tablet	Montelukast Sodium 4MG
	Montinex	Tablet	Montelukast Sodium 5MG
	Roflast	Tablet	Roflumilast 500 MCG
	Simendan	Injection	Levosimendan 12.5 MG/5ML

Therapeutic Class	Brand Name	Dosage Type	Generic Name with Strength
ComC	Teslar	Tablet	Amlodipine Besilate+Telmisartan 5/40MG
	Teslar	Tablet	Amlodipine Besilate+Telmisartan 5/80MG
	Becovir	Tablet	Tenofovir Disoproxil Fumarate 300MG
	Caviral	Tablet	Entecavir 0.50MG
	Caviral	Tablet	Entecavir 0.5MG
	Copeg	Capsule	Ribavirin 200MG
	Fixvel	Tablet	Sofosbuvir & Velpatasvir 400MG/100MG
	Pegin	Injection	Peginterferon alfa 2a 135MCG/0.4 ML
	Pegin	Injection	Peginterferon alfa 2a 180 MCG/0.5 ML
	TAF	Tablet	Tenofovir Alafenamide 25 MG
Cytostat Aromatase	Inhibitor	Bepanthin	Cream Permithrin INN 5%
	Finataz	Capsule	Finasteride USP 5mg + Tadalafil USP 5mg 5MG+5MG
	Lexel	Tablet	Letrozole USP 2.5mg 2.5 MG
Diabetes Portfolio	Glipxen	Tablet	Linagliptin + Metformin Hydrochloride 2.5MG+500MG
	Glipxen	Tablet	Linagliptin + Metformin Hydrochloride 2.5MG+850MG
	Glipxen	Tablet	Linagliptin 5MG
	Glymax	Tablet	Glimepiride (Micronised) 1MG
	Glymax	Tablet	Glimepiride (Micronised) 2MG
	Glymax	Tablet	Glimepiride (Micronised) 3MG
	Glymax	Tablet	Glimepiride (Micronised) 4MG
	Liqu-E	Capsule	Vitamin E [Alpha Tocopherol Acetate] 200MG
	Magnilife	Cream	Apis mellifica + Gelsemium sempervirens + Gnaphalium
	Sinjard	Tablet	Empagliflozin + Metformin Hydrochloride 12.5MG+500MG
	Sinjard	Tablet	Empagliflozin + Metformin Hydrochloride 5MG+1000MG
	Sinjard	Tablet	Empagliflozin + Metformin Hydrochloride 5MG+500MG
	Sinjard	Tablet	Empagliflozin 10MG
	Sinjard	Tablet	Empagliflozin 25 MG
	Sinjard	Tablet	Empagliflozin+Linagliptin 10MG+5MG
	Sinjard	Tablet	Empagliflozin+Linagliptin 25MG+5MG
	Tirza	Injection	Tirzepatide (Injectable Grade) 2.5MG
	Tirza	Injection	Tirzepatide (Injectable Grade) 5MG
	Tirza	Injection	Tirzepatide (Injectable Grade) 7.5MG
	Xelmet	Tablet	Metformin Hydrochloride 1GM
	Xelmet	Tablet	Metformin Hydrochloride 500MG
	Xelmet	Tablet	Metformin Hydrochloride 850 MG
Gastro	Alvenor	Tablet	Micronised Diosmin & Hesperidin 1000MG
	Alvenor	Tablet	Micronised Diosmin + Hesperidin 500MG
	Clenpic	Oral Solution	sodium picosulfate 5MG/5ML
	Clenpic	Tablet	sodium picosulfate 10MG
	Liqumint	Capsule	Peppermint Oil 0.2ML
	Lubilax	Capsule	Lubiprostone 24 Ã‚Î¼G
	Lubilax	Capsule	Lubiprostone 8 Ã‚Î¼G

Therapeutic Class	Brand Name	Dosage Type	Generic Name with Strength
Gastro	Noburn	Suspension	Domperidone Maleate 60 ML
	Noburn	Tablet	Domperidone Maleate 10MG
	Peritop	Tablet	Itopride Hydrochloride 50MG
	Protoloc	Tablet	Pantoprazole sodium 20MG
	Prupride	Tablet	Prucalopride Succinate 1MG
	Prupride	Tablet	Prucalopride Succinate 2MG
	Simegal	PFS	Magaldrate + Simethicone 200 ML
	Spasverin	Tablet	Alverine Citrate 60MG
	Tivis	Tablet	Tiemonium Methylsulphate 50MG
Hemato	ATO	Injection	Arsenic Trioxide 10MG
	Axita	Tablet	Axitinib 5MG
	Azacitid	Injection	Azacitidine 100MG
	Azacitid	Tablet	Azacitidine 300MG
	Bendamax	Injection	Bendamustine 25 MG
	Bleonix	Injection	Bleonix 15UNIT/VIAL
	Bortez	Injection	Bortezomib 1MG
	Bortez	Injection	Bortezomib 2MG
	Carfilez	Injection	Carfilzomib (Injectable Grade) 10MG
	Carfilez	Injection	Carfilzomib (Injectable Grade) 30MG
	Criston	Injection	Vincristine 2MG
	Cytabin	Injection	Cytarabine 1000MG
	Cytabin	Injection	Cytarabine 100MG
	Dacarzin	Injection	Dacarbazine 200MG
	Dasanix	Tablet	Dasatinib 100MG
	Dasanix	Tablet	Dasatinib Monohydrate 20MG
	Deferox	Tablet	Deferasirox 500MG
	Deferox	Tablet	Deferox 250MG
	Deferox	Tablet	Deferox 500MG
	Hydronix	Capsule	Hydroxyurea 500MG
	Ibrucon	Capsule	Ibrutinib 140MG
	Leukin	Tablet	Mercaptopurine 50MG
	Linamide	Capsule	Lenalidomide 10MG
	Linamide	Capsule	Lenalidomide 25 MG
	L-spar	Injection	L-Asparaginase 10000 IU
	L-spar	Injection	L-Asparaginase 5000 IU
	Pomide	Capsule	Pomalidomide INN Micr. 2MG
	Pomide	Capsule	Pomalidomide INN Micr. 4MG
	Rubicin	Injection	Daunorubicin Hydrochloride 20MG
	Thalimide	Capsule	Thalidomide 100MG
	Thalimide	Capsule	Thalidomide 50MG
	Trexonate	Injection	Methotrexate 1GM
	Trexonate	Injection	Methotrexate 50MG

Therapeutic Class	Brand Name	Dosage Type	Generic Name with Strength
Hemato	Velvin	Injection	Vinblastine Sulfate 10MG
	Venclax	Tablet	Venetoclax(Micronized)+Dibasic Calcium Phosphate (Anhydrous calcium Hydrogen Phosphate) 100MG
	Venclax	Tablet	Venetoclax(Micronized)+Dibasic Calcium Phosphate (Anhydrous calcium Hydrogen Phosphate) 10MG
Hepatic	Avanix	Tablet	Avatrombopag Maleate INN 20MG
	Ursotab	Tablet	Ursodeoxycholic Acid 150MG
	Ursotab	Tablet	Ursodeoxycholic Acid 300MG
Immuno	Nivomab	Injection	Nivolumab Inj. 100MG
	Nivomab	Injection	Nivolumab Inj. 40MG
	Pemro	Injection	Pembrolizumab 100MG
Inj. Chem	Carboplat	Injection	Carboplatin 150MG
	Carboplat	Injection	Carboplatin 450 MG/45ML
	Cyclotox	Injection	Cyclophosphamide 1GM
	Cyclotox	Injection	Cyclophosphamide 200MG
	Docexan	Injection	Docetaxel 20MG
	Docexan	Injection	Docetaxel 80MG
	Erubin	Injection	Epirubicin HCL 10MG
	Erubin	Injection	Epirubicin HCL 50MG
	Erubin	Injection	Epirubicine 10MG
	Erubin	Injection	Epirubicine 50MG
	Fluroxan	Injection	Fluorouracil 250MG
	Fluroxan	Injection	Fluorouracil 500MG
	Folinex	Injection	Folinic Acid 50MG
	Gemoxen	Injection	Gemcitabine 1GM
	Gemoxen	Injection	Gemcitabine 200MG
	Gemoxen	Injection	Gemcitabine Hydrochloride 1000MG
	Gemoxen	Injection	Gemcitabine Hydrochloride 200MG
	Ifomes	Injection	Mesna 400MG
	Irinox	Injection	Irinotecan 100MG
	Irinox	Injection	Irinotecan 300MG
	Irinox	Injection	Irinotecan 40MG
	L-Dox	Injection	Doxorubicin Hydrochloride 20 mg/ 10 mL (as Liposomal) Formulated Vial 20MG
	L-Dox	Injection	Doxorubicin Hydrochloride 50 mg/ 25 mL (as Liposomal) Formulated Vial 50MG
	Nab-Xelpac	Injection	Nab-Paclitaxel 100MG
	Pemetrex	Injection	Pemetrexed 100MG
	Pemetrex	Injection	Pemetrexed 500MG
	Platinex	Injection	Cisplatin 10MG
	Platinex	Injection	Cisplatin 50MG
	Topoxin	Injection	Etoposide 100MG
	Xaloplat	Injection	Oxaliplatin Inj. 100MG
	Xaloplat	Injection	Oxaliplatin Inj. 200MG
	Xaloplat	Injection	Oxaliplatin Inj. 50MG
	Xelpac	Injection	Paclitaxel 100MG

Therapeutic Class	Brand Name	Dosage Type	Generic Name with Strength
Inj. Chem	Xelpac	Injection	Paclitaxel 260MG
	Xelpac	Injection	Paclitaxel 30 MG
	Xelpac	Injection	Paclitaxel 300MG
	Xifos	Injection	Ifosfamide 1GM
	Xifos	Injection	Ifosfamide 2GM
	Xorubin	Injection	Doxorubicin HCL 10MG
	Xorubin	Injection	Doxorubicin HCL 50MG
	Xorubin	Injection	Doxurobicin Hydrochloride 10MG
	Xorubin	Injection	Doxurobicin Hydrochloride 50MG
Iron Supp.	Aurifer	Tablet	"Ferric Citrate 210MG"
	Enrifer	Injection	Ferric Carboxymaltose 500MG
	Xenofer	Injection	Iron Sucrose 100MG
LVP	Infusol	Infusion	Dextrose anhydrous and Sodium Chloride 500 ML
	Infusol	Others	5% Dextrose Anhydrous 500 ML
	Lipofit	Infusion	Refined Soyabean Oil + Purified Egg Lecithin + Glycerol 250ML
	Lipofit	Infusion	Refined Soyabean Oil + Purified Egg Lecithin + Glycerol 500 ML
	Plasmex	Infusion	Hydroxyethyl Starch 0.06
	Xemocid	Infusion	Amino acid, Electrolytes & Sorbitol 500ML
	Xenosol	Infusion	Sodium Chloride 0.9% 100ML
	Xenosol	Infusion	Sodium Chloride 0.9% 250ML
	Xenosol	Others	0.9% Sodium Chloride 500ML
MAB	Adali	Injection	Adalimumab (50 mg/mL) INN F. Bulk 40MG/0.8 ML
	Bevastim	Injection	Bevacizumab 100MG
	Bevastim	Injection	Bevacizumab 400MG
	Cetuxim	Injection	Cetuximab 100MG
	Rituxim	Injection	Rituximab 100MG
	Rituxim	Injection	Rituximab 500MG
	Trastunix	Injection	Trastuzumab 440MG
Nephro	Alfacon	Tablet	Alpha Ketoanalogue 600MG
	Daprosis	Tablet	Daprodustat 2MG
	Daprosis	Tablet	Daprodustat 4MG
	Daprosis	Tablet	Daprodustat 6MG
	Darbesis	Injection	Darbepoetin alfa 25 MCG
	Darbesis	Injection	Darbepoetin alfa 40 MCG
	Darbesis	Injection	Darbepoetin alfa 60MCG
	Eposis	Injection	Erythropoietin Alfa 10000 IU
	Eposis	Injection	Erythropoietin Alfa 2000 IU
	Eposis	Injection	Erythropoietin Alfa 3000 IU
	Eposis	Injection	Erythropoietin Alfa 4000 IU
	Eposis	Injection	Erythropoietin Alfa 5000IU
	Firendia	Tablet	Finerenon 10MG
	Firendia	Tablet	Finerenon 20MG

Therapeutic Class	Brand Name	Dosage Type	Generic Name with Strength
LVP	Lanfos	Chewable Tablet	Lanthanum carbonate 250MG
	Mezest	Tablet	Megestrol Acetate 160MG
	Mezest	Tablet	Megestrol Acetate 40MG
	MMF	Tablet	Mycophenolate mofetil 500MG
	Renesis	Tablet	Roxadustat 100MG
	Renesis	Tablet	Roxadustat 150MG
	Renesis	Tablet	Roxadustat 20MG
	Renesis	Tablet	Roxadustat 50MG
	Renesis	Tablet	Roxadustat 70 MG
	Tacrograf	Capsule	Tacrolimus Monohydrate (Micronized) 0.5MG
	Tacrograf	Capsule	Tacrolimus Monohydrate (Micronized) 1MG
Neuro	Mirogab	Tablet	Mirogabalin 10MG
	Mirogab	Tablet	Mirogabalin 15MG
	Mirogab	Tablet	Mirogabalin 2.5 MG
	Mirogab	Tablet	Mirogabalin 5MG
	Prokind	Tablet	Propantheline Bromide 15MG
	Regab	Capsule	Pregabalin 100MG
	Regab	Capsule	Pregabalin 150MG
	Regab	Capsule	Pregabalin 25 MG
	Regab	Capsule	Pregabalin 50MG
	Regab	Capsule	Pregabalin 75 MG
Non-ComC	ETP	Tablet	Eltrombopag 50MG
	ETP	Tablet	Eltrombopag Olamine 12.5 MG
	ETP	Tablet	Eltrombopag Olamine 25 MG
	FXR	Tablet	Obeticholic Acid 10MG
	FXR	Tablet	Obeticholic Acid 5MG
	Imruza	Tablet	Azathioprine 25 MG
	Imruza	Tablet	Azathioprine 50MG
	Oliver	Tablet	L-Ornithine L-Aspartate 150MG
	Pancreon	Capsule	Pancreatin EC Pellets (70 % W/W) 10000+8000+600IU
	Pancreon	Capsule	Pancreatin EC Pellets (70 % W/W) 25000+18000+1000IU
	Rifax	Tablet	Rifaximin 200MG
	Rifax	Tablet	Rifaximin 550 MG
	Sarozar	Tablet	Saroglitazar Magnesium (Micronized) 2MG
	Semaslim	Injection	Semaglutide INN 0.25mg 0.25MG
	Semaslim	Injection	Semaglutide INN 0.5mg 0.5MG
	Semaslim	Injection	Semaglutide INN 1.7mg 1.7MG
	Semaslim	Injection	Semaglutide INN 1mg 1MG
	Semaslim	Injection	Semaglutide INN 2.4mg 2.4MG
	Varipress	Injection	Terlipressin acetate 1 MG/8.5 ML
Noradrenalin	Levofed	Injection	Norepinephrine 2MG+2ML
	Levofed	Injection	Norepinephrine 4MG/4ML

Therapeutic Class	Brand Name	Dosage Type	Generic Name with Strength
NSAIDS	Acebid	Tablet	Aceclofenac 100MG
	Acupain	Injection	Ketorolac Tromethamine 30MG
	Acupain	Tablet	Ketorolac Tromethamine 10MG
	Annova	Gel	Naproxen USP 15GM
	Annova	Gel	Naproxen USP 30GM
	Annova	Suspension	"Naproxen USP 50ML"
	Annova	Tablet	Naproxen 250MG
	Annova	Tablet	Naproxen 500MG
	Annova	Tablet	Naproxen+ Esomeprazole 375MG+20MG
	Annova	Tablet	Naproxen+ Esomeprazole 500MG+20MG
	Coxitor	Tablet	Etoricoxib 120 MG
	Coxitor	Tablet	Etoricoxib 60MG
	Coxitor	Tablet	Etoricoxib 90MG
Oral chem	Cyclotox ORO	Tablet	Cyclophosphamide 50MG
	Herlyn	Tablet	Neratinib Maleate 40MG
	Loncil	Tablet	Trifluridine+Tipiracil Hydrochloride 15MG+6.14MG
	Loncil	Tablet	Trifluridine+Tipiracil Hydrochloride 20MG+8.19MG
	Xitabin	Tablet	Capcitabine 500MG
	Zytix	Tablet	Abiraterone 250MG
	Zytix	Tablet	Abiraterone 500MG
Ortho	Denbac	Capsule	Dantrolene Sodium 25 MG
	Denbac	Capsule	Dantrolene Sodium 50MG
	Diacer	Tablet	Diacerein + Glucosamine HCL 50MG+750MG
	Flexibac	Syrup	Baclofen 0.100GM/100ML
	Flexibac	Tablet	Baclofen 10MG
	Flexibac	Tablet	Baclofen 25 MG
	Flexibac	Tablet	Baclofen 5MG
	Lizorex	Tablet	Linezolid 100MG/5ML
	Lizorex	Tablet	Linezolid 2MG/ML
	Lizorex	Tablet	Linezolid 400MG
	Lizorex	Tablet	Linezolid 600MG
	Mecab	Tablet	Methocarbamol 500MG
	Mecab	Tablet	Methocarbamol 750MG
	Tetrazin	Tablet	Tetrabenazine 12.5 MG
	Tetrazin	Tablet	Tetrabenazine 25 MG
Others	Anastrol	Tablet	Anastrozole 1MG
	Apaluda	Tablet	Apalutamide 60MG
	Bical	Tablet	Bicalutamide 50MG
	Duratocin	Injection	Carbetocin 100MCG
	Folinex	Tablet	Calcium Folinate BP Oral Grd. 15MG
	Folinex	Tablet	Folinic Acid 5MG
	Lexel	Tablet	Letrozole 2.5 MG

Therapeutic Class	Brand Name	Dosage Type	Generic Name with Strength
Others	Melafit	Tablet	"Melatonin BP 3MG"
	Montinex	Chewable Tablet	Montelukast Sodium 10MG
	Pidonex	Tablet	Pidotimod 400MG
	Pidonex	Tablet	Pidotimod 800MG
	Regora	Tablet	Regorafenib 40MG
	Relugoli	Tablet	Relugolix 120 MG
	Tamoxi	Tablet	Tamoxifen 20MG
	Temonix	Capsule	Temozolomide 100MG
	Temonix	Capsule	Temozolomide 250MG
	TOCO	Injection	Atosiban Acetate 37.5MG
	TOCO	Injection	Atosiban Acetate 6.75MG
	WFI	Injection	Water For Injection 10ML
	WFI	Injection	Water for Injection 5ML
	Xonimide	Tablet	Zonasamide 50MG
	Zaluta	Tablet	Enzalutamide 40MG
Probiotic	Biorenal	Capsule	Pre & Probiotic with Vitamin k2-7
Psychy	Agotin	Tablet	Agomelatine 25 MG
	Amipride	Tablet	Amisulpride 100MG
	Amipride	Tablet	Amisulpride 200MG
	Amipride	Tablet	Amisulpride 50MG
	Ciko	Tablet	Citicoline Sodium 500MG
	Ilodon	Tablet	Iloperidone 2MG
	Ilodon	Tablet	Iloperidone 6MG
	Milran	Tablet	Milnacipran 12.5MG
	Milran	Tablet	Milnacipran 50MG
	Miraclon	Tablet	Clonazepam 0.5MG
	Miraclon	Tablet	Clonazepam 1MG
	Miraclon	Tablet	Clonazepam 2MG
	Mirapin	Tablet	Mirtazapine 15MG
	Rimidon	Tablet	Primidone 250MG
	Rimidon	Tablet	Primidone 50MG
	Xolitra	Tablet	Flupentixol + Melitracen 0.5 MG FLUPENTIXOL
Sanitizer	Hyginex	Others	Ethanol 60ML
	Hyginex	Others	Ethanol Hand sanitizer 50ML
	Hyginex	Spray	IsopropylAlcohol 60ML
Sedative	Pediclor	Syrup	Chloral Hydrate 143.3 MG/5 ML
	Slipaid	Tablet	Doxepin 3MG
	Slipaid	Tablet	Doxepin 6MG
Skin	Arsenor	Tablet	Apremilast 10MG
	Arsenor	Tablet	Apremilast 30MG
SSRI	Dapotin	Tablet	Dapoxetine HCl 30 MG
Steroids	Betamet	Cream	Permithrin INN 0.05%

Therapeutic Class	Brand Name	Dosage Type	Generic Name with Strength
Steroids	Primovate	Cream	Clobetasol Propionate 0.05%
	Primovate	Ointment	Clobetasol Propionate 0.05%
	Xalcort	Suspension	Deflazacort 6MG/5ML
	Xalcort	Tablet	Deflazacort 18MG
	Xalcort	Tablet	Deflazacort 24MG
	Xalcort	Tablet	Deflazacort 30MG
	Xalcort	Tablet	Deflazacort 36MG
	Xalcort	Tablet	Deflazacort 6MG
SuppC	Aproxi	Tablet	Aprepitant 125MG
	Aproxi	Tablet	Aprepitant 40MG
	Aproxi	Tablet	Aprepitant 80MG
	BioBran	Sachet	Arabinoxylan 100 MG
	BioBran	Tablet	Arabinoxylan 250 MG
	Fibroz	Capsule	Nintedanib 100MG
	Fibroz	Capsule	Nintedanib 150MG
	Filgrast	Injection	Filgrastim 300MCG/0.5 ML
	Immufen	Cream	Urea, SyriCalm, Shea butter, Oil complex omega plus, hydrolyzed silk & glycine soja oil
	Immufen	Gel	Urea, SyriCalm, Shea butter, Oil complex omega plus, hydrolyzed silk & glycine soja oil
	Pulmofib	Tablet	Pirfenidone 267 MG
	Pulmofib	Tablet	Pirfenidone 534 MG
	Pulmofib	Tablet	Pirfenidone 801 MG
	Trisela	Injection	Trilaciclib 300MG
	Xoleron	Injection	Zolendronic Acid 4MG
TGT-Oth	Abeza	Tablet	Abemaciclib INN Micr. 150MG
	Abeza	Tablet	Abemaciclib INN Micr. 200MG
	Certus	Tablet	Lapatinib 250MG
	Darota	Tablet	Darolutamide INN Micr. 300MG
	Imanix	Tablet	Imatinib 100MG
	Imanix	Tablet	Imatinib Mesylate 400MG
	Nirova	Capsule	Niraparib 100MG
	Nirova	Capsule	Niraparib Tosylate INN Micr. 100MG
	Olapar	Tablet	Olaparib 100MG
	Olapar	Tablet	Olaparib 150MG
	Palker	Capsule	Palbociclib 125 MG
	Ribolib	Tablet	Ribociclib 200MG
	Sunitix	Capsule	Sunitinib 37.5 MG
	Sunitix	Capsule	Sunitinib 50MG
	Xevirol	Tablet	Everolimus 5MG
	Xevirol	Tablet	Everolimus INN 5MG
	Zopanib	Tablet	Pazopanib 400MG
	Zopanib	Tablet	Pazopanib Hydrochloride 200MG
	Zytix	Tablet	Abiraterone 250MG

Therapeutic Class	Brand Name	Dosage Type	Generic Name with Strength
TGT-TKI	Afatin	Tablet	Afatinib 40MG
	Alkriz	Capsule	Crizotinib 250MG
	Caboz	Tablet	Cabozanitib 20MG
	Elacentra	Tablet	Elacestrant Dihydrochloride INN 345MG
	Erlonix	Tablet	Erlotinib 100MG
	Erlonix	Tablet	Erlotinib 150MG
	Gefinix	Tablet	Gefitinib 250MG
	Lenva	Capsule	Lenvatinib 4MG
	Lenva	Capsule	Lenvatinib Mesylate 10MG
	Ositag	Tablet	Osimertinib 80MG
	Soranix	Tablet	Sorafenib Tosylate 200MG
	Sotoras	Tablet	Sotorasib INN Micr. 120MG
	Tucatin	Tablet	Tucatinib INN Micr. 150MG
Vitamins	Allion	Tablet	Multivitamin & Multimineral MULTIVITAMIN & MUL
	Becobion	Injection	Thiamine Hydrochloride (B1)+ Pyrodoxine Hydrochloride (B6)+ Cyanocobalamin (B12) 100+200+0.20 MG
	Becobion	Injection	Vitamin B1, B6 & B12 100+100+1 MG
	Biotin	Capsule	Biotin 5MG
	Biotin	Capsule	"Biotin 2.5MG"
	Biotin	Tablet	Biotin 1MG
	D-gain	Capsule	Cholecalciferol (Vitamin D) 20000IU
	D-gain	Capsule	Cholecalciferol (Vitamin D) 40000IU
	D-gain	Tablet	Cholecalciferol (Vitamin D) 2000IU
	Eyepro	Capsule	Leutin,Vitamin C, Vitamin E, Cooper <(>&<)> Zinc
	Humphry	Tablet	Calcium Orotate 400MG
	Humphry	Tablet	Calcium Orotate 740MG
	Imuzin	Syrup	Vitamin B Complex + Zinc 100ML
	Imuzin	Tablet	Vitamin B Complex + Zinc 5+2+2+20+10MG
	Imuzin	Tablet	Zinc sulfate monohydrate 20MG
	Liquical	Capsule	Calcitriol 0.25MCG
	Mg	Tablet	Magnesium 365 MG
	Ovocal	Tablet	Calcium (from eggshell source) & Vitamin D3 500MG+200IU
	Ovocal	Tablet	Calcium (from eggshell source) & Vitamin D3 600MG+400IU
	Ovocal	Tablet	Calcium Carbonate + Vitamin D3 + Multimineral MULTI VITAMIN & MU
	Ovocal	Tablet	Eggshell Calcium + Vitamin D3 + 19 Vitamin & Minerals MULTI VITAMIN & MU
	Protebon-D	Tablet	Calcium + Vitamin D3 500MG + 200IU
	Sixvit	Tablet	Pyridoxine Hydrochloride 20MG
	Xvit	Capsule	Zinc, Iron, Folic Acid, B-Vit, Vit-C MULTI VITAMIN & MU

FINANCIAL

CALENDAR

October 29 2024

Adoption of Q1 Un-audited FS

Period from 01 July 2024 to 30 September 2024

January 29 2025

Adoption of Unaudited Half Yearly FS

Period from 01 July 2024 to 31 December 2024

April 29 2025

Adoption of Q3 Un-audited FS

Period from 01 January 2025 to 31 march 2025

October 22 2025

Adoption of Annual Audited FS

Period from 01 July 2024 to 30 June 2025

October 22 2025

Announcement of Cash Dividend

21% for General Shareholders & No Dividend for Sponsor/Directors

October 22 2025

Announcement of Record Date

Record Date is 16 November 2025

November 27 2025

Notice

Annual General Meeting

December 23 2025

AGM Day

24th Annual General Meeting

January 22 2026

Payment of Dividend

Dividend Payment to Shareholders as of Record Date

A GAME-CHANGER IN DIABETES, OBESITY AND CARDIOMETABOLIC HEALTH

FASTER *weight reduction* > up to **13.1 kg** in 20 weeks

MAXIMUM *weight reduction* > up to **26.3 kg** in 72 weeks

Once Weekly

Tirza

Tirzepatide INN

2.5 mg/0.5 mL

5 mg/0.5 mL

7.5 mg/0.5 mL



BEACON
Chronic Care

MESSAGE FROM

CHAIRMAN



Nurun Nahar Karim
Chairman

> **Guided by purpose and driven by innovation, Beacon continues to transform challenges into opportunities -creating sustainable growth for our shareholders and hope for patients worldwide.**

Dear Shareholders,

Welcome to our 24th Annual General Meeting. This report for the year ended 30 June 2025 details a period of significant challenge and, more importantly, of Beacon's resolute response.

Amidst global economic pressures and local market shifts, our fundamentals held strong. Our strategy worked. The results we present today are a testament to the power of our three core pillars:

Our People: Whose ingenuity and dedication drive our success.

Our Platforms: Our state-of-the-art facilities and systems ensure quality and efficiency.

Our Purpose: Delivering life-saving medicines that earn trust at home and abroad.

Looking ahead, we are channeling this momentum. We will continue to innovate, optimize, and execute with discipline. Our goal is not just to adapt to the future of healthcare but to help shape it, creating sustainable value for you, our shareholders.

I pray to the almighty Allah for the continual success of Beacon in future.

Nurun Nahar Karim

Nurun Nahar Karim
Chairman

REPORT OF THE

MANAGING DIRECTOR



Mohammad Ebadul Karim
Managing Director

> **With innovation at our core and quality as our promise, Beacon continues to expand its global footprint, transforming challenges into opportunities and creating value for patients, partners, and shareholders alike.**

Dear Shareholders,

Assalamu Alaikum,

On behalf of the Board of Directors and myself, it is my distinct pleasure to welcome you to the 24th Annual General Meeting of Beacon Pharmaceuticals PLC. We are grateful for your continued trust and participation.

By the grace of Almighty Allah, the past financial year has been a powerful demonstration of our Company's resilience and strategic agility. We operated in a complex global environment, navigating persistent challenges including currency volatility, rising raw material costs, and geopolitical tensions. Yet, it is precisely in such conditions that our commitment to excellence and our proactive strategies have proven most effective.

I am immensely proud of our team. Their dedication, expertise, and unwavering focus have been the driving force behind our ability to not only withstand these headwinds but to also identify and seize new opportunities for growth. Their collective efforts have been instrumental in solidifying Beacon's leadership in the Bangladeshi pharmaceutical sector and strengthening our footprint in international markets.

This steadfast commitment forms the foundation upon which we will continue to build. As you will see in the following report, our resolve has translated into tangible progress and performance, setting a confident course for the future.

Performance Overview

We are pleased to share that Beacon Pharmaceuticals PLC has continued its growth momentum over the past few years.

During the financial year, our revenue reached BDT 12.54 billion, reflecting a 17.20% increase over the previous year's figure of BDT 10.70 billion. Our operating profit also rose sharply by 28.84%, due to effective cost management and operational efficiency. However, the rising interest rates had an impact on our net profitability, resulting in an 81.67% increase in Net Profit After Tax (NPAT) and an 81.67% rise in Earnings Per Share (EPS) despite strong operating performance.

Operating Results

Key Operating Results FY 2024–2025

- Sales increased by 17.20%
- Gross profit rose by 17.99%
- Operating profit surged by 28.84%
- Net profit after tax grew by 81.67%
- Net asset value per share increased by 9.47%
- Earnings per share (EPS) improved by 81.67%

New Product

Beacon Pharmaceuticals PLC is dedicated to addressing critical health challenges by developing advanced treatments for unmet medical needs in oncology, immunology, metabolic disorders, and hematology. Our strategy has always been to pioneer novel therapies and advanced treatment options, earning a trusted position among physicians.

We are continuously expanding our portfolio to provide patients with effective and accessible treatments. In line with this mission, we plan to launch a diverse range of high-tech products in 2025, targeting significant unmet needs across oncology, autoimmune conditions, metabolic disorders, and transplant care. These includes

1. **Oncology:** We have introduced several key cancer

treatment products, including Erubin Aqua (Epirubicin) Injection, Xorubin Aqua (Doxorubicin) Injection, Herlyn Tab. 40mg, Elacentra Tab. 345mg, Abeza Tab. 150mg, Abeza Tab. 200mg, Axita Tab. 5mg, Darota Tab. 300mg, Sotoras Tab. 120mg, Tucatin 150 (Tucatinib) tablet, Irinox 300 mg (Irinotecan) injection. These therapies target a range of cancers, such as breast, colorectal and prostate adenocarcinomas. Each product addresses various stages of the disease, from early intervention to metastatic and relapsed cases, by leveraging advanced mechanisms to inhibit tumor progression.

2. **Hematology:** As an extension of our flagship brand, we have launched Pomide Cap. 2mg and Pomide Cap. 4mg which is indicated for Multiple Myeloma.

3. **Antiplatelets:** With a strong focus on advancing cardiac care, we launched Fibanix (Tirofiban 12.5 mg/250 mL IV infusion) and Frilinta (Ticagrelor 90 mg tablet) to enhance outcomes for patients with acute coronary syndrome (ACS) and those undergoing percutaneous coronary intervention (PCI). Fibanix, a glycoprotein IIb/IIIa receptor inhibitor, represents a significant milestone as the first Tirofiban brand introduced in Bangladesh. Frilinta, an oral $P2Y_{12}$ receptor antagonist, delivers advanced oral antiplatelet therapy to complement our comprehensive cardiovascular treatment portfolio.

4. **Dermatology:** For the treatment of all types of fungal infections, we have introduced SUBA Technology based Super Bioavailable Itraconazole Itrazen SB Capsule 65mg. For the patients suffering from primary insomnia, delayed sleep phase syndrome, Jet Lag we have launched Melafit Tablet 3mg, that restores sleep naturally. We have launched Lulima Cream 1% for the treatment of superficial fungal infections e.g. Tinea Corporis, Tinea Cruris, Tinea Pedis, Tinea Versicolor, Cutaneous Candidiasis. For Rapid Clearance of Skin Inflammation, we have introduced Primovate Cream 0.05% and Primovate Ointment 0.05%. It is very effective in Eczema, Psoriasis, Contact Dermatitis, Itching & Inflammation, Lichen Planus, Seborrheic Dermatitis. For fast relief from skin itching and inflammation we have also launched Betamet Cream 0.05% Indications: Eczema, Psoriasis, Contact Dermatitis, Urticaria Oral candidiasis is a very painful sufferings for patients of all age group especially immunocompromised patients. To restores smile in oral candidiasis we have launched Candisore Oral Gel 2%. At this moment highly contagious disease Scabies is a great concern for public health. We have introduced Bepanthin Cream 5% for the treatment of scabies.

Antibiotic for Treating Resistant Infections

We have launched Linezolid under the brand name Lizorex to empower physicians with a powerful, modern antibiotic that tackles resistant infections and meets urgent clinical needs. Lizorex sets a new standard in addressing urgent clinical need that strengthen our portfolio.

First Time Manufactured in Bangladesh

We have introduced a ray of hope for expectant mothers under the brand name Toco (Atosiban) that helps transform a threatened preterm birth into a full-term success by prolonging pregnancy for up to 31 days. In addition, Toco supports embryo implantation, thereby enhancing the chances of successful pregnancy in assisted reproductive procedures.

Pain Management

We have launched Annova Gel 10% 15gm and 30 gm for acute pain and arthritis management. Also, launched Annova Suspension 120mg/ml for pediatric fever and chronic pain. We have also introduced Mecab 500 mg & 750 mg Tablet which improves pain intensity & pain related disability. It is a USFDA Approved OTC antispasmodic. It is safe & well tolerated muscle relaxant.

Latest Drug for IBS D

We have launched Ramos 2.5 mcg Tablet and Ramos 5 mcg Tablet which is the latest drug for IBS D.

Iron Deficiency Anaemia

For effective treatment of iron deficiency anaemia, we have launched Aurifer which is the smallest-sized ferric citrate tablet in Bangladesh. It increases hemoglobin level to 11.32 g/dl within only three weeks.

Drug for Treatment of Macular Degeneration

We have introduced Eyepro which reduces the progression of age-related macular degeneration.

BPH Management

We have launched Fintaz that ensures faster & better relief of BPH, improving erectile dysfunction.


A Global Leader in Oncology Access

At Beacon Pharmaceuticals PLC, our mission is to make advanced and affordable oncology and biopharmaceutical treatments accessible to patients across the globe. Guided by this vision, Beacon has emerged as a dynamic, globally oriented pharmaceutical leader from South Asia.

Our success is driven by a strong international presence and a steadfast commitment to quality. With more than 450 registered products and distribution in over 125 countries, Beacon's growing footprint reflects our dedication to innovation, accessibility, and patient care. Our state-of-the-art manufacturing facilities are built to USFDA-compliant standards, ensuring uncompromising quality, safety, and efficacy in every product we deliver. In

addition to oncology and specialty biopharmaceuticals, we have expanded our portfolio to include general formulations, cephalosporins, and nutraceuticals, broadening our contribution to global health.

We extend heartfelt gratitude to our shareholders, partners, and global stakeholders for their continued trust and collaboration. As we move forward, Beacon remains committed to advancing healthcare equity—exporting not just medicines, but care, compassion, and confidence—as we continue to redefine the global oncology and pharmaceutical landscape, one market at a time.




Mohammad Ebadul Karim
Managing Director

Our Commitment

Our commitment to becoming a leading global pharmaceutical company is demonstrated through our investment in medical advancement. Over the past year, we have engaged thousands of practitioners and students across the country through educational programs and scientific seminars. By equipping healthcare professionals with knowledge of the latest international treatment standards, we are fulfilling our promise to deliver value to every stakeholder we serve.

“DEVOTED TO INNOVATION COMMITTED TO QUALITY”



Pioneering the
latest innovations in
cancer treatment **since 2021**

IMMUNOTHERAPY

The Master-Key of Cancer Treatment

BEACON®


Light for life

FINANCIAL PERFORMANCE REVIEW FOR THE FY 2024-25




PROFIT AND LOSS STATEMENT & OCI

(BDT in Million)




PROFIT AND LOSS STATEMENT & OCI

(BDT in Million)




STATEMENT OF FINANCIAL POSITION

(BDT in Million)



STATEMENT OF FINANCIAL POSITION

(BDT in Million)



PERFORMANCE RATIOS

PERCENTAGE (%)









LIQUIDITY AND SOLVENCY RATIOS

TIMES











EFFICIENCY RATIOS

TIMES




CASH FLOW RATIOS




FIVE YEARS FINANCIAL HIGHLIGHTS

(BDT in Million)


REVENUE




GROSS PROFIT



OPERATING PROFIT



PROFIT BEFORE TAX



PROFIT AFTER TAX




EPS (BDT PER SHARE)




FIVE YEARS FINANCIAL HIGHLIGHTS

(BDT in Million)


TOTAL ASSETS




TOTAL LIABILITIES




SHAREHOLDERS' EQUITY




NAV (BDT PER SHARE)



NOCF (BDT PER SHARE)




MARKET PRICE (BDT PER SHARE)




FIVE YEARS FINANCIAL HIGHLIGHTS

(KEY RATIOS)


CURRENT RATIO




RETURN ON EQUITY (%)




GP RATIO (%)




DEBT EQUITY RATIO (%)



RETURN ON ASSETS (%)




PRICE EARNINGS RATIO (%)




FIVE YEARS FINANCIAL HIGHLIGHTS
(DIVIDEND DISTRIBUTION)


CASH DIVIDEND DECLARED (%)




DIVIDEND YIELD (%)



DIVIDEND DECLARED BDT in Million




DIVIDEND DISTRIBUTED BDT in Million




STATEMENT OF VALUE ADDITION


Particulars	FY2024-2025		FY2023-2024	
	BDT (Figures in Million)	Percentage	BDT (Figures in Million)	Percentage
Value Added				
Revenue & Other Income	14,427		12,228	
Less: Bought-in Materials & Services	7,724		6,712	
	6,703		5,516	
Applications				
Salaries and Benefits to Employees	2,376	35.45%	2,232	40.46%
Duties & Taxes to Govt. Exchequer	2,071	30.90%	1,758	31.88%
Interest to Lenders	1,308	19.52%	1,003	18.18%
Dividend to shareholders	290	4.32%	372	6.74%
Retained by the company	657	9.80%	151	2.75%
	6,703	100.00%	5,516	100.00%




Salaries and Benefits to Employees




Duties & Taxes to Govt. Exchequer



Interest to Lenders



Dividend to Shareholders



Retained by the Company

1st time in Bangladesh

Ovocal-D

Calcium 500 mg (eggshell source) & Vitamin D_3 200 IU Tablet

Ovocal-DX


Calcium 600 mg (eggshell source) & Vitamin D_3 400 IU Tablet

The Most Premium Calcium of Bangladesh

Quality certified by

TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER

USA



TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER
Jerry H. Hodge School of Pharmacy
Department of Pharmaceutical Sciences

Certificate of Analysis

Product Name : Ovocal-D Tablet
Generic Name : Calcium 500 mg (eggshell source) & Vitamin D_3 200 IU
Manufactured by : Beacon Pharmaceuticals Limited, Bangladesh

Test Parameters	British Pharmacopoeia Standard	Lab Test Result of Ovocal-D Tablet
Drug Content (mg)	450 mg - 550 mg	545 mg
Friability (%)	Not more than 1%	0.998%
Hardness (Newton)	245.11- 392.22	248.43 ± 03.84
Disintegration Time	Not more than 30 minutes	56.95 ± 1.50 Seconds

Comments: **Ovocal-D Tablet meets British Pharmacopoeia quality standards in all the tests performed in our laboratory.**

Fakhrul Ahsan, Ph.D.
University Distinguished Professor

TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER
Jerry H. Hodge School of Pharmacy
Department of Pharmaceutical Sciences

In-Vivo Absorption rate analysis of different Calcium Preparations of Bangladesh

Drugs Used:
- Calcium Preparation from Limestone (Rock) Source
- Calcium Preparation from Algae Source
- Calcium Preparation from Coral Source
- Calcium Preparation from Eggshell Source

* All the Calcium Preparations are manufactured in Bangladesh.

Graphical Presentation:

Calcium Preparation from Limestone (Rock) Source — Maximum absorption at 120 min
Calcium Preparation from Coral Source — Maximum absorption at 60 min
Calcium Preparation from Algae Source — Maximum absorption at 30 min
Calcium Preparation from Eggshell Source — Maximum absorption at 15 min

Serum Calcium Conc (µg) — Time (hr)

Result:

Test Parameters	Calcium Preparation	Test Result
Order of Calcium Release (Minute)	Calcium Preparation from Limestone (Rock) Source	T_{max} = 120 min
	Calcium Preparation from Coral Source	T_{max} = 60 min
	Calcium Preparation from Algae Source	T_{max} = 30 min
	Calcium Preparation from Eggshell Source	T_{max} = 15 min

Comments:
1. Calcium Preparation from Limestone (Rock) Source has slowest absorption rate (T_{max} = 120 min).
2. Calcium Preparation from Coral Source has modest absorption rate (T_{max} = 60 min).
3. Calcium Preparation from Algae Source has modest absorption rate (T_{max} = 30 min) & fastest elimination rate.
4. Calcium Preparation from Eggshell Source has shown fastest absorption rate (T_{max} = 15 min) among different Calcium preparations in Bangladesh.

All the tests performed in our laboratory.

Fakhrul Ahsan, Ph.D.
University Distinguished Professor

BEACON®
Pharmaceuticals PLC

MANUFACTURING OPERATION



MANUFACTURING OPERATION

Beacon Pharmaceuticals PLC is one of the leading and fastest-growing pharmaceutical companies in Bangladesh, distinguished for its commitment to delivering high-quality, safe, and effective medicines across diverse therapeutic areas. Since commencing operations in 2006, the company has continually invested in state-of-the-art infrastructure, innovative manufacturing technologies, and international best practices to strengthen its position in both domestic and global pharmaceutical markets.

The company's manufacturing plant in Bhaluka, Mymensingh, serves as a flagship site for the production of pharmaceutical preparations. Strategically located in a lightly populated woodland area, the site spans approximately 30 acres, with several small-scale textile firms within a 2 km radius. The location provides both environmental tranquility and operational efficiency, ensuring an optimal setting for large-scale pharmaceutical manufacturing.

Beacon Pharmaceuticals PLC was developed from a greenfield site under the expert consultancy and supervision of the world-renowned pharmaceutical engineering firm, Telstar S.A., Spain. This collaboration ensured that the facility design incorporates modern industrial architecture, optimized process flow, and advanced containment systems, reflecting international standards in pharmaceutical manufacturing.

At Beacon, quality, safety, and compliance form the foundation of all operations. The company strictly adheres to Good Manufacturing Practice (GMP) guidelines, focusing on contamination prevention, efficient material and personnel flow, and robust containment measures. Production machinery is equipped with state-of-the-art containment systems, while electronic data management is compliant with CFR Part 11, ensuring secure record-keeping, traceability, and auditability of all critical manufacturing data.

In addition to GMP, the company maintains adherence to Good Engineering Practices (GEP) in utilities and facility management, ensuring reliable operation of critical systems such as HVAC, water treatment, and clean steam generation. Laboratory operations are conducted under Good Laboratory Practices (GLP), with rigorous quality control and analytical testing to ensure product integrity, potency, and stability.

Beacon's sterile manufacturing processes are fully compliant with EU-GMP standards, employing advanced aseptic processing, isolator technologies, and sterilization protocols. Personnel hygiene and safety are given the highest priority through structured gowning procedures, hygiene protocols, and regular training, ensuring both employee safety and product sterility.

The company also places strong emphasis on environmental, health, and safety management, fully aligning operations with ISO environmental and occupational safety standards. Waste management, energy conservation, and water-saving initiatives are implemented across the facility, demonstrating Beacon's commitment to sustainable and responsible manufacturing practices.

Warehouse and storage facilities are designed in accordance with international GMP standards, ensuring the safe, controlled, and secure storage of raw materials and finished products. Temperature, humidity, and handling conditions are continuously monitored to preserve product quality throughout the supply chain.

Through these comprehensive measures, Beacon Pharmaceuticals PLC exemplifies world-class pharmaceutical manufacturing excellence, delivering medicines that not only meet regulatory requirements but also uphold the trust and expectations of patients, healthcare professionals, and international partners. The company's continuous investment in technology, compliance, and human resources ensures that it remains at the forefront of pharmaceutical innovation and global healthcare advancement.

Manufacturing Plant at a Glance

The site comprises of buildings for pharmaceutical productions, for quality assurance, for warehouse, for engineering support, for research & development facility, for quality control laboratories, for storage of solvents, for office and canteen, for storage of inflammable substances, for diesel storage (required for generator), for waste water (effluent) treatment plant, incinerator for designated wastes, for prayer room, for training room, guard barrack, for scrap yard, for retention sample storage and dormitories for staffs.



Manufacturing Operations Overview

Beacon Pharmaceuticals PLC has strategically expanded its manufacturing capabilities over the years to meet growing domestic and international demand. The state-of-the-art facilities is as follows:


General Production Facility-1 (GPF-1): Serving as the foundation for oral solid and liquid dosage form production.

Oncology Production Facility (OPF-1): Dedicated to the manufacture of advanced cancer therapies.

General Production Facility-2 (GPF-2): Enhancing the company's capacity for oral and liquid formulations.

Parenteral Production Facility-1 (PPF-1): Specializing in sterile injectable products with advanced aseptic processing technologies.

Topical Production Facility-1 (TPF-1): Focusing on high-quality semi-solid and topical formulations.



General Production Facility (GPF-1 & 2): Manufacturing Excellence in Pharmaceutical Production

General Production Facility-1 (GPF-1) is a cornerstone of our pharmaceutical manufacturing operations, embodying our commitment to producing high-quality, safe, and effective medicines. Strategically located in our industrial complex, GPF-1 is designed to meet and exceed international standards, ensuring that our products consistently fulfill their intended therapeutic purposes.

Facility Design and Infrastructure

GPF-1 is meticulously designed to support a wide array of pharmaceutical manufacturing processes. The facility encompasses:

Modular Production Lines: Tailored for the efficient manufacture of various dosage forms, including tablets, capsules, and oral suspensions.

Advanced HVAC Systems: Engineered to maintain stringent environmental controls, ensuring optimal conditions for pharmaceutical production.

Automated Material Handling Systems: Facilitating seamless movement of raw materials and finished products, enhancing operational efficiency.

Dedicated Quality Control Laboratories: Equipped with state-of-the-art instruments to perform in-process and final product testing, ensuring compliance with pharmacopeial standards.

Manufacturing Capabilities

GPF-1 is equipped to handle diverse manufacturing needs:

Oral Solid Dosage Forms: Production of tablets and capsules, employing advanced compression and encapsulation technologies.

Oral Liquids: Manufacture of syrups and suspensions, utilizing precision filling and sealing equipment.

Packaging Lines: Automated systems for blister packing, bottle filling, and labeling, ensuring product integrity and traceability.

General Production Facility: 1



General Production Facility: 2



Oncology Manufacturing Facility (OPF 1): Advancing Cancer Care Through Precision and Innovation

The Oncology Facility stands as a flagship unit of Beacon Pharmaceuticals PLC, representing the company's unwavering commitment to providing advanced, life-saving cancer therapies that meet global quality and safety standards. Purpose-built to handle complex and high-potency active pharmaceutical ingredients (HPAPIs), this facility is a model of innovation, regulatory compliance, and technical excellence in oncology drug manufacturing.

Facility Overview and Design
The Oncology Facility is designed in strict compliance with EU-GMP and WHO-cGMP standards. Developed in collaboration with leading European pharmaceutical engineering consultants, it incorporates advanced containment systems and isolator technology to ensure both product sterility and operator safety.

Key design features include

Dedicated Isolated Production Zones: Prevent cross-contamination during the handling of potent cytotoxic and cytostatic compounds.

Controlled Airflow and Pressure Gradients: Maintain cleanroom integrity across all production areas.

Fully Automated Material Transfer Systems: Reduce manual intervention, ensuring precision and product safety.

Ergonomically Designed Layout: Optimizes process flow, minimizes contamination risk, and enhances efficiency.

Manufacturing Capabilities
The Oncology Facility is equipped to manufacture a diverse range of oncology formulations, including:

Oral Solid Dosage Forms: Tablets and capsules containing highly potent anticancer APIs.

Lyophilized and Liquid Injectables: Produced using advanced aseptic filling systems to ensure sterility and stability.
Targeted Therapy Products: Specialized formulations designed to improve efficacy while minimizing systemic toxicity.

Each manufacturing process is supported by validated equipment and automated control systems that ensure consistency, precision, and traceability from raw materials to finished products.

Oncology Production Facility-1



Parenteral Production Facility-1 (PPF-1): Precision, Purity, and Pharmaceutical Excellence

The Parenteral Production Facility-1 (PPF-1) of Beacon Pharmaceuticals PLC stands as a hallmark of sterile manufacturing excellence, dedicated to producing high-quality injectable formulations that meet global regulatory and therapeutic standards. Designed and constructed in accordance with EU-GMP, WHO-cGMP, and ISO Class Cleanroom specifications, the facility embodies Beacon's commitment to precision, patient safety, and innovation in sterile drug manufacturing.

Facility Overview and Infrastructure:
PPF-1 is a state-of-the-art sterile manufacturing complex purpose-built for the production of parenteral dosage forms, including small-volume injectables (SVIs), large-volume injectables (LVIs), and lyophilized products. The facility layout ensures a unidirectional process flow—from raw material entry to finished goods dispatch—maintaining the highest standards of aseptic control and cross-contamination prevention.

Key Infrastructure Highlights

Classified Cleanroom Areas: ISO Class 100 (Grade A/B) for aseptic processing, supported by Grade C/D preparation areas.

Advanced HVAC Systems: Equipped with HEPA filtration and pressure cascade control to ensure microbial and particulate-free environments.

Automated Material and Personnel Airlocks: Maintain sterility and minimize human intervention.

Validated Water Systems: Including Water for Injection (WFI), Purified Water, and Clean Steam generation units.

Separate Entry and Exit Routes: For material and personnel to maintain segregation of clean and non-clean zones.

Manufacturing Capabilities

PPF-1 is equipped with advanced production lines for sterile manufacturing, incorporating modern technologies and automation to ensure consistency, precision, and sterility at every stage.

Major Manufacturing Capabilities Include

Aseptic Solution Preparation: Using closed systems and sterile filtration (0.22 µm) under laminar airflow.

Vial and Ampoule Filling Lines: Fully automated filling, stoppering, and sealing operations under Grade A laminar flow.

Lyophilization (Freeze-Drying): Enables production of thermolabile products with enhanced stability and shelf life.

Prefilled Syringe Systems: State-of-the-art filling technology ensuring precision dosing and patient convenience.

Terminal Sterilization Units: Autoclaves and dehydrogenation tunnels ensuring microbial integrity of finished products.

Parenteral Production Facility-1



Topical Production Facility-1 (TPF-1): Excellence in Dermatological and Topical Formulations

Topical Production Facility-1 (TPF-1) represents a core component of Beacon Pharmaceuticals PLC's manufacturing capabilities, dedicated to the production of high-quality topical pharmaceutical products. Purpose-built to handle semi-solid dosage forms, TPF-1 integrates advanced technology, stringent quality standards, and regulatory compliance to deliver effective, safe, and patient-friendly dermatological therapies.

Facility Overview and Infrastructure

TPF-1 is designed in strict adherence to WHO-cGMP and EU-GMP standards, ensuring that all semi-solid formulations—including creams, ointments, gels, and lotions—are manufactured under controlled, hygienic, and contamination-free conditions.

Key Infrastructure Features

Cleanroom Production Areas: ISO Class C and D cleanrooms for preparation, blending, and filling of topical formulations.

Advanced HVAC and Environmental Control Systems: Maintain optimal temperature, humidity, and particulate control.

Automated Mixing and Homogenization Units: Ensure uniformity, consistency, and stability of formulations.

Material Handling Systems: Designed for safe transfer of raw materials and finished products, minimizing contamination risks.

Dedicated Packaging Lines: For tubes, jars, and bottles with automated filling, labeling, and sealing systems.

Manufacturing Capabilities

TPF-1 is equipped to manufacture a broad range of topical pharmaceutical products, incorporating state-of-the-art technologies:

Creams and Ointments: Produced with precision mixing and homogenization to ensure uniform active ingredient distribution.

Gels and Lotions: Formulated to optimize viscosity, stability, and patient compliance.

Sterile Topical Products: For specialized applications, manufactured under controlled aseptic conditions when required.

Packaging Flexibility: Products are packaged in tubes, jars, or bottles with automated labeling and coding for traceability.

Each process is validated and controlled to guarantee consistency, quality, and compliance with international pharmacopeial standards.

Topical Production Facility-1



Beacon Pharmaceuticals PLC's manufacturing operations demonstrate technical excellence, innovation, and global compliance. Through its state-of-the-art facilities—covering oral solids, parenteral, topicals, and oncology products—the company consistently produces medicines that are safe, effective, and high-quality.

Integration with research and development accelerates the commercialization of innovative therapies, particularly in complex therapeutic areas. Simultaneously, Beacon ensures environmental sustainability, operator safety, and social responsibility are core aspects of its operations.

In essence, the manufacturing operations at Beacon Pharmaceuticals PLC establish a benchmark of quality, reliability, and innovation, reinforcing the company's leadership in both domestic and international pharmaceutical markets.

DURING THE FY 2024-2025

PRODUCTS LAUNCHED

Products 57, Generics 26 & 1st time in Bangladesh 8




Primovate
Primovate
Ramos 5
Ramos 2.5
Savesto 50
Nebinex 5
Frilinta 90
Cyclotox
AproxiEzy
BEACON
Herlyn
RINVA
Tucatin
SOTORAS
Darota
Axita
abeza
Sinjard-L 10
Belsar-Plus
Tirza


GLOBAL FOOTPRINT

At Beacon Pharmaceuticals PLC, our vision has always been clear — to make advanced, affordable, and life-saving oncology and biopharmaceutical treatments accessible to patients across the globe. As part of this mission, the International Marketing Division plays a pivotal role in expanding Beacon's international presence and ensuring that our high-quality oncology portfolio reaches those who need it most, regardless of geography. Moving forward, we are planning to strengthen Beacon's position as one of the most dynamic and globally oriented pharmaceutical companies in South Asia. Our company has been at the forefront of driving this international expansion by identifying emerging opportunities, building sustainable partnerships, and ensuring compliance with diverse regulatory frameworks across continents. Today, Beacon's oncology products have reached 135 countries, spanning Asia, Africa, the Middle East, Europe, and Latin America, with each new collaboration reaffirming our commitment to innovation, quality, and patient well-being.

Expanding Horizons — Entering New Markets: The year under review has been one of significant strategic progress. Guided by our long-term vision, we have successfully entered several new markets and initiated registration processes for a diverse range of oncology products. These new ventures mark not only the geographical expansion of Beacon's footprint but also the deepening of our engagement with healthcare systems and patient communities worldwide. These expansions are not merely commercial milestones; they represent lives changed, hope delivered, and progress realized. By entering new territories, Beacon continues to fulfill its mission of reducing the global cancer care gap through affordability and accessibility.

Strengthening Existing Relationships: While expansion remains a core focus, maintaining and nurturing our long-standing partnerships has been equally vital to our success. Beacon's business model thrives on collaboration — with distributors, healthcare providers, regulators, and governments — and our International Marketing Division has been instrumental in ensuring these partnerships remain robust, transparent, and mutually beneficial. Our ongoing efforts to optimize operational efficiency and enhance supply chain resilience have also ensured that our partners experience uninterrupted access to Beacon's products, even in challenging global economic conditions. This commitment to consistency and quality has allowed us to maintain double-digit growth in export revenues while strengthening Beacon's reputation as a trusted oncology brand worldwide.

Regulatory Excellence: A Global Footprint of Approvals. One of the proudest achievements of our division has been the successful registration of a growing number of oncology and specialty products across multiple regulatory jurisdictions. Each product registration is the result of meticulous documentation, stringent quality assurance, and collaboration between our technical, regulatory, and marketing teams. These approvals not only enable market access but also demonstrate the global recognition of Beacon's manufacturing excellence and adherence to international GMP and WHO guidelines.



Reshaping the Global Oncology Landscape: Beacon Pharmaceuticals has redefined the oncology landscape by pioneering access to complex, high-quality generics and biosimilars that address the world's most pressing cancer treatment challenges. Through our export initiatives, we are not merely selling medicines; we are reshaping how cancer care is delivered and democratizing access to advanced treatments that were once beyond the reach of patients in many parts of the world.

Our journey is driven by purpose to bridge borders, break barriers, and bring hope to those fighting cancer worldwide. Together, we are not only exporting medicines; we are exporting care, compassion, and confidence — reshaping the global oncology landscape, one market at a time.

A Fixed dose combination (FDC) that gives multiple solutions

Sinjard-L

Empagliflozin & Linagliptin



Ensures...

- ✔ Powerful glycemic control
- ✔ Superior Cardio Renal safety
- ✔ Convenient Once daily dosing

▸ Available in **calendar packaging**

BEACON
Chronic Care

Flexibac

Since 2006

Baclofen

Keeps patients mobile

Marshall University Research Corporation, USA
QUALITY VERIFIED



The 1st & only Muscle Relaxant of Bangladesh with…

polpharma®

US-DMF grade raw materials from **Polpharma, Poland**

MARSHALL UNIVERSITY® Research Corporation

Quality verified by **Marshall University Research Corporation, USA**

BEACON®
Pharmaceuticals PLC

BOARD OF DIRECTORS' PROFILE



PROFILE OF

BOARD MEMBERS



NURUN NAHAR KARIM

Chairman

Ms. Nurun Nahar Karim holds a Master of Social Sciences (MSS) in Political Science from the University of Dhaka. She is married to Mr. Mohammad Ebadul Karim, a prominent industrialist.

With her extensive experience in industry and strategic management, Ms. Karim has been instrumental in guiding the company's growth and sustainability. Her visionary leadership, coupled with her strong commitment to excellence and innovation, has significantly contributed to the expansion and success of the Beacon Group.

Ms. Karim serves as the Chairman of several leading organizations, including Beacon Pharmaceuticals PLC, Beacon Nutraceuticals Limited, MEK Auto Bricks Limited, MEK Industries Limited, MEK Pharmatech Limited, Beacon Oncology Limited, and Mujibunnessa Medical College & Hospital Limited.

In addition, she is a Director of Beacon Developments Limited, Beacon Point Limited, Beacon Economic Zone Limited, Beacon Medicare Limited, Beacon Cephalosporin Limited, Beacon Power Systems Limited, Beacon Business Solutions Limited, and Kohinoor Chemical Co. (BD) Limited.

Under her dynamic leadership, Ms. Karim continues to inspire growth, innovation, and ethical business practices, positioning Beacon Group as a leading contributor to Bangladesh's industrial and healthcare sectors.



MOHAMMAD EBADUL KARIM

Managing Director

Mr. Mohammad Ebadul Karim began his business career after completing his graduation, driven by a strong entrepreneurial vision and a passion for excellence. Over the years, he has demonstrated outstanding leadership, strategic foresight, and exceptional management capabilities, successfully guiding a diversified portfolio of enterprises across multiple sectors.

He currently serves as the Managing Director of Beacon Pharmaceuticals PLC, Beacon Developments Limited, Beacon Nutraceuticals Limited, MEK Auto Bricks Limited, MEK Industries Limited, MEK Pharmatech Limited, Mujibunnessa Medical College & Hospital Limited, and Beacon Oncology Limited.

In addition, he holds the position of Chairman at several renowned organizations, including Beacon Power Systems Limited, Beacon Point Limited, Beacon Medicare Limited, Beacon Cephalosporin Limited, EREBA Capsules Limited, Beacon Economic Zone Limited, and Beacon Business Solutions Limited. He also serves as a Director of Kohinoor Chemical Co. (BD) Limited.

Mr. Karim's visionary leadership and relentless dedication have played a pivotal role in transforming Beacon Group into one of the leading conglomerates in Bangladesh. His extensive international exposure, strategic insights, and commitment to innovation have earned him numerous national and international awards, underscoring his contribution to the growth of Bangladesh's pharmaceutical and industrial sectors.



MOHAMMAD NIAZUL KARIM

Director

Mr. Mohammad Niazul Karim, son of Mr. Md. Ebadul Karim, holds a Bachelor's degree in Business Administration from the Independent University, Bangladesh (IUB). Soon after completing his graduation, he actively joined the family business, applying his strong analytical skills and keen understanding of industrial operations to the company's continued success.

He serves as a director of several companies within the Beacon Group, including Beacon Pharmaceuticals PLC, Beacon Developments Limited, Beacon Cephalosporin Limited, Beacon Nutraceuticals Limited, and others. He is also the Managing Director of Beacon Point Limited, Beacon Medicare Limited, and Beacon Economic Zone Limited. Through his dynamic leadership and strategic vision, Mr. Karim continues to play a vital role in driving innovation and sustainable growth across the group's enterprises.



ULFAT KARIM

Director and Chief Operating Officer (COO)

Mr. Ulfat Karim, the youngest son of Mr. Md. Ebadul Karim, holds a Bachelor of Science (Hons) degree in Business and Management (Marketing) from Brunel University, London. A dynamic and visionary young entrepreneur, he embodies innovation, strategic foresight, and operational excellence, bringing a fresh perspective to corporate leadership and organizational growth.

Mr. Karim began his career at Beacon Pharmaceuticals PLC, one of the leading pharmaceutical companies in Bangladesh, where he served as Executive Director from 9 August 2021 to 9 August 2023. Owing to his outstanding performance and leadership skills, he was appointed as Director and Chief Operating Officer (COO) of the company effective 10 August 2023.

As COO, Mr. Karim has been instrumental in driving Beacon's operational transformation, focusing on efficiency, innovation, and sustainable growth. Under his leadership, the company has achieved remarkable milestones.

He successfully introduced a series of cost-control measures across production, supply chain, and procurement functions, leading to a significant reduction in overall operating costs while maintaining product quality and compliance with international standards. Through diversification of product lines, expansion of export markets, and modernization of marketing strategies, Mr. Karim has played a key role in achieving double-digit revenue growth year-on-year, strengthening Beacon's position in both local and international markets.

His data-driven decision-making and emphasis on lean operations contributed to a substantial increase in net profit after tax, reflecting strong financial discipline and operational excellence including fostered a culture of accountability, teamwork, and continuous learning across departments, empowering young professionals to take ownership of their roles and drive innovation.

Mr. Ulfat Karim's leadership exemplifies a blend of youthful energy, modern business insight, and a deep commitment to operational excellence—qualities that continue to propel Beacon Pharmaceuticals PLC and its affiliated ventures toward sustainable growth and long-term success.



REZANUR CHOWDHURY

Independent Director

Mr. Rezanur Chowdhury is a Chartered Accountant, certified by the Institute of Chartered Accountants of Bangladesh (ICAB) in 1983. With over 43 years of extensive experience in accounting, finance, and taxation, he has served in key positions in both local and international organizations, including British-American Tobacco Co. Ltd., Bangladesh, and Anchor Electronics Sdn. Bhd., Malaysia.

Throughout his distinguished career, Mr. Chowdhury has contributed significantly to the fields of financial management and tax consultancy. He has also participated in various international training programs and seminars, continuously enhancing his professional expertise. Before joining Beacon Pharmaceuticals PLC as an Independent Director, he was actively engaged in finance and tax advisory services, earning high regard for his professional integrity and insight.



MOHAMMED ARIFUL HOQUE FCA

Independent Director

Mohammed Ariful Hoque joined Beacon Pharmaceuticals PLC as an Independent Director in 2025. A Fellow Chartered Accountant (FCA) of the Institute of Chartered Accountants of Bangladesh (ICAB) and an Associate Chartered Accountant (ACA) of the Institute of Chartered Accountants in England and Wales (ICAEW), he brings a wealth of expertise in finance, audit, and corporate governance to the Board.

With over 17 years of professional experience, Mr. Hoque has developed extensive proficiency in statutory audit, bookkeeping, tax compliance, financial reporting, and payroll management. He is also a member of the Institute of Internal Auditors of Bangladesh. His leadership style emphasizes integrity, precision, and continuous professional development within his teams.


Mr. Hoque is currently a Partner at Hanif & Arif, Chartered Accountants, where he oversees client operations, ensuring timely statutory compliance, high-quality deliverables, and alignment with the latest regulatory changes.

Before joining Hanif & Arif, Mr. Hoque led the Accounting and Business Consulting service line at EY Bangladesh from August 2021 to September 2023, focusing on financial statement preparation in accordance with IFRS and Bangladesh laws, as well as internal audit outsourcing and co-sourcing services. His contributions in designing and implementing Standard Operating Procedures (SOPs) have significantly enhanced clients' internal control environments and operational efficiency.

Earlier in his career, he was a Partner at A. Qasem & Co., Chartered Accountants, where he led statutory audit and consulting engagements for major multinational corporations and prominent local conglomerates.

Mr. Hoque holds both BBA and MBA degrees in Finance from the University of Chittagong. Known for his strategic insight and dedication to professional excellence, he continues to contribute actively to the development of the accounting profession in Bangladesh.

In his role as Independent Director at Beacon Pharmaceuticals PLC, Mr. Hoque is committed to upholding strong corporate governance practices, ensuring financial transparency, and supporting the company's vision of achieving sustainable growth and global leadership in the pharmaceutical industry



PROF. A B M FAROQUE

Independent Director

Professor A B M Faroque joined Beacon Pharmaceuticals PLC as an Independent Director in 2024. A distinguished academic and researcher in pharmaceutical technology, he has over 45 years of experience in teaching, research, and industry development. He currently serves as the Dean of the School of Science and Engineering at Southeast University.

Professor A B M Faroque has held several prestigious positions at the University of Dhaka, including Dean and Chairman of the Department of Pharmaceutical Technology and the Department of Pharmacy, as well as Director of the Biomedical Research Centre. His scholarly work, comprising numerous national and international publications, has made significant contributions to the advancement of Bangladesh's pharmaceutical sector.

Beyond academia, Professor A B M Faroque has played vital roles in national and international policy formulation. He served as Convener of the National Drug Policy Formulation Sub-Committee under the Directorate General of Drug Administration (DGDA) and as Team Leader for the inspection of all pharmaceutical companies in Bangladesh. He has also been an active contributor to WHO and UNICEF initiatives, including projects on iodine deficiency control, universal salt iodization, and nutrition programs.

In his role at Beacon Pharmaceuticals PLC, Professor A B M Faroque continues to provide strategic guidance and expertise, supporting the company's mission to achieve global excellence in the pharmaceutical industry.



PROFESSOR DR. SHAMEM ARA MILI

Independent Director

Professor Dr. Shamem Ara Mili has joined Beacon Pharmaceuticals PLC as an Independent Director in 2025. She is working as a Professor in the Department of Accounting and Information Systems at Comilla University, Bangladesh as well. She has also served as the Director of MBA (Evening) Program in the same Department. Dr. Mili has achieved PhD Degree from Universiti Sains Malaysia, Malaysia, with a focus on corporate governance, human capital management disclosure, firm value, and financial reporting timeliness of the listed companies in Bangladesh. She has also achieved an MPhil Degree from Islamic University, Bangladesh, with a focus on corporate social performance of the listed pharmaceutical companies in Bangladesh.

Dr. Mili has completed MBA and BBA (Hon's) from the Department of Accounting and Information Systems of Rajshahi University, Bangladesh. She has achieved Taposhi Rabeya Hall Gold Medal for outstanding academic achievement in BBA (Hon's). Dr. Mili has participated in several international conferences, and published a number of papers in internationally reputed Journals. She has been committed to making a bridge between academic knowledge and corporate practices, as well as committed to contributing to corporate governance, ESG, human capital management and business innovation practices in the corporate sectors of Bangladesh.

PROFILE OF

EXECUTIVE DIRECTOR



RISANA KARIM

Executive Director

Risana Karim, daughter of Mr. Md. Ebadul Karim, leads Beacon Pharmaceuticals PLC with a dynamic vision, overseeing operations and driving the organization's mission in alignment with stakeholder strategies. With a Bachelor of Pharmacy from North South University and an MSc in Marketing from Brunel University London, she combines academic excellence with over a decade of industry expertise to navigate the complexities of the pharmaceutical sector.

Ms. Karim's leadership is rooted in fostering innovation, creating new markets opportunities, and enhancing productivity and competitiveness to create a positive impact that extends beyond the organization. With a keen understanding of industry trends and the foresight to anticipate future opportunities, Ms. Karim proactively builds partnerships with global innovators to shape the future of healthcare.

Ms. Karim exemplifies inclusive leadership, inspiring transformative change across Beacon while championing a better quality of life for all stakeholders.

PROFILE OF
CFO, CS AND HIA



MD. JALAL UDDIN FCA

Chief Financial Officer (CFO) & Head of IT

Md. Jalal Uddin FCA is a distinguished finance professional with over 15 years of progressive leadership experience in top-tier corporate and professional services environments. A Fellow Member of the Institute of Chartered Accountants of Bangladesh (ICAB), he joined Beacon Pharmaceuticals PLC in April 2022 as Head of Internal Audit. Demonstrating exceptional strategic and financial acumen, he was appointed Chief Financial Officer in May 2023 and subsequently assumed the additional responsibility of Head of IT in January 2024.

In his dual capacity, Mr. Uddin has been instrumental in strengthening Beacon's financial governance and driving its digital transformation agenda. Under his leadership, the Company successfully implemented the Rise with SAP S/4HANA system - a landmark initiative that modernized financial management, enhanced operational efficiency, and reinforced data-driven decision-making.

Prior to joining Beacon Pharmaceuticals, Mr. Uddin held key leadership positions at Robi Axiata Limited, where he served as Head of Financial Process, Control, Ethics, and Integrity. His extensive expertise spans financial reporting, treasury and cash flow management, cost and budgetary control, tax and VAT compliance, risk management, and assurance services.

A firm believer in the integration of finance and technology, Mr. Uddin has a proven track record in developing robust policies, control frameworks, and authority matrices while driving process simplification, automation, and digitalization within complex business environments. His visionary leadership continues to position Beacon Pharmaceuticals PLC as a front-runner in financial excellence and technological advancement within the pharmaceutical industry.



MD. SHAHABUDDIN FCS

Company Secretary (CS)

Mr. Md. Sahabuddin FCS serves as the Company Secretary of Beacon Pharmaceuticals PLC, bringing with him a wealth of experience in corporate governance, regulatory affairs, and capital market operations. He is a Fellow Member of the Institute of Chartered Secretaries of Bangladesh (ICSB) and holds both MBA and BBA degrees from the University of Dhaka, along with an LL.B. degree from the National University of Bangladesh.

Before joining Beacon Pharmaceuticals PLC, Mr. Sahabuddin held the position of Company Secretary at Marico Bangladesh Limited, where he made notable contributions in strengthening corporate governance and compliance structures. Over his distinguished career, he has also served in key leadership roles at A. K. Khan & Company Limited, Urmi Group, Walton Group, and the Federation of Bangladesh Chambers of Commerce and Industry (FBCCI), where he played an instrumental role in advancing organizational governance and compliance excellence.

In his current role at Beacon Pharmaceuticals PLC, Mr. Sahabuddin provides strategic leadership in ensuring transparency, fostering robust corporate governance practices, and maintaining the highest standards of ethical conduct and regulatory compliance across all levels of the organization. His dynamic leadership and professional acumen continue to contribute significantly to Beacon's sustainable growth and reputation for integrity in the corporate sector.



RAHAMAT ARA HUDA FCA, FCMA

Head of Internal Audit (HIA)

Miss Rahamat Ara Huda FCA, FCMA is an accounting professional having more than 15 years' experience in the field of accounts & finance, strategic planning & budgeting, project & product feasibility analysis, cost management, budget and polices, cost-volume profit analysis, product pricing, financial accounting Plans, fund management, financial operation management, capital budgeting, TAX and VAT management, financial report preparation, financial & other regulatory reporting, internal audit and risk based auditing management. Miss Rahamat Ara Huda FCA, FCMA is playing as Head of Internal Audit at Beacon Pharmaceuticals PLC. As a Chartered Accountant & Cost and Management Accountant she has diversified working experiences in senior leadership position of different organizations.

Miss Rahamat Ara Huda FCA, FCMA has started her career at Anwar Group of Industries. Later she joined Maheen Dizayn Etiket (BD.) Limited and Maheen Label Tex Limited (sister concern of Impress group). Miss Rahamat Ara Huda FCA, FCMA worked Maheen Dizayn Etiket (BD.) Limited and Maheen Label Tex Limited for more than seven years as Departmental Head of Internal Audit, Head of Accounts & Finance and General Manager (Accounts & Finance). Before joined Beacon Pharmaceuticals PLC she worked at Walton Hi- Tech Industries PLC as Deputy & Acting Head of Internal Audit & Compliance. She has completed CA articleship from UHY Syful Shamsul Alam & Co. one of leading Chartered accounting firm in Bangladesh. Miss Rahamat Ara Huda FCA, FCMA is a member of Cost Audit Standard Committee of ICMAB for the year 2025. Miss Rahamat Ara Huda FCA, FCMA is engaged with various professional and social groups and work for development of accounting profession and society.



Rituxim

Rituximab 100 mg & 500 mg Injection

The new treatment paradigm for NHL & CLL



The API of Rituxim has been collected from

BIOCAD
Biopharmaceutical Company

BEACON®
Light for life

LEADING FROM
THE FRONT



FROM LEFT TO RIGHT

Monjurul Alam	Director, Business Development
Md. Jalal Uddin FCA	Chief Financial Officer and Head of IT
S. M. Mahmudul Haque	Executive Vice President, Marketing & Sales
Md. Anisur Rahman Khan	Executive Vice President, Estate and Public Relations
Shams Minhaz Monzur	Executive Vice President, Project Management
Md. Hafiz Imtiaj	Head of Human Resources



FROM LEFT TO RIGHT

S M Foysal Habib	Senior Vice President, Marketing & Sales
Md. Rezaul Karim	Senior Vice President, Marketing & Sales
Bappa Sarker	Senior Vice President, Marketing & Sales
Md. Shahabuddin FCS	Company Secretary
Syeda Shahanawas Shilpi	Vice President, Supply Chain Management
Rahamat Ara Huda FCA, FCMA	Head of Internal Audit

Equip your patient's journey with Safer Metformin

Xelmet XR 500

Metformin Hydrochloride BP



NDMA Risk Free SAFER Metformin

- ❏ USDMF and EDMF grade API
- ❏ Also available as Xelmet 500, 850 mg & XR 1gm tablets

BEACON
Chronic Care

SUSTAINABILITY REPORTING




SUSTAINABILITY REPORTING

AS PER IFRS S1 AND IFRS S2

Beacon Pharmaceuticals PLC has adopted both IFRS S1 and IFRS S2 for the first time, marking a significant shift in how the company reports on sustainability and climate-related risks. IFRS S1 (General Requirements for Disclosure of Sustainability-related Financial Information) sets guidelines for companies to provide comprehensive, transparent, and comparable sustainability disclosures, focusing on governance, strategy, risk management, and metrics. This standard ensures that Beacon Pharmaceuticals PLC aligns its sustainability reporting with global financial reporting standards.

IFRS S2 (Climate-related Disclosures) specifically addresses climate-related risks and opportunities, requiring companies like Beacon Pharmaceuticals PLC to disclose information on their climate impact, including risk management strategies, and targets for addressing climate change. The standard is closely aligned with the recommendations of the Task Force on Climate-related Financial Disclosures (TCFD) and emphasizes transparency in how companies manage and mitigate climate risks.

Beacon Pharmaceuticals PLC adherence to the core content of IFRS S1 & IFRS S2 demonstrates its commitment to transparent and comprehensive sustainability reporting. IFRS S1 outlines key areas for sustainability-related disclosures, including:



Strategy For Sustainability (IFRS S1 & S2)

Beacon's strategy in line with IFRS S1 and S2 revolves around integrating sustainability into their core business model, focusing on both sustainability-related financial risks and climate-related impacts. It has identified Risks and opportunities which are linked with sustainability based on company internal assessment, industry analysis and external forces analysis.

RISKS (IFRS S1)

- Fluctuating foreign exchange rates
- High interest rate
- Strong competition
- Shortage of skilled workers
- High energy and utility costs
- Dependence on imported raw materials
- Price volatility of raw materials

OPPORTUNITIES (IFRS S1)

- Increase export demand
- Low labor cost
- Opportunities of toll manufacturing
- Increase Chronic disease
- Use of renewable energy
- Launch awareness campaigns
- Increase demand of OTC Market medicine

Strategy For Sustainability (IFRS S1 & S2)

Beacon Pharmaceuticals PLC commitment to sustainability is reflected in its comprehensive approach to identifying and addressing climate-related risks and opportunities in alignment with IFRS S2. As climate change increasingly impacts business operations, Beacon recognizes the necessity of integrating climate considerations into its strategic framework. The company has undertaken a rigorous process of assessing both physical risks—such as the effects of extreme weather events on its supply chain and infrastructure—and transition risks, which arise from evolving regulations, market dynamics. Through detailed internal evaluations, industry benchmarking, and analysis of external trends, Beacon has identified a range of sustainability-related opportunities and risks.

The following is a comprehensive list of opportunities and risks that Beacon may identify in accordance with IFRS S2, with a focus on climate-related factors and sustainability considerations.

Climate related risks & opportunities (IFRS S2)

Physical Risks

Acute Risks



Floods



Extreme rainfall



Heat wave

Chronic Risks



Temperature increases



Water scarcity and resource depletion



Sea level rise

Transition Risks

Transition risks related to climate change are associated with the shift towards a low-carbon economy. These risks arise from changes in regulations, market dynamics, technological advancements, and societal expectations. For Beacon, adapting to these transition risks is crucial to maintaining compliance, competitiveness, and resilience in a more climate-conscious landscape. Here's a breakdown of the key climate-related transition risks for Beacon:

Transition Risks



Regulatory risks



Market and consumer preferences



Technology risks



Reputation risks

Climate Related Opportunities (IFRS S2)

Opportunities

Beacon Pharmaceuticals has significant opportunities to leverage climate action as a driver for growth and innovation. As climate change reshapes the healthcare landscape, pharmaceutical companies like Beacon can play a crucial role in promoting environmental sustainability while strengthening their operations. By adopting energy-efficient practices, investing in renewable energy, and innovating with eco-friendly product solutions, Beacon can enhance its resilience, reduce operational costs, and meet the growing demand for sustainable healthcare.

Opportunities



Increase climate related diseases



Attracting sustainable investment

Beacon embarks on its journey toward enhanced sustainability; it is essential to assess the landscape of potential risks and opportunities that may arise. By categorizing these elements based on their occurrence timeframes, Beacon can strategically navigate challenges and leverage advantages associated with sustainability initiatives. The following table summarizes the identified sustainability risks and opportunities along with their expected timeframes for occurrence.

Risks (IFRS S1)	Short Term (1-2 years)	Medium Term (3-5 years)	Long Term (>5 years)
Fluctuating foreign exchange rates	√	√	We expect that it will ease for this timeframe.
High interest rate	√	Beacon plan to reduce term & short loan	This risk will be very little in this timeframe.
Strong competition	√	√	√
Shortage of skilled workers	√	√	This risk will be reduced in this timeframe.
High energy and utility costs	√	√	May be reduced.
Dependence on imported raw materials	√	√	May be reduced.
Price volatility of raw materials	√	√	√

Opportunities (IFRS S1)	Short Term (1-2 years)	Medium Term (3-5 years)	Long Term (>5 years)
Increase export demand	√	√	√
Low labor cost	√	√	√
Increase demand of OTC Market medicine	√	√	√
Opportunities of toll manufacturing	√	√	√
Increase Chronic disease	√	√	√
Use of renewable energy	√	√	√
Launch awareness campaigns	√	√	√

Physical risks (Acute risks)

Climate related risks (IFRS S2)	Short Term (1-2 years)	Medium Term (3-5 years)	Long Term (>5 years)
Floods	√	√	√
Extreme rainfall	√	√	√
Heat wave	√	√	√

Physical risks (Chronic risks)

Climate related risks (IFRS S2)	Short Term (1-2 years)	Medium Term (3-5 years)	Long Term (>5 years)
Temperature increases	√	√	√
Water scarcity and resource depletion	√	√	√
Sea level rise	√	√	√

Transition risks

Climate related risks (IFRS S2)	Short Term (1-2 years)	Medium Term (3-5 years)	Long Term (>5 years)
Regulatory Risks	√	√	√
Market and Consumer Preferences	√	√	√
Technology Risks	√	√	√
Reputation Risks	√	√	√

Climate related opportunities

Climate Related Opportunities (IFRS S2)	Short Term (1-2 years)	Medium Term (3-5 years)	Long Term (>5 years)
Increase climate related diseases	√	√	√
Attracting Sustainable Investment	√	√	√

Impact of Risks and Opportunities on Financial Position, Profit or Loss Statement and Cash Flow

For Beacon, aligning with IFRS S1 (general sustainability-related disclosures) and IFRS S2 (climate-related disclosures) requires analyzing risks and opportunities that impact its financial position, profit or loss statement, and cash flow. This involves identifying how sustainability and climate-related risks affect the company's revenue, operating costs, asset valuation, and financial resilience. Below is a summary of the key impacts Beacon might encounter on each of these financial statements.

Risks (IFRS S1)	Financial Position	Profit or Loss Statement	Cash Flow
Fluctuating foreign exchange rates	It has impact on financial position in short, medium term and long term due to dependency on import of raw material.	It has impact on Profit or Loss Statement in short, medium term and long term due to dependency on import of raw material.	It has impact on cash flow in short, medium term and long term due to dependency on import of raw material.
High interest rate	Interest rate risk will impact on financial position in short and medium term and ease in long term.	Interest rate risk will impact on Profit or Loss Statement in short and medium term and ease in long term.	Interest rate risk will impact on cash flow in short and medium term and ease in long term.
Strong competition	The financial position will be impacted by strong competition in short, medium and long term.	The profit & loss statement will be impact-ed by strong competition in short, medium and long term.	The cash flow will be impacted by strong competition in short, medium and long term.
Shortage of skilled workers	A shortage of skilled labor impacts the financial position by increasing operational costs, potentially leading to lower productivity, delayed project timelines, and higher recruitment and training expenses in short, medium and long term.	A shortage of skilled labor impacts the profit or loss statement by increasing operational costs, potentially leading to lower productivity, delayed project timelines, and higher recruitment and training expenses in short, medium and long term.	Shortage of skilled labor impacts the cash flow statement and need to pay more cash due to increase operational costs, potentially leading to lower productivity, delayed project timelines, and higher recruitment and training expenses in short, medium and long term.

Risks (IFRS S1)	Financial Position	Profit or Loss Statement	Cash Flow
 High energy and utility costs	High energy and utility costs impact the financial position by increasing operating expenses, which can reduce overall profitability and erode cash reserves. These higher costs may strain profit margins, particularly if the company cannot pass on the increased expenses to customers through price adjustments. Over time, persistently high energy-efficient costs can necessitate additional capital expenditures on energy technology or infrastructure upgrades. This cost has huge impact in short, medium and long-term.	High energy and utility costs impact profit or loss by raising operating expenses, which can directly reduce profit margins if these increased costs cannot be offset by higher product prices. This erodes profitability, particularly in energy -intensive operations, as a greater portion of revenue goes toward covering these basic expenses. Additionally, high utility costs can lead to reduced production if companies cut back to save energy, potentially lowering sales revenue and further impacting net income. This cost has huge impact in short, medium and long-term.	Shortage of skilled labor impacts the cash flow statement and need to pay more cash due to increase operational costs, potentially leading to lower productivity, delayed project timelines, and higher recruitment and training expenses in short, medium and long-term.
 Dependence on imported raw materials	Heavy dependence on imported raw materials impact the financial position by increasing vulnerability to exchange rate fluctuations, which can raise costs and reduce profitability when local currency weakens. Additionally, reliance on imports may lead to higher logistical expenses and increased exposure to supply chain disruptions, which can interrupt production and impact revenue. Import dependency has short, medium & long-term impact.	Heavy dependence on imported raw materials impacts profit or loss by making the company susceptible to currency fluctuations, which can increase costs when the exchange rate is unfavorable, thereby reducing profit margins. Additionally, reliance on imports can lead to higher transportation and customs expenses, further impacting profitability. Supply chain disruptions, such as delays or shortages, can cause production slowdowns, potentially resulting in lost sales and revenue. These factors collectively reduce profitability, as the cost of goods sold rises and revenue generation becomes more unpredictable. Import dependency has short, medium & long-term impact.	Heavy dependence on imported raw materials impacts cash flow by increasing cash outflows due to potential fluctuations in import costs, which can rise with changes in exchange rates or transportation expenses. Delays in the supply chain can lead to increased inventory holding costs and necessitate larger cash reserves to manage production disruptions. These factors can lead to a tighter cash flow situation and increase financial risk. Import dependency has short, medium & long-term impact.

RISKS (IFRS S1)	Financial Position	Profit or Loss Statement	Cash Flow
 Price volatility of raw materials	Price volatility of raw materials impact the financial position by introducing uncertainty into cost management and profitability forecasting. When raw material prices fluctuate significantly, it can lead to unpredictable costs of goods sold, affecting profit margins and also This can strain cash reserves and financial flexibility. It has impact on short, medium and long-term.	Price volatility of raw materials impacts profit or loss by causing fluctuations in the cost of goods sold, which can directly affect profit margins. When raw material prices rise unexpectedly, companies may face increased production costs that can reduce profitability. It has impact on short, medium and long-term.	Price volatility of raw materials impacts cash flow by creating uncertainty in cash outflows related to procurement and production costs. When raw material prices fluctuate, it can lead to unpredictable cash requirements, making it challenging to manage working capital effectively. It has impact on short, medium and long-term.
Opportunities (IFRS S1)	**Financial Position**	**Profit or Loss Statement**	**Cash Flow**
 Increase export demand	Increased export demand strengthens a company's financial position by boosting assets, particularly cash, accounts receivable, and inventory, as sales grow and production ramps up to meet international demand and it has also impact short, medium and long-term business strategy.	Increased export demand can significantly impact the profit or loss statement of a company, usually boosting revenue and profitability, although it may also introduce new expenses. Here's how higher export demand affects each major component of the profit or loss statement. it has also impact short, medium and long-term business strategy.	An increase in export demand typically boosts cash inflows from sales within operating activities, as higher revenue from international markets enhances liquidity. To support this growth, the company might invest in new equipment or facilities, resulting in outflows in investing activities.it has also impact short, medium and long- term business strategy.
 Low labor cost	Low labor costs positively impact a company's financial position by reducing operating expenses, which in turn boosts profitability and enhances retained earnings, strengthening equity. This benefit will continue for good period of time.	Low labor costs positively impact the profit or loss statement by reducing the cost of goods sold (COGS) or operating expenses, directly increasing gross profit and operating profit margins. We hope this benefit will continue for good period of time.	Low labor costs positively impact cash flow by reducing operating expenses, leading to higher cash inflows from operating activities as the company retains more of its revenue as profit. We hope this benefit will continue for good period of time.

Opportunities (IFRS S1)	Financial Position	Profit or Loss Statement	Cash Flow
 Opportunities of toll manufacturing	Toll manufacturing for other products provide significant opportunities that can positively impact a company's balance sheet by diversifying its revenue streams and optimizing its asset management engaging in toll manufacturing, a company can generate additional income without the need for heavy capital investments in new production facilities or equipment, thereby minimizing capital expenditures and reducing associated depreciation costs. It has short, medium and long term impact on business.	Toll manufacturing for other products create substantial opportunities that can positively impact a company's profit or loss statement by generating additional revenue streams without the overhead of developing new products or investing in manufacturing infrastructure. By producing goods for other companies, the company can earn service fees or margins on production without incurring significant costs. It has short, medium and long term impact on business.	Toll manufacturing for other products offer significant opportunities to enhance cash flow by creating additional revenue streams with relatively low upfront investment and operational risk. By entering into toll manufacturing agreements, a company can generate immediate cash inflows from production contracts without the need for substantial capital expenditures on equipment or facilities. It has short, medium and long term impact on business.
 Increase Chronic disease	An increase in chronic disease prevalence can impact a company's balance sheet. Increased demand for chronic disease treatments boosts revenues, contributing to stronger cash reserves and higher accounts receivable if sales are made on credit, thereby increasing current assets.	An increase in chronic disease prevalence positively impacts a pharmaceutical company's profit or loss statement by driving sustained demand for medications that treat these conditions, resulting in higher sales revenue and improved gross profit margins. Chronic diseases typically require ongoing treatment, leading to repeat purchases and stable, long-term revenue streams.	An increase in chronic disease prevalence positively impacts a pharmaceutical company's cash flow by generating consistent and recurring revenue from the ongoing demand for medications and treatments. As patients require long-term prescriptions and therapies, the company experiences a steady influx of cash from sales.
 Use of renewable energy	The use of renewable energy positively impacts a company's balance sheet by reducing operating costs and enhancing asset value over time. By investing in renewable energy sources, such as solar or wind power, companies can decrease their reliance on fossil fuels, leading to lower energy expenses and improved profit margins.	The use of renewable energy positively impacts a company's profit or loss statement by reducing energy costs and enhancing overall profitability. By investing in renewable energy sources, such as solar or wind, companies can lower their utility expenses, resulting in a decreased cost of goods sold and improved gross profit margins.	The use of renewable energy has a positive impact on cash flow by significantly reducing energy costs and providing more predictable expense management. By transitioning to renewable energy sources such as solar or wind, companies can lower their utility bills, resulting in increased cash inflows from operating activities.

Opportunities (IFRS S1)	Financial Position	Profit or Loss Statement	Cash Flow
Launch awareness campaigns	Launching awareness campaigns positively impacts a company's balance sheet by enhancing brand equity and potentially driving revenue growth through increased customer engagement and loyalty. These campaigns can lead to higher sales volumes as consumers become more informed about the company's products.	Launching awareness campaigns positively impacts a company's profit or loss statement by driving increased sales and enhancing overall profitability. By educating consumers about the benefits and features of products or services, these campaigns can lead to higher demand, resulting in increased revenues.	Launching awareness campaigns can have a positive impact on cash flow by driving increased sales and generating more immediate cash inflows from customer purchases. As awareness of the brand or products grows, the company may experience a surge in demand, leading to higher revenues and quicker cash collections from sales.
Increase demand of OTC Market medicine	An increase in demand for over-the-counter (OTC) market medicines significantly enhances a company's financial position by boosting revenues and improving cash flow from operations. Higher sales translate into increased cash inflows, which can strengthen the company's liquidity and overall cash reserves. This opportunities will be for short, medium and long-term.	An increase in demand for over-the-counter (OTC) market medicines positively impacts the profit or loss statement by driving higher sales revenue, which directly boosts gross profit margins. As demand surges, the company can benefit from economies of scale. This opportunities will be for short, medium and long-term.	An increase in demand for over-the-counter (OTC) market medicines leads to higher cash inflows from sales, significantly enhancing cash flow from operating activities. As customers purchase more OTC products, the company experiences an uptick in revenue, improving liquidity. This opportunities will be for short, medium and long-term.
RISKS (IFRS S2)	**Financial Position**	**Profit or Loss Statement**	**Cash Flow**
 Floods	Floods can significantly impact a company's balance sheet by causing substantial damage to physical assets, inventory, and infrastructure, leading to increased liabilities and reduced asset values. When flooding occurs, companies may face immediate costs related to repairs, replacement of damaged goods, and disruptions in operations, which can strain cash reserves and affect working capital.	Floods can have a detrimental impact on a company's profit or loss statement by disrupting operations and leading to significant financial losses. The immediate effects of flooding often include damage to inventory, equipment, and facilities, resulting in increased costs for repairs and replacement, which elevate the cost of goods sold and reduce gross profit margins.	Floods can severely impact a company's cash flow by causing immediate disruptions to operations and incurring unexpected expenses. The damage to physical assets and inventory often leads to increased cash outflows for repairs, replacements, and recovery efforts, straining available cash reserves. Additionally, operational interruptions may result in lost sales and delayed revenue.

Risks (IFRS S2)	Financial Position	Profit or Loss Statement	Cash Flow
 Extreme rainfall	Extreme rainfall significantly impacts a company's balance sheet by disrupting operations and affecting asset values. Additionally, operational disruptions can affect cash flow and revenue generation, leading to a decline in current assets, such as accounts receivable, if sales are lost during the interruption.	Extreme rainfall can adversely impact a pharmaceutical company's profit or loss statement by disrupting production and increasing operational costs. When heavy rainfall causes facility damage or leads to production delays, the company may experience significant losses in revenue due to an inability to meet customer demand or fulfill orders.	Extreme rainfall can significantly impact a pharmaceutical company's cash flow by disrupting operations and incurring unexpected expenses. When heavy rainfall damages facilities or equipment, the company may face immediate cash outflows for repairs and replacements, straining available cash reserves.
 Heat wave	A heat wave can significantly impact a pharmaceutical company's balance sheet by affecting operational efficiency, asset values, and overall financial stability. Additionally, if the company experiences product spoilage, particularly for temperature-sensitive pharmaceuticals, this can result in significant write-offs, further diminishing asset values.	The heat wave causes spoilage of temperature-sensitive products, the company may incur significant losses in inventory value, contributing to a higher cost of goods sold and lowering gross profit margins. Increased energy costs for cooling and maintaining optimal storage conditions further strain operating expenses, potentially eroding net income.	If temperature-sensitive products spoil due to inadequate storage conditions, the company could face unexpected inventory write-offs, further reducing cash reserves. Additionally, the increased energy costs associated with cooling facilities can lead to higher operating expenses, straining cash flow from operating activities.
 Temperature increases	Temperature increases can significantly impact the balance sheet of Beacon Pharma by heightening the risk of spoilage and degradation of temperature-sensitive pharmaceutical products, which could lead to substantial write-offs and decreased inventory values. The combination of increased costs, decreased asset values, and potential impacts on liquidity could weaken Beacon Pharma's financial position, reflecting negatively on its balance sheet.	Temperature increases can adversely affect the profit or loss statement of Beacon Pharma by increasing the risk of product spoilage and operational disruptions. When temperatures rise, there is a higher likelihood that temperature-sensitive medications may degrade, leading to inventory write-offs that directly increase the cost of goods sold and reduce gross profit margins.	Temperature increases can negatively impact the cash flow of Beacon Pharma by leading to increased operational costs and potential revenue losses. As temperatures rise, the risk of spoilage for temperature-sensitive pharmaceutical products increase, resulting in unexpected write-offs and reduced cash inflows from inventory.

Risks (IFRS S2)	Financial Position	Profit or Loss Statement	Cash Flow
Water scarcity and resource depletion	Water scarcity and resource depletion can have a profound impact on the balance sheet of Beacon Pharma by increasing operational costs and potentially limiting production capacity. As water becomes scarcer, the company may face higher costs for sourcing and managing water resources, which can lead to increased operating expenses reflected in the balance sheet.	Water scarcity and resource depletion can significantly impact the profit or loss statement of Beacon Pharma. If water scarcity disrupts manufacturing processes, it can result in lower production volumes and lost sales, negatively affecting revenue generation. Overall, the challenges posed by water scarcity and resource depletion can lead to increased costs and decreased revenues, ultimately harming the profitability of Beacon Pharma.	Water scarcity and resource depletion can adversely affect the cash flow of Beacon Pharma by increasing operational costs and potentially disrupting production. Overall, the challenges presented by water scarcity and resource depletion can create significant cash flow pressures for Beacon Pharma.
Sea level rise	Sea level rise can significantly impact the balance sheet of Beacon Pharma by posing risks to its physical assets and operational infrastructure, particularly if facilities are located in vulnerable coastal areas. Increased flooding and storm surges can lead to damage or loss of buildings, equipment, and inventory.	Sea level rise can adversely impact the profit or loss statement of Beacon Pharma by disrupting operations and increasing costs associated with damage control and mitigation efforts. Overall, the financial consequences of sea level rise can lead to decreased revenues and increased expenses, ultimately harming the profitability of Beacon Pharma.	Sea level rise can significantly impact the cash flow of Beacon Pharma by causing disruptions in operations and increasing unexpected costs. Overall, the financial pressures resulting from sea level rise can create significant cash flow challenges for Beacon Pharma, pursue growth opportunities.
Regulatory risks	Regulatory risks can significantly impact the balance sheet of Beacon Pharma by introducing uncertainties that may affect asset valuations and increase liabilities. Overall, the uncertainties and potential financial burdens associated with regulatory risks can lead to diminished asset values and increased liabilities, reflecting negatively on Beacon Pharma's balance sheet.	Climate-related regulatory risks can significantly impact the profit or loss statement of Beacon Pharma by introducing additional compliance costs and potential operational disruptions. As governments and regulatory bodies increasingly implement stricter environmental regulations to address climate change. Overall, the financial implications of climate-related regulatory risks can create significant challenges for Beacon Pharma, resulting in increased costs and potential revenue losses, thereby adversely affecting its profitability.	If Beacon Pharma fails to comply with these regulations, it may face fines, legal liabilities, and potential disruptions in production, all of which can result in unexpected cash outflows. Furthermore, adapting to climate-related regulations might require changes in supply chain management, potentially increasing costs for raw materials and logistics.

Risks (IFRS S2)	Financial Position	Profit or Loss Statement	Cash Flow
 Market and consumer preferences	Market and consumer preferences related to climate issues can significantly influence the balance sheet of Beacon Pharma by affecting asset values and operational strategies. As consumers increasingly demand environmentally friendly and sustainable products, Beacon Pharma may need to invest in greener manufacturing processes, sustainable sourcing of raw materials, and environmentally conscious packaging solutions, which can increase fixed assets on the balance sheet. Overall, the need to align with evolving market and consumer preferences regarding climate change can lead to increased capital expenditures and potential reductions in asset values, reflecting on Beacon Pharma's balance sheet.	Market and consumer preferences related to climate issues can have a significant impact on the profit or loss statement of Beacon Pharma by influencing sales and operational costs. As consumers become more environmentally conscious, there is an increasing demand for sustainable and eco-friendly pharmaceutical products. If Beacon Pharma fails to adapt to these changing preferences, it may experience a decline in sales and market share, adversely affecting revenue. Overall, the interplay between market preferences and climate-related considerations can significantly influence Beacon Pharma's financial performance.	Market and consumer preferences related to climate change can significantly impact the cash flow of Beacon Pharma by influencing both revenue generation and operational expenditures. As consumers increasingly seek environmentally sustainable and responsibly produced pharmaceutical products, Beacon Pharma may need to invest in greener production processes and sustainable sourcing, resulting in higher upfront capital expenditures that can strain cash flow.
 Technology risks	Climate-related technology risks can have a substantial impact on the balance sheet of Beacon Pharma by affecting asset values and capital structure. As the company faces pressure to adopt sustainable technologies and practices, significant investments in new equipment, renewable energy sources, and environmentally friendly production processes may increase fixed assets on the balance sheet.	Climate-related technology risks can significantly impact the profit or loss statement of Beacon Pharma by influencing operational costs and revenue generation. As the pharmaceutical industry moves toward more sustainable practices, Beacon Pharma may face substantial expenses related to the development and implementation of new technologies aimed at reducing carbon emissions and increasing energy efficiency.	it may experience substantial cash outflows for equipment upgrades, energy-efficient systems, and waste management solutions. These investments can strain short-term cash flow, especially if the expected financial returns take time to materialize. Ultimately, how effectively Beacon Pharma manages these climate-related technology risks will be crucial for maintaining healthy cash flow.

Risks (IFRS S2)	Financial Position	Profit or Loss Statement	Cash Flow
Reputation risks	Climate-related reputation risks can have a significant impact on the balance sheet of Beacon Pharma by affecting asset values and stakeholder perceptions. If the company is perceived as environmentally irresponsible or failing to take adequate measures to address climate change, it may face a decline in consumer trust and brand equity. Overall, the financial repercussions of reputation risks related to climate issues can result in diminished asset values and increased liabilities, thereby adversely affecting Beacon Pharma's balance sheet.	Reputation risks related to climate change can significantly impact the profit or loss statement of Beacon Pharma by affecting consumer behavior and sales. If the company is perceived as not adequately addressing environmental concerns, it may face backlash from consumers and stakeholders, leading to decreased brand loyalty and reduced market demand for its products. This decline in sales can negatively impact revenue, thereby affecting overall profitability.	Reputation risks related to climate change can significantly affect the cash flow of Beacon Pharma by influencing consumer purchasing decisions and increasing operational costs. If the company is perceived as failing to address environmental concerns, it may experience a decline in sales and revenue, leading to reduced cash inflows from operations. Overall, the financial impact of reputation risks associated with climate change can create significant cash flow challenges for Beacon Pharma, affecting its ability to fund operations and invest in growth opportunities.
Opportunities (IFRS S2)	**Financial Position**	**Profit or Loss Statement**	**Cash Flow**
Increase climate related diseases	The rise in climate-related diseases present a significant opportunity for Beacon Pharma, potentially impacting its balance sheet positively. As climate change contributes to the spread and severity of diseases like respiratory illnesses, vector-borne infections, and heat-related conditions, the demand for pharmaceuticals targeting these issues are expected to grow. This increased demand and expanded product line can strengthen both the revenue and asset sides of Beacon Pharma's balance sheet, driving profitability and overall financial resilience.	The increase in climate-related diseases offers a promising growth opportunity for Beacon Pharma, with a likely positive impact on its profit or loss statement. As climate change drives a rise in diseases such as respiratory issues, infectious diseases, and heat-related ailments, demand for medications in these areas are expected to surge. Additionally, new product offerings tailored to climate-sensitive health needs may strengthen Beacon's competitive edge, support revenue growth and potentially increasing net profit margins over time.	The rise in climate-related diseases present Beacon Pharma with an opportunity to enhance its cash flow. As demand for treatments addressing climate-sensitive health issues grow-such as those for respiratory ailments and vector-borne diseases. Beacon can experience increased sales, resulting in stronger operating cash flows. Over time, this sustained demand for climate-related therapies could create a more resilient, steady cash flow stream, supporting Beacon's ongoing growth and financial stability.

Opportunities (IFRS S2)	Financial Position	Profit or Loss Statement	Cash Flow
 Attracting sustainable investment	Attracting sustainable investment in response to opportunities related to climate-sensitive diseases can positively impact Beacon Pharma's balance sheet. Beacon Pharma not only diversifies its capital sources but also positions itself as a robust, socially responsible investment, enhancing its balance sheet and financial resilience.	Attracting sustainable investment for addressing climate-related diseases can positively influence Beacon Pharma's profit or loss statement. Overall, sustainable investment allows Beacon to expand its offerings while reducing costs, contributing to increased profitability and improved financial performance.	Attracting sustainable investment to develop treatments for climate-related diseases can significantly enhance Beacon Pharma's cash flow. This strengthened cash flow provides a solid foundation for reinvestment in further innovation and strategic growth, fostering long-term financial health and flexibility.

Key Strengths of Xaloplat Aqua

- Increased Drug Availability in the Body
- Rapid Onset of Therapeutic Effect
- Convenient Mode of Administration
- With Complimentary 5% DA




1ST TIME EVER IN BANGLADESH


Xaloplat AQUA
Oxaliplatin
200 mg



Xaloplat AQUA
Oxaliplatin

BEACON®
Light for life


Floods
Extreme rainfall
Heat wave
Temperature increases
Water Scarcity and Resource Depletion
Sea Level Rise
Regulatory Risks
Market and Consumer Preferences
Technology Risks
Reputation Risks
Price volatility of raw materials
Dependence on imported raw materials
High energy and utility costs
Shortage of skilled workers
Strong competition
High interest rate
Fluctuating FX rates
IFRS S2
IFRS S1
Risk
Business Model
Product Portfolio
R & D
Manufacturing
Market Focus
Infrastructure
Human Resources (HR) Management
Technological Development
Procurement
Inbound Logistics
Operation
outbound Logistics
Marketing & Sales
Services
Regulatory Compliance
Sustainability and CSR
Sales and Distribution
Customer Relationship


Opportunities IFRS S1
Opportunities IFRS S2
Increase export demand
Low labor cost
Increase demand of OTC market medicine
Opportunities of toll manufacturing
Increase chronic disease
Use of renewable energy
Launch awareness campaigns
Increase climate related diseases
Attracting sustainable investment

Strategy To Address Risks And Opportunities

Beacon strategy to address climate-related risks and opportunities, in alignment with IFRS S1 and S2, emphasizes resilience, growth, and sustainability across its operations. To mitigate risks, Beacon is enhancing supply chain adaptability, strengthening compliance with evolving environmental regulations, and investing in energy-efficient technologies to reduce operational vulnerabilities. Recognizing the opportunities presented by climate-sensitive health needs, Beacon is expanding its product range which are impacted by climate change, and adopting sustainable sourcing and packaging practices to appeal to eco-conscious markets.

Risks as per IFRS S1

Strategy to address risks

	Short term (1-2 years)	Medium term (3-5 years)	Long term (> 5 years)
Fluctuating foreign exchange rates	1. Scenario planning 2. Improving cash flow management	1. Diversifying currency exposure 2. Dynamic financial planning	1. Long-term hedging programs 2. Pricing power development
High interest rate	1. Negotiate better terms 2. Improve cash flow management	1. Diversify funding sources 2. Utilize retained earnings to reduce loan	1. Create a Comprehensive financial strategy 2. Review capital structure regularly
Strong competition	1. Aggressive marketing campaigns 2. Competitive pricing	1. Product line expansion 2. Enhance brand loyalty programs	1. Brand positioning strategy 2. Sustainable practices integration
Shortage of skilled workers	1. Competitive compensation packages 2. Upskilling programs for current staff	1. Employer branding initiatives 2. Customized training and development	1. Invest in technology and automation 2. Develop a culture of continuous learning

Opportunities As Per IFRS S1

Strategy to address opportunities

	Short term (1-2 years)	Medium term (3-5 years)	Long term (> 5 years)
Increase export demand	1. Identify high-demand markets 2. Secure export licenses and certifications	1. Expand product range for export 2. Enhance brand image and reputation	1. Develop a sustainable export model 2. Continuously innovate and expand portfolio
Low labor cost	1. Identify low-cost labor 2. Provide training to enhance productivity	1. Build strong relationships with local workers 2. Implement employee incentive programs	1. Develop sustainable practices in production
Increase demand of OTC market medicine	1. Launch targeted marketing campaigns 2. Optimize product placement in retail	1. Expand product line 2. Monitor and adapt to consumer trends	1. Explore customization of OTC products 2. Build a strong brand identity
Opportunities of toll manufacturing	1. Identify potential toll manufacturers 2. Establish clear partnership agreements	1. Build long-term relationships with partners 2. Implement cost-effective production strategies	1. Evaluate and optimize toll manufacturing partners 2. Engage in strategic alliances
Increase chronic disease	1. Market research on chronic disease trends 2. Product line expansion	1. Develop specialized chronic disease medications 2. Launch a chronic disease product	1. Expand to emerging markets 2. Chronic disease awareness campaign
Launch awareness campaigns	1. Employee awareness program 2. Customer awareness	1. Sustainable packaging awareness 2. Community health & environment campaigns	1. Behavioral change campaigns 2. Advocacy & policy campaigns

Climate Related Risks As Per IFRS S2

Strategy to address climate related risks

	Short term (1-2 years)	Medium term (3-5 years)	Long term (> 5 years)
Floods	Conduct flood risk assessments	Invest in flood-resilient infrastructures	Invest in climate-resilient facilities
Extreme rainfall	Develop an extreme weather emergency plan	Invest in resilient infrastructure	Incorporate climate resilience into corporate strategy
Heat wave	Conduct heat risk assessments	Increase green spaces around facilities	Invest in renewable energy solutions
Temperature increases	Conduct temperature risk assessments	Invest in energy-efficient equipment	Invest in advanced Cooling technologies
Water scarcity and resource depletion	Provide training on water-saving techniques	Optimize manufacturing processes	Promote water-efficient R&D
Sea level rise	Identify high-risk locations	Participate in community sea level rise adaptation plans	Promote coastal resilience research

Climate Related Risks As Per IFRS S2

	Short term (1-2 years)	Medium term (3-5 years)	Long term (> 5 years)
Regulatory risks	Enhance reporting practices	Develop an Internal climate compliance audit program	Prepare frameworks for potential climate liability risks
Market and consumer preferences	Conduct market research on consumer preferences	Expand eco-friendly product options	Redesign product life cycles for sustainability
Technology risks	Develop a technology resilience plan	Optimize network resilience	Engage in climate-related technology advocacy
Reputation risks	Increase transparency with regular updates	Develop a Corporate Social Responsibility (CSR) program	Work toward zero waste operations

Climate Related Opportunities As Per IFRS S2

Strategy to address climate related opportunities

	Short term (1-2 years)	Medium term (3-5 years)	Long term (> 5 years)
Increase climate related diseases	Research on key climate-related diseases	Invest in R&D for climate-resilient medicines	Engage in climate-health policy advocacy
Attracting sustainable investment	Develop a comprehensive sustainability report	Publish an annual climate impact report	Introduce sustainable health products for climate-related diseases

Resilience Strategy For Sustainability Related Risks

Beacon Pharmaceuticals PLC resilience strategy, in line with IFRS S1 and S2, focuses on identifying, assessing, and mitigating sustainability and climate-related risks to safeguard long-term value creation. The strategy integrates climate risks—both physical and transitional—into the company's risk management framework, ensuring the resilience of operations, supply chains, and financial performance. By implementing robust risk assessment processes, Beacon aims to enhance its ability to adapt to the impacts of climate change, including regulatory changes, market shifts, and environmental events. The company's strategy also includes clear action plans to manage and disclose climate-related risks, with a focus on reducing emissions, ensuring resource efficiency, and aligning its business model with sustainable practices that contribute to long-term environmental and financial stability.

Here is a list of resilience strategies for managing sustainability & climate-related risks at Beacon Pharma, structured in accordance with IFRS S1 and S2, categorized for practical application. This includes various measures that Beacon can implement to address both physical and transitional climate risks, as well as their governance and disclosure requirements.

Resilience Strategy	Category	Short term 1-2 Years	Medium term 3-5 Years	Long term >5 Years
Develop a comprehensive climate risk management framework	Governance	Establish initial risk management structure	Enhance data collection systems	Integrate climate risks into corporate governance
Conduct climate risk scenario analysis	Risk Management	Conduct initial risk assessments	Analyze long-term climate scenarios	Regularly update scenario analysis based on new data
Set short- and long-term climate-related goals	Strategy	Establish immediate sustainability targets	Review and adjust targets based on progress	Integrate into long-term strategic planning
Implement a Climate Risk Task Force	Governance	Form a cross-departmental team	Expand task force responsibilities	Ensure ongoing governance and risk oversight
Disclose climate-related risks and opportunities in annual reports	Reporting	Publish initial climate risk disclosures	Regularly update and refine disclosures	Align disclosures with global frameworks
Identify and assess physical climate risks (flooding, temperature rise)	Risk Management	Begin assessing immediate physical risks	Expand risk assessments to include diverse regions	Conduct regula re-assessment of physical risks
Map supply chain vulnerabilities to climate impacts	Risk Management	Identify vulnerable supply chain points	Develop strategies for supply chain resilience	Long-term supply chain redesign for resilience
Develop climate-resilient infrastructure	Operations	Begin evaluating infrastructure vulnerabilities	Implement adaptive infrastructure solutions	Fully integrate resilient infrastructure into facilities
Integrate renewable energy sources into operations	Operations	Pilot renewable energy projects	Scale renewable energy adoption	Try to achieve low carbon-energy consumption
Enhance employee training on climate change impacts	Human Resources	Conduct awareness training sessions	Provide ongoing training opportunities	Integrate climate change in leadership development
Incorporate climate risk into financial risk models	Financial Management	Modify financial models to account for climate risk	Refine financial models for greater accuracy	Fully integrate climate risk into financial strategies

Resilience Strategy	Category	Short term 1-2 Years	Medium term 3-5 Years	Long term >5 Years
Identify and address regulatory risks related to climate change	Risk Management	Monitor climate-related regulations	Develop policies to adapt to regulatory changes	Advocate for favorable climate regulations
Strengthen disaster recovery and business continuity plans	Operations	Review current plans for climate-related scenarios	Update and test plans for resilience	Ensure plans are continuously refined and practiced
Explore climate-risk insurance options	Risk Management	Evaluate climate-related insurance policies	Investigate new insurance products	Integrate climate risks into long-term insurance strategy
Support sustainable product innovations	Product Development	Start with green product initiatives	Scale up eco-friendly product offerings	Become an industry leader in sustainable products
Promote internal resource efficiency (energy, waste, materials)	Operations	Introduce quick resource efficiency measures	Implement company-wide efficiency programs	Achieve industry-leading resource efficiency
Monitor climate changing trends and their business impacts	Risk Management	Set up an early warning system for climate events	Integrate trend monitoring into operational planning	Establish long-term climate forecasting systems
Develop a climate-aligned financial risk management strategy	Financial Management	Identify key financial risks related to climate	Design strategies to mitigate climate financial risks	Long-term climate risk-aligned capital allocation
Invest in adaptive technologies for operations and manufacturing	Innovation	Pilot adaptive technologies for climate resilience	Scale up investment in climate-resilient technologies	Lead in technological innovation for climate resilience
Design a climate risk disclosure framework for investors	Reporting	Publish first climate risk disclosure for investors	Align disclosures with emerging global standards	Continuously update to comply with evolving standards
Build climate risk considerations into the corporate culture	Corporate Culture	Initiate climate awareness across teams	Cultivate a culture of sustainability within the company	Deeply embed sustainability into company values
Set targets for reducing climate-related supply chain disruptions	Risk Management	Identify areas with potential climate disruptions	Create contingency plans for supply chain risks	Achieve robust, climate- resilient supply chain management
Develop a detailed climate adaptation strategy for operations	Strategy	Create initial adaptation plans for key operations	Implement key adaptation strategies	Continuously update adaptation plans as climate impacts evolve

Risk Management of Sustainability Risks and Opportunities

Beacon Pharmaceuticals PLC risk assessment in alignment with IFRS S1 and S2 involves a comprehensive approach to evaluating climate-related risks that could impact its financial position, operations, and long-term growth. Under IFRS standards, risks are categorized as physical, transition, and financial, each with its unique implications for Beacon's business and value chain. Physical risks encompass both acute and chronic climate-related disruptions. Acute risks, such as extreme weather events, pose immediate threats to Beacon's facilities and logistics, potentially causing delays in production and distribution, which could lead to revenue losses and increased operational costs. Chronic risks, like prolonged temperature changes, affect the availability of essential resources such as water, which is critical for pharmaceutical manufacturing. These shifts may also increase the demand for treatments related to climate-sensitive diseases, influencing Beacon's product strategy and operational adjustments. In response, Beacon is investing in resilient infrastructure, including flood-resistant manufacturing sites and climate-controlled storage facilities, while also diversifying its supplier base to ensure continued operations even during climate events.

Finally, financial risks associated with climate-related events include potential increases in capital costs, insurance premiums, and operating expenses, all of which could affect Beacon's financial resilience. With investors increasingly prioritizing companies with strong ESG practices, Beacon's commitment to IFRS S1 and S2 is essential to maintain access to sustainable investment.

We follow following risk management process to address sustainability risks and opportunities



Risks	Risks Assessment Process	Priority
Fluctuating foreign exchange rates	Continuous monitoring of currency trends, with financial modeling to predict potential impacts on costs and revenues.	Medium
High Interest Rate	Regular analysis of economic trends, monitoring interest rate changes, and modeling potential impacts on financial metrics.	High
Strong competition	Ongoing market analysis to monitor competitor activities, product pricing, and new market entrants; evaluation of market trends.	High
Shortage of skilled workers	Workforce analysis through regular skill gap assessments, industry benchmarking, and feedback from HR on recruitment trends.	Medium
High energy and utility costs	Regular monitoring of energy cost trends, utility rate forecasts, and analysis of energy consumption patterns across facilities.	High
Heavy dependence on imported raw materials	Regular analysis of supply chain reliability, supplier risk assessments, and monitoring of geopolitical developments in key sourcing regions.	High
Price volatility of raw materials	Regular monitoring of raw material price trends, market analysis of commodity markets, and review of supplier pricing changes.	High

Opportunities	Risks Assessment Process	Priority
Increase export demand	Monitor and assess potential risks related to foreign regulations, trade barriers, and market volatility.	High
Low labor cost	Assess risks related to labor strikes, quality issues, or wage inflation.	High
Increase demand of OTC market medicine	Assess potential risks related to regulatory changes, market saturation, or increased competition.	High
Opportunities of toll manufacturing	Identify risks related to quality control, reliance on external partners, regulatory compliance, and potential supply chain disruptions.	Medium
Increase chronic disease	Identify risks such as market competition, regulatory hurdles, pricing pressures, or changes in patient access to healthcare.	High
Use of renewable energy	Identify risks related to initial capital investment, fluctuating renewable energy prices, potential supply interruptions, and regulatory challenges.	High
Launch awareness campaigns	Identify risks related to message misinterpretation, ineffective targeting, potential regulatory non-compliance, and competition.	Medium

THE LIPOSOMAL FORMULATION

Becobion

1st Time in Bangladesh

Vitamin B_1 + B_6 + B_{12}

The first & only Liposomal Vitamin B_1+B_6+B_{12} in Bangladesh

Liposome
BREAKS
the absorption barrier



Ensures 95% absorption

Ensures 8 times more bioavailability

Raw material from Ibart, Poland

Does not decrease vitamin B_{12} level in patient using Metformin

BEACON®
Pharmaceuticals PLC

CORPORATE SOCIAL RESPONSIBILITY



CORPORATE SOCIAL RESPONSIBILITY

At Beacon Pharmaceuticals PLC, our mission extends beyond developing and delivering life-changing medicines. We believe that our responsibility is to all our stakeholders: patients, healthcare professionals, employees, shareholders, communities, and the planet. Our CSR strategy is integrated into our core business operations and is built on three foundational pillars: Patient Access & Health Equity, Environmental Stewardship, and Our People & Communities.

Patient Access & Health Equity

Our primary social responsibility is to the patients we serve. We are committed to ensuring that our innovations reach those who need them, regardless of geography or economic circumstance.

- **Innovative & Ethical R&D:** Our clinical trials are conducted with the highest ethical standards, ensuring patient safety, informed consent, and data integrity.
- **Health System Strengthening:** We invest in programs to train healthcare workers, improve diagnostic capabilities, and support public health infrastructure in underserved regions, helping to build resilient health systems for the future.
- **Transparency & Compliance:** We adhere to strict ethical marketing practices and ensure transparent interactions with healthcare professionals.

Environmental Stewardship

We recognize the impact of our operations on the environment and are committed to protecting planetary health, which is intrinsically linked to human health.

- **Ambitious Climate Goals:** We have committed to achieving net-zero carbon emissions across our operations by increasing our use of renewable energy sources at our manufacturing and R&D sites.
- **Sustainable Operations:** Our water stewardship program focuses on reducing consumption and ensuring wastewater is treated to the highest standards before release.
- **Responsible Sourcing:** We work closely with our suppliers to ensure they meet our stringent environmental and social standards, promoting sustainability throughout our entire value chain.

Our People & Communities

- **Culture of Inclusion & Diversity:** We are committed to creating a workplace where every employee feels valued, respected, and empowered to contribute their best.
- **Community Engagement:** Through the Beacon of Hope Foundation, our corporate philanthropic arm, we support local health initiatives, education programs, and community development projects









Breast Cancer Awareness Program

Various Awareness Program

















Fruits Festival






Pohela Falgun






Beacon Cricket Tournament

















In Breathing Difficulties (COPD & Ashtma)

Doxoven

Doxophylline INN

200 mg Tablet
400 mg Tablet
400 mg SR Tablet
100 mg/5 mL Syrup 60 mL
100 mg/5 mL Syrup 100 mL

Makes Breathing Easier

Ultimate Barrier Against Oxygen, Light, Moisture & Gas



EDC free RM

No risk of cancer

Safe for long term use in Chronic Cough, Asthma & COPD



Alu-Alu Blister

600 times higher barrier performance than PVC

Ensures premium quality

Right Perforation Technology

Each tablet can be separated smoothly

Better patients' compliance

Available as



BEACON® Pharmaceuticals PLC



BUSINESS & VALUE CHAIN MODEL ANALYSIS

BUSINESS MODEL

Beacon Pharmaceuticals PLC operates with a business model centered around the development, manufacturing, and marketing of a wide range of pharmaceutical products, particularly focusing on generic and specialty medicine of oncology. The company's approach is driven by continuous innovation, investing significantly in research and development to pioneer advanced treatments that meet international quality benchmarks. Beacon Pharmaceuticals PLC's robust manufacturing capabilities, along with its strong distribution networks and strategic partnerships, ensure that it can deliver on its commitment to health impact at scale. Through this multifaceted approach, Beacon Pharmaceuticals PLC not only strengthens its market position but also solidifies its role in driving sustainable, long-term growth while contributing to improved health outcomes worldwide.

Key Components of Business Model



Business model of Beacon Pharmaceuticals PLC is built on a commitment to affordable, high-quality pharmaceuticals, primarily in high-need therapeutic areas like oncology. Focused on serving emerging markets, particularly in Bangladesh and expanding across Asia, the Middle East, and Africa, Beacon Pharmaceuticals PLC aims to enhance healthcare accessibility. Sustainability is a cornerstone of its model, integrated across ethical sourcing, efficient manufacturing, and eco-friendly packaging, in alignment with IFRS S1 and S2 standards. With robust R&D investments and cutting-edge manufacturing capabilities, Beacon Pharmaceuticals PLC leverages innovation and strategic partnerships to deliver impactful treatments and support resilient healthcare systems in its target regions.

1 Product Portfolio

Beacon Pharma's product portfolio is strategically focused on high-demand therapeutic areas, including Oncology, Hematology, Hepatology, Nephrology, Antibiotics, Analgesics, Anti-Diabetics, Respiratory, Cardiovascular, Dermatology, Gastrointestinal, Infectious Diseases, Immunology, Rheumatology, Pediatrics, and Nutritional Supplements, among others.. The portfolio features a range of advanced, affordable medications tailored to treat chronic and life-threatening diseases.

2 Research and Development

Research and Development (R&D) is a fundamental pillar of Beacon Pharma's business model, driving its mission to deliver advanced, accessible healthcare solutions. The company invests significantly in R&D to develop cutting-edge treatments, particularly in high-need areas like oncology, hepatitis, and cardiology. Beacon Pharma's state-of-the-art research facilities, staffed by skilled scientists and researchers

3 Manufacturing

Beacon Pharma's business model is built around the principles of Good Manufacturing Practice (GMP), ensuring that all pharmaceutical products are produced to the highest quality standards. The company invests in state-of-the-art manufacturing facilities and technologies to comply with stringent regulatory requirements, fostering a culture of quality assurance and continuous improvement.

4 Market Focus

Beacon Pharma's market focus centers on providing accessible, affordable, and high-quality medicine to underserved populations, primarily in emerging markets. They emphasize offering essential medicines and specialized pharmaceuticals that address critical healthcare needs, such as treatments for cancer, cardiovascular diseases, and infections.

5 Regulatory Compliance

Beacon Pharma's business model prioritizes strict regulatory compliance to meet both national and international standards, ensuring product safety, efficacy, and ethical business practices. The company adheres to the guidelines set by regulatory authorities such as the FDA, WHO, and various national drug regulatory agencies, allowing them to maintain quality control across all production and distribution processes.

6 Sustainability and CSR

Beacon Pharma's business model embeds sustainability and corporate social responsibility (CSR) at its core, striving to make a positive impact on society while minimizing its environmental footprint. The company's CSR initiatives focus on providing affordable medicines to underserved communities, supporting healthcare infrastructure, and raising awareness on critical health issues.

7 Sales and Distribution

Beacon Pharma's sales and distribution model is designed to maximize reach and accessibility, especially in emerging markets and underserved regions. The company employs a robust distribution network that leverages partnerships with local distributors, healthcare providers, and government agencies to ensure their medicines reach patients effectively and affordably.

8 Customer Relationship

Customer relationship strategy is built on fostering trust, engagement, and long-term partnerships with healthcare providers, patients, and stakeholders. The company is dedicated to addressing the specific needs of its customers by offering high-quality, affordable medicines and actively gathering feedback to refine its offerings.

Stakeholder of Business Model



Patients



Healthcare Professionals



Regulatory Authorities



Contract Manufacturers



Distributors



Pharmacy Chains



Investors



Government Entities



Community Organizations

Stakeholder of Business Model

Competitors



Technology Providers



Logistics Companies



Legal Advisors



Raw Material Supplier



Environmental Agencies



Finance Provider



Employee



Consumer Advocacy Groups




VALUE CHAIN MODEL

Beacon Pharmaceuticals PLC's value chain encompasses all the essential activities involved in the research, development, production, and distribution of pharmaceutical products, each stage meticulously designed to deliver high-quality, accessible healthcare solutions. From inbound logistices, R&D and regulatory compliance to manufacturing, logistics, and post-market support, Beacon Pharmaceuticals PLC's processes emphasize not only product safety and efficacy but also sustainability and ethical sourcing. The company integrates IFRS S1 and S2 sustainability standards throughout its operations, managing environmental and social impacts across the value chain. This structured approach enables Beacon Pharmaceuticals PLC to optimize resource use, maintain regulatory alignment, and uphold its commitment to improving healthcare outcomes while prioritizing sustainable and responsible business practices. The value chain of Beacon Pharmaceuticals PLC is crucial as it underpins the company's ability to develop, produce, and deliver safe, effective, and accessible pharmaceutical products. By streamlining each stage—from research and development to manufacturing, distribution, and customer support—Beacon Pharmaceuticals PLC can enhance efficiency, reduce costs, and ensure consistent product quality, all while maintaining regulatory compliance. Additionally, embedding sustainability within the value chain aligns with IFRS S1 and S2 standards, allowing Beacon Pharmaceuticals PLC to address environmental and social impacts proactively. This comprehensive approach not only strengthens Beacon Pharma's competitive advantage but also reinforces its commitment to ethical and sustainable healthcare, benefiting both the business and the broader community.

Primary Activities



Support Activities



Primary Activities

Inbound Logistics	1. Raw Material Sourcing 2. Quality Control of Raw Materials 3. Inventory Management 4. Storage and Warehousing 5. Temperature-Controlled Storage 6. Material Handling Systems	7. Supplier Audits 8. Transportation Logistics 9. Customs and Import Compliance 10. Document Management 11. Risk Management 12. Just-In-Time (JIT) Delivery
Operations	1. API Processing 2. Formulation Development 3. Manufacturing Process Design 4. Batch Production 5. Production Scheduling 6. Quality Assurance (QA)	7. Quality Control (QC) 8. GMP Compliance 9. Automation in Production 10. Sterilization Procedures 11. Waste Management 12. Production Facility Maintenance
Outbound Logistics	1. Inventory Management 2. Warehouse Operations 3. Order Processing 4. Distribution Planning 5. Transportation Management 6. Temperature-Controlled Shipping	7. Real-Time Tracking of Shipments 8. Order Fulfillment Accuracy 9. Distribution Network Management 10. Documentation and Record-Keeping 11. Customs Compliance for Exports 12. Packaging for Distribution
Marketing And Sales	1. Market Research and Analysis 2. Target Market Identification 3. Brand Positioning 4. Product Portfolio Strategy 5. Pricing Strategy 6. Sales Force Development	7. Physician Outreach Programs 8. Product Launch Planning 9. Advertising and Promotion 10. Digital Marketing 11. Sales Analytics and Reporting 12. Promotional Material Distribution
Service	1. Customer Support Hotline 2. Technical Support for Healthcare Provider 3. Medication Adherence 4. Recall Management 5. Feedback Collection from Patients and Providers	6. After-Sales Support for Distributors 7. Complaint Management System 8. Educational Webinars and Workshops 9. Service Quality Audits 10. Product Usage Analytics 11. Customer Loyalty Programs 12. Product Usage Guidelines for Patients

Support Activities

Infrastructure

1. Corporate Governance
2. Regulatory Compliance Management
3. Risk Management Framework
4. IT Infrastructure and Support
5. Facility Management
6. Product Lifecycle Management
7. Inventory Control Systems
8. Business Intelligence and Analytics
9. Knowledge Management
10. Project Management
11. Innovation Management
12. Research and Development (R&D) Support
13. Environmental, Health, and Safety
14. Audit and Internal Control Systems

Human Resources (Hr) Management

1. Recruitment and Talent Acquisition
2. Onboarding Programs
3. Job Role Alignment
4. Employee Training Programs
5. Leadership Development Programs
6. Performance Appraisal Systems
7. Mentorship Programs
8. Employee Engagement Activities
9. Succession Planning
10. Employee Feedback Mechanisms
11. Workplace Safety Training
12. Compensation and Benefits Management
13. Employee Recognition Programs
14. Soft Skills Training
15. Cross-Functional Training
16. Team-Building Activities

Technological Development

1. Smart Manufacturing Systems
2. Advanced Quality Control Equipment
3. Digitalized R&D Processes
4. Big Data Analytics
5. Automated Packaging Solutions
6. Cloud Computing for Data Storage
7. ERP System for Process Integration
8. Supply Chain Management Software
9. Energy-Efficient Manufacturing Technologies
10. Customer Relationship Management (CRM) Software
11. Automated Inventory Management
12. Digitalized R&D Processes

Procurement


1. Raw Material Sourcing
2. Supplier Selection Process
3. Supplier Relationship Management
4. Vendor Risk Assessment
5. Quality Assurance of Incoming Materials
6. Contract Negotiation
7. Cost Management and Optimization
8. Sustainable Procurement Practices
9. Supply Chain Transparency
10. Inventory Management
11. Procurement Planning
12. Bulk Purchasing and Economies of Scale
13. Supplier Audits
14. Lead Time Optimization

1st TIME IN BANGLADESH

Roxadustat INN

RENESIS

20 mg, 50 mg, 70 mg, 100 mg & 150 mg Tablet



The Renaissance of Erythropoiesis

Unique in Erythropoiesis

- Increases endogenous production of HB
- Increases iron mobilization, transportation and absorption
- Decreases hepcidin level
- Overcomes functional iron deficiency
- Overcomes hyporesponsiveness of ESA
- More than oral alternative to IV Iron and ESA therapy

BEACON®

Light for life



INTEGRATED REPORTING

Guided by the enduring conviction 'Light for Life,' Beacon Pharmaceuticals embodies an ethos rooted in growth, compassion, and equitable access to healthcare. This philosophy permeates every dimension of the organization—shaping its strategic decisions, operational practices, and stakeholder engagement.

At the core of Beacon's mission lies a steadfast commitment to creating a transformative impact across its stakeholder network. The company strives to enhance the well-being of its employees and their families, ensure affordable and accessible healthcare solutions for its customers and patients, and generate sustainable value for its shareholders, investors, and business partners.

Beacon's sense of responsibility extends well beyond the boundaries of corporate performance. Through continuous innovation, responsible business conduct, and community-oriented initiatives, the company contributes meaningfully to the socioeconomic development of Bangladesh while expanding its footprint in the global healthcare landscape. In doing so, Beacon upholds its broader purpose of improving lives and protecting the planet, reaffirming its role as a catalyst for positive change in society.

Defining our integrated report:

Our Integrated Report serves as a comprehensive yet concise communication that illustrates how Beacon Pharmaceuticals PLC's strategic direction, governance framework, operational performance, and future prospects collectively contribute to the creation, preservation, or potential erosion of value over the short, medium, and long term.

It provides a clear understanding of how the organization's business model and strategic priorities are influenced by both internal dynamics—such as resources, capabilities, and culture—and external factors, including market conditions, regulatory frameworks, global health trends, and socio-economic developments.

Through this report, Beacon seeks to demonstrate the interconnectedness between its strategy, governance practices, risk management, and performance outcomes, presenting a holistic view of how the company delivers sustainable value to its diverse stakeholders.

Ultimately, the Integrated Report reflects Beacon's commitment to transparency, accountability, and responsible value creation, offering stakeholders a well-rounded perspective on how the organization positions itself to achieve enduring growth while addressing the evolving needs of the healthcare sector and society at large.

Approach to our reporting:

This Integrated Report provides an in-depth overview of Beacon Pharmaceuticals PLC's governance framework, detailing the structure, policies, and oversight mechanisms that guide the company's decision-making processes. It outlines the key strategic decisions and initiatives undertaken during the reporting period, demonstrating how these actions have contributed to measurable progress toward achieving the organization's long-term strategic objectives.

The report offers a comprehensive assessment of the risks, opportunities, and trade-offs associated with each of Beacon's strategic pillars—such as innovation, operational excellence, market expansion, sustainability, and stakeholder engagement. By analyzing these dimensions, the report highlights how Beacon balances short-term performance goals with long-term value creation, ensuring resilience and adaptability in a rapidly evolving business environment.

Furthermore, it illustrates the interconnected nature of internal and external factors—including governance practices, resource allocation, regulatory developments, technological advancements, and global health dynamics—that collectively influence Beacon's capacity to create sustainable and shared value.

Through this integrated perspective, the report underscores Beacon's commitment to transparent governance, responsible decision-making, and sustainable growth, reinforcing its role as a forward-looking organization dedicated to improving health outcomes while generating enduring value for all stakeholders.

Purpose of our integrated annual report:

This Integrated Report presents a comprehensive assessment of our value creation capabilities, encompassing both financial statements, SDG goals and the ESG Report. The ESG Report highlights critical environmental, social, and governance factors that may impact our performance if not effectively managed. Designed for a diverse group of stakeholders—including employees, communities, customers, investors, and regulatory bodies—this report provides an in-depth overview of our performance, prepared in alignment with recognized reporting standards.

Our audited annual financial statements present statutory and regulatory information required by the:

- The Companies Act 1994
- International Financial Reporting Standards (IFRS)
- Regulatory Requirements (BSEC, DSE, CSE) and other applicable laws
- BSEC Corporate Governance Code 2018

- Listings Requirements of Dhaka and Chittagong Stock Exchange

Through this report, we ensure primary communications with our stakeholders, though it is prepared mainly for capital providers and shareholders.

Integrated reporting boundaries:

In alignment with the International Integrated Reporting Council (IIRC) framework, Beacon Pharmaceuticals PLC defines its reporting boundary through a principle of connectivity and material influence. While our financial statements are anchored to the legal entity of Beacon Pharmaceuticals PLC, our Integrated Report tells a broader story. We recognize that our ability to create sustainable value is intrinsically linked to a wide network of external relationships and dependencies.

Our process for determining this boundary is methodical and strategic, moving from the core entity outward to encompass our entire value creation ecosystem.



Material Risks: We include stakeholders who pose a substantive risk to our business model and value creation. Key examples are:

- **Regulatory Bodies:** Their decisions on drug approvals, labeling, and safety warnings directly determine our market access and revenue.
- **Critical Suppliers:** Providers of active pharmaceutical ingredients (APIs), specialized raw materials, or single-source components. A disruption in their supply poses a direct operational risk.
- **Healthcare Payers and Governments:** Their reimbursement policies and pricing negotiations significantly impact the commercial viability and accessibility of our medicines.


Strategic Opportunities: Our boundary encompasses partners who are essential to our innovation and growth. This includes:

- Academic and Research Institutions at the forefront of scientific discovery, with whom we collaborate on basic research.
- Patient Advocacy Groups that provide invaluable insights into disease burden and treatment outcomes, shaping our clinical development programs.
- Technology Partners developing digital health platforms, AI-driven diagnostics, or advanced drug delivery systems that complement our portfolio.

Significant Outcomes: We account for stakeholders who are meaningfully affected by our operations, both positively and negatively. This involves:

- **Patients and Healthcare Professionals:** They are the ultimate beneficiaries (and users) of our products, and their health outcomes and trust are our primary concern.
- **Local Communities:** Those surrounding our manufacturing and R&D facilities, who are affected by our environmental footprint (e.g., water usage, emissions) and our role as a local employer.
- **The Natural Environment:** While not a stakeholder in the traditional sense, we account for our dependence and impact on natural capital (air, water, biodiversity) as a critical resource.

About our capitals:



Financial Capital:

We maintain a disciplined financial strategy, leveraging retained earnings and strategic capital allocation to fund high-potential R&D, expand our global footprint, and deliver sustainable returns to shareholders. Our financial resilience ensures long-term operational agility and strategic growth.

Our financial performance at a glance




ROCE has increased by 30% mainly due to increase in EBIT by 33%, whereas the capital employed was increased by only 3%.

At end of FY2024-25, we have achieved a Gross Profit Margin growth of 18% due to increase in revenue by 17.2%, whereas COGS increased by 16.36%.




Our financial solvency at a glance



Current Ratio has increased to 1.54 time from last years ratio 1.37 times, almost 12% growth in solvency. Besides, the Quick Ratio has also improved to 1.14 time from 1.06, which indicates improvement in solvency.

By end of FY2024-25 we were able to reduce Gearing Ratio to 1.48 from 1.64, which indicates a reduction to our financial risk exposure. The reduction was mainly due to reduction in total debt by 2%.



Our financial efficiency at a glance



Net Asset Turnover increased to 0.76 from 0.66, around 14% growth mainly due to increase in revenue by 17%.

The receivables collection period reduced to 72 days from 94 days. This was possible mainly due reduction in total trade receivables by 10% at end of FY2024-25.



Manufacturing Capital:

We maintain a global network of advanced manufacturing facilities and research laboratories, equipped with cutting-edge technologies. This infrastructure is strategically designed to ensure production excellence, regulatory compliance, and operational scalability, while simultaneously driving efficiencies that reduce our environmental footprint.

Production Facilities

Oral Solids Unit

high-speed tablet compression machines, capsule filling machines, and coating systems



Liquid Formulations Unit

syrups, suspensions, and solutions with precision mixing tanks, homogenizers, and filtration systems



Parenteral & Sterile Products Unit

ISO-classified cleanrooms with aseptic filling lines and lyophilization capabilities for injectables



Dedicated Oncology Production Zone

specialized area with enhanced containment protocols for handling cytotoxic drugs



Utilities & Support System

- **HVAC & Air Handling:** Advanced climate control systems ensure precise temperature, humidity, and air quality levels across production and storage areas.
- **Water Systems:** Reverse osmosis (RO) and water-for-injection (WFI) systems provide ultrapure water for formulations and cleaning processes.
- **Steam & Compressed Air Systems:** High-capacity systems support sterilization, manufacturing, and auxiliary operations.
- **Power & Backup Systems:** Uninterrupted power supply systems and generators ensure continuous operations without disruption.

Advanced Technology

- **Automated Production Lines:** Reduce human error, increase throughput, and ensure batch-to-batch consistency.
- **Process Control Systems:** Digital systems monitor critical parameters such as temperature, humidity, pressure, and fill volume in real time.
- **Data Logging & Traceability:** Automated systems provide full batch traceability, ensuring compliance with international standards.
- **High-Speed Packaging Lines:** Ensure efficient production and minimize manual handling.
- **Serialization & Tamper-Evident Features:** Comply with regulatory requirements and enhance product safety.

Intellectual Capital:

Our proprietary knowledge base, comprising patented formulations, regulatory expertise, and specialized manufacturing processes, forms the bedrock of our innovation pipeline. This capital is continuously enhanced through targeted research and development, strategic licensing, and the protection of critical intellectual property.

R&D Infrastructure

- **Formulation Development Laboratories:** Equipped with advanced mixers, granulators, and coating systems for solid and liquid formulations.
- **Analytical Research Labs:** Utilize sophisticated instruments such as HPLC, GC, FTIR, UV-Vi's spectrophotometers, and stability chambers.
- **Pilot Production Plant:** Enables pre-commercial scale production for validation and regulatory submission.
- **Dedicated Oncology R&D Zone:** Designed for cytotoxic research and development under strict containment and air-handling systems.
- **Collaboration Network:** Partnerships with universities, research bodies, and technology firms foster knowledge exchange and innovation.

Technological integrations


- **Enterprise Resource Planning (ERP):** Enables real-time coordination between R&D, production, inventory, and finance functions.
- **SAP Ariba:** Beacon Pharmaceuticals PLC has integrated SAP Ariba with its SAP ERP system, allowing seamless synchronization between procurement, finance, and inventory management.
- **Laboratory Information Management System (LIMS):** Provides secure data capture, validation, and traceability of all analytical processes.
- **Manufacturing Execution System (MES):** Ensures process uniformity, electronic batch recording, and data-driven decision-making.
- **Automation and Robotics:** Used in weighing, filling, and packaging operations to reduce human error and improve throughput.
- **Digital Quality Assurance:** Beacon applies data-driven quality control using in-line sensors and automated monitoring tools to maintain global GMP standards.

Digital Transformation

- **Data-Driven Decision Systems:** Real-time dashboards provide insights into production, quality, and sales metrics.
- **Predictive Maintenance:** Machine learning algorithms help predict and prevent equipment downtime.
- **Regulatory Data Analytics:** Digital systems streamline dossier preparation, submission tracking, and compliance documentation.
- **Cybersecurity:** Robust data protection systems safeguard proprietary research and operational data.

Core Research Areas

- **Oncology Research:** Beacon is the first company in Bangladesh to manufacture oncology drugs in a dedicated facility compliant with international containment standards. Its R&D team has developed more than 65 cancer formulations, covering oral, injectable, and targeted therapies.
- **Biotechnology and Biosimilars:** The company invest in the development of complex biological products, including monoclonal antibodies, peptide drugs, and biosimilar formulations.
- **Antiviral and Specialty Therapeutics:** R&D extends to the development of antiviral and immunomodulatory medicines targeting life-threatening diseases such as Hepatitis, HIV, and other chronic conditions.



- **Novel Drug Delivery Systems (NDDS):** The company focuses on enhancing bioavailability and patient compliance through controlled-release tablets, liposomal formulations, and novel coating technologies.
- **Process Innovation and Scale-up:** Beacon's R & D ensures seamless scale-up from laboratory trials to industrial production using advanced modeling and simulation tools, ensuring cost-efficiency and product uniformity.

Human Capital:

Our specialized scientific, technical, and commercial workforce represents a cornerstone of our competitive advantage. We are committed to fostering a culture of excellence, integrity, and inclusion, underpinned by robust investments in continuous professional development, stringent health and safety protocols, and comprehensive well-being programs.

R&D Infrastructure

- **Total Workforce:** 4,771 employees across sales & marketing, accounts & finance, internal audit, HR & admin, manufacturing, R&D, quality, regulatory, and supply chain functions.
- **New Hires:** 1,200 skilled professionals joined the organization in 2024-25, bringing fresh expertise and innovation.
- **Total Training Hours:** 10,000 hours delivered through programs covering technical skills, regulatory compliance, leadership, and soft skills.
- **Retention Rate:** 85% of employees retained, reflecting a supportive and rewarding workplace culture.
- **Workplace Safety:** Zero major incidents reported in 2024-25.
- **Gender Diversity:** 30% female employees, reflecting Beacon's commitment to gender equality.



- **Talent Acquisition and Retention:** We strengthened our recruitment framework to attract professionals with specialized expertise across research, manufacturing, quality assurance, regulatory compliance, and commercial functions. Comprehensive retention programs, including performance-based rewards and career progression opportunities, have helped maintain a motivated and loyal workforce.
- **Training and Development:** Beacon Pharmaceuticals invested in structured training programs covering advanced manufacturing techniques, regulatory compliance, R&D innovation, leadership, and soft skills. Continuous learning initiatives ensure that employees are aligned with global industry standards and best practices.
- **Health, Safety, and Well-being:** Employee well-being is a key priority. We implemented comprehensive health and safety protocols across all operations, promoted work-life balance, and provided wellness programs to support mental and physical health.
- **Diversity, Equity, and Inclusion:** We foster a workplace that values diversity and inclusion, promoting equal opportunities irrespective of gender, age, or background. This inclusive environment encourages creativity, collaboration, and innovation.
- **Performance Management:** Beacon Pharmaceuticals maintains a structured performance evaluation system, linking individual contributions to organizational goals. Clear performance metrics, coupled with feedback mechanisms, ensure accountability, recognize excellence, and drive continuous improvement.

Social & Relationship Capital:

We cultivate and maintain trusted, long-term relationships with a broad network of stakeholders, including healthcare professionals, regulatory bodies, supply chain partners, and local communities. This relational equity is fundamental to our social license

- **Employees:** Regular communication channels, including town halls, feedback surveys, and performance review meetings. Active involvement in decision-making processes, particularly in R&D, manufacturing, and quality assurance. Implementation of recognition programs and career development plans to strengthen engagement.
- **Customers & Patients:** Commitment to patient safety, product efficacy, and accessibility. Multi-channel communication to provide product information, usage guidelines, and regulatory compliance details. Collection of feedback through customer service, healthcare provider interactions, and surveys.
- **Communities:** Community health initiatives, awareness campaigns, and healthcare support programs in regions where the company operates. Educational programs and scholarships for local students in science, technology, and healthcare disciplines.
- **Regulators & Industry Bodies:** Transparent communication with national and international regulatory authorities. Active participation in industry forums, standard-setting bodies, and collaborative research networks.
- **Suppliers & Partners:** Ethical sourcing, timely payments, and compliance with procurement policies. Use of SAP Ariba platform to strengthen transparency, efficiency, and accountability in supplier relationships.



Key Community Initiatives

- **Healthcare Camps and Awareness Programs:** Offering free or subsidized medical check-ups, vaccinations, and health education.
- **Educational Support:** Scholarships, training programs, and career guidance in science and healthcare for students in surrounding communities.
- **Environmental Awareness:** Participating in local initiatives to promote environmental stewardship and responsible resource use.
- **Support During Emergencies:** Contributing to disaster relief and emergency health interventions.

Partnerships and Collaborations

- Collaboration with government health agencies to support national health initiatives.
- Engagement with professional associations and research networks for innovation and knowledge exchange.
- Partnerships with local NGOs and educational institutions to improve community health and education.

Social Impact Through Patient & Doctors Abiding Ethical Governance:

Patient-Centric Initiative

> Compliance with WHO-GMP, EU-GMP, and MHRA standards ensures product safety.
> Transparency in product labeling, clinical data, and pharmacovigilance reports.
> Education and awareness programs targeting disease management and responsible medicine use.

Healthcare Professional Engagement

> Collaborative workshops, seminars, and medical conferences facilitate knowledge sharing.
> Clinical support teams provide accurate product information, enhancing patient outcomes.

Governance Practices

> Clear Code of Conduct for employees, suppliers, and partners.
> Regular audits and risk assessments to ensure compliance with national and international regulations.
> Robust internal communication and whistleblowing mechanisms to maintain ethical standards.

Strategic Value of Social Capital

- Building trust with employees, customers, regulators, and communities.
- Supporting innovation through collaborative and engaged teams.
- Enhancing organizational resilience and adaptability.
- Strengthening reputation and credibility in domestic and international markets.
- Facilitating regulatory compliance and ethical business practices.
- Driving sustainable value creation through societal contribution and community development.

Natural Capital:


We recognize our dependence on essential environmental resources and are committed to their stewardship. Our operational strategy integrates sustainable resource management—focusing on water conservation, energy efficiency, and emissions reduction—to minimize our ecological impact and ensure long-term resource availability.

Energy Management

- **Energy-Efficient Equipment:** The company employs high-efficiency boilers, HVAC systems, and production machinery designed to minimize energy consumption.
- **Renewable Energy Initiatives:** Beacon has initiated steps to integrate renewab le energy sources such as solar power into its manufacturing operations to reduce dependency on fossil fuels.
- **Energy Audits and Monitoring:** Regular internal energy audits and the use of automated monitoring systems enable the company to track and reduce its overall energy footprint.

Water Resource Management

- **Efficient Water Systems:** The plant is equipped with reverse osmosis (RO) and water-for-injection (WFI) systems that ensure optimal utilization and recycling of water in production processes.
- **Zero Discharge Objective:** Beacon's water management practices aim for zero liquid discharge, ensuring that no untreated wastewater is released into the environment.
- **Rainwater Harvesting and Reuse:** The company has implemented rainwater harvesting structures to collect and reuse rainwater for non-production purposes such as landscape irrigation and utility cleaning.




Waste Management and Pollution Control

- **Hazardous Waste Handling:** The company follows government and international guidelines for the collection, labeling, and disposal of hazardous waste, including cytotoxic residues from oncology production.
- **Effluent Treatment Plant (ETP):** A fully functional and upgraded ETP ensures that wastewater from the plant undergoes biological and chemical treatment before discharge.
- **Solid Waste Management:** Non-hazardous wastes such as packaging materials, plastics, and paper are segregated at the source and recycled through authorized vendors.
- **Emission Control Systems:** Beacon's production facilities are equipped with dust collectors, scrubbers, and filtration systems to ensure clean.

Sustainable Sourcing

- **Environmentally Responsible Procurement:** The company prioritizes suppliers and vendors who adhere to environmental and ethical standards in raw material sourcing and manufacturing.
- **Reduced Packaging Footprint:** Beacon has adopted lightweight, recyclable, and biodegradable packaging materials wherever feasible.
- **Optimized Logistics:** Efficient transportation planning and load optimization minimize fuel consumption and reduce greenhouse gas emissions across the supply chain.



Climate Risk Management and Resilience

The pharmaceutical industry faces growing challenges from climate changes, including supply disruptions, temperature-sensitive logistics, and increased resource costs. Beacon Pharmaceuticals proactively identifies and mitigates these risks through assessing and managing alternate channels.


- **Environmental Risk Assessment:** The company conducts periodic assessments to identify potential climate-related risks to production and supply operations.
- **Resilient Infrastructure:** Facilities are designed to withstand weather fluctuations and ensure consistent performance under varying conditions.
- **Carbon Footprint Reduction:** Beacon's commitment to energy efficiency, waste minimization, and renewable integration collectively contributes to lower greenhouse gas emissions.

Integration of Capital Input and Outcome with SDG Goals

At Beacon Pharmaceuticals, our strategic management of the six capitals—Human, Intellectual, Manufacturing, Financial, Social, and Natural—forms the foundation of our commitment to the United Nations Sustainable Development Goals (SDGs). This integrated approach ensures that our business operations create value not only for our shareholders but also for society and the planet.

The Integrated Annual Report of FY2024–25 encapsulates Beacon Pharmaceuticals PLC's unwavering commitment to transparency, accountability, and sustainable performance. It provides an integrated view of how our governance, strategy, and operations collectively drive value creation and resilience in a rapidly evolving healthcare sector.

Through disciplined execution, innovation, and responsible leadership, Beacon continues to strengthen its position as a trusted partner in healthcare—delivering excellence to patients, value to shareholders, and enduring benefit to society. Our focus remains on building a sustainable future founded on integrity, innovation, and operational excellence.



Financial Capital

Input

- Equity Fund
- Debt Fund
- Retained Earnings

With BDT 2,310 million equity fund and BDT 2,728 million debt fund, Beacon Pharmaceuticals PLC started its 2024-25 financial year. Throughout the year BDT 2,891 million was reinvested in operation from Retained Earnings. To operate day to day operation effectively from working capitals, the entity took in a combination of sales collection and short-term loans.

Outcome

- Company Value
- Shareholder Value
- SDG Served

Throughout the FY2024-25 Beacon Pharmaceuticals PLC was able to generate a revenue of BDT 12,542 million, around 17.2% growth compared to previous financial year. Besides, more advanced technology and machines were installed to ensure modern facilities in production. BDT 20 million spent on CSR, BDT 44 million spent on R&D, and BDT 13 million spent on energy generation, which served the SDG goals 7,8 & 9.



Key Points

• Performance	• 17% Revenue growth
• Efficiency	• ROCE increased to 16.19% from 12.44%
• Solvency	• Return on shareholders' funds increased by 60%

Input > Value chain activities > Output

SDG Goal 07: Beacon Pharmaceuticals PLC has accomplished Affordable & Clean Energy through installing private electric station at factory.

SDG Goal 08: The company has ensured Decent Work & Economic Growth by continuous development and expansion of production facilities.

SDG Goal 09: Large scale production facilities, warehouse with advanced technologies and increasing R&D spendings have ensured Industry, Innovation and Infrastructure goal.

Manufactured Capital



SDG Goal 03: Continuous innovation and introduction of quality medication ensuring Good Health & Well-Beings.

SDG Goal 06: Beacon has installed high performing technology to recycle water to ensure Clean Water & Sanitation.

SDG Goal 07: Beacon Pharmaceuticals PLC has accomplished Affordable & Clean Energy through installing private electric station at factory.

SDG Goal 08: The company has ensured Decent Work & Economic Growth by continuous development and expansion of production facilities.

SDG Goal 09: Large scale production facilities, warehouse with advanced technologies and increasing R&D spendings have ensured Industry, Innovation and Infrastructure goal.

SDG Goal 12: With advanced machineries and automation system, chemical & waste management process, Beacon ensured Responsible Consumption & Production.

Intellectual Capital

Input

- Scientific Expertise
- Advanced Software
- Patent Portfolio

To ensure continuous development of products quality and introduce new products, Beacon Pharmaceuticals PLC has experienced and expert scientist group. With regular clinical development and regulatory affairs knowledge, Beacon strongly follows SOP in quality control, manufacturing and R&D. To ensure efficiency and accuracy in each operational process, advanced software like SAP is in the process. With unique formulas and chemical compounds, Beacon stands at top of Oncology medication in Bangladesh.

Outcome

- Revenue Growth
- Innovative Pipeline
- SDG Served

A revenue of BDT 350 million was achieved from all the new products launched in FY24-25. Thus, the new products contributes around 2.37% of total revenue generated in FY2024-25. Besides, few more non-existing products are already in the pipeline to be launched in near future, which will reduce consumers' buying cost from other countries and may save many lives.



Key Points

- Scientific talent
- R&D
- Strategic Partnership
- Patented medicines
- Financial return
- Competitive advantage

Input > Value chain activities > Output

SDG Goal 03: Continuous innovation and introduction of quality medication ensuring Good Health & Well-Beings.

SDG Goal 04: On the training learning and various training sessions, ensured Quality Education.

SDG Goal 08: The company has ensured Decent Work & Economic Growth by continuous development and expansion of production facilities.

SDG Goal 09: Large scale production facilities, warehouse with advanced technologies and increasing R&D spendings have ensured Industry, Innovation and Infrastructure goal.

SDG Goal 12: With advanced machineries and automation system, chemical & waste management process, Beacon ensured Responsible Consumption & Production.

SDG Goal 17: By facilitating knowledge sharing among important stakeholders and building relationship beyond country border, Beacon has achieved Partnerships of the Goals.

Human Capital

Input

- Acquisition
- Development
- Engagement

In Beacon, the acquisition of human resource follows CV screening, written exam and interview session. To ensure the best talent hunt, our HR process never discriminate between genders. The acquisition is just a start in the development of our talents. Throughout FY2024-25 a sum of BDT 229 million for employee welfare and entertainment purpose and BDT 42 million for training and medical purpose, were spent to ensure employees' continuous development and proper engagement in good health.

Outcome

- Performance
- Health & Safety
- SDG Served

Growth in our sales and business was only possible because of the undue performance of our human resources. We were abled to maintain 84% retention rate and 70:30 male and female employment ratio in FY24-25. Besides, Beacon's business reputation attracted employees from competition to join Beacon. The cross-industry recruitment rate has also increased. Throughout of FY2024-25 we have encountered zero major incidents and managed to conduct session on various health related safety programs.



Key Points

- competitive pay
- world-class training
- supportive culture
- low turnover
- high safety
- strong employer brand

Input > Value chain activities > Output

SDG Goal 03: Continuous innovation and introduction of quality medication ensuring Good Health & Well-Beings.

SDG Goal 04: On the training learning and various training sessions, ensured Quality Education.

SDG Goal 05: Beacon HR system always focuses on recruiting the best talent regardless of gender priority which ensures Gender Equality.

SDG Goal 08: The company has ensured Decent Work & Economic Growth by continuous development and expansion of production facilities.

SDG Goal 10: Large scale production facilities, warehouse with advanced technologies and increasing R&D spendings have ensured Industry Innovation and Infrastructure goal.

SDG Goal 16: Beacon has achieved Peace, Justice and Strong Institutions by encouraging ethical leadership and following standard policies to ensure zero corruption.

Social & Relationship Capital

Input

- Patient Community
- Healthcare Professional
- Supplier & Partner

As part of CSR, Beacon Pharmaceuticals PLC has spent BDT 14 million in FY2024-25 which is almost 48% higher than previous year, and for the purpose of direct patient community donation, an amount of BDT 6 million was spent. Besides, Beacon always tries to keep the life saving medicine prices within best possible range so that consumers feel safe. For continuous professional development, Beacon launched CME (Continuous Medical Education) and RMP (Rural Medical Program) events on regular basis. Overall, to ensure best quality final product and maintain minimum finished stocks, Beacon always tries to keep good relation with suppliers.

Outcome

- Regulatory Access
- Brand & Reputation
- SDG Served

We have achieved high drug approval success rate due to our quality R&D and relationship with Regulatory bodies through proper maintenance of compliance. At any cost, Beacon maintain the brand value and market reputation, which results in high patient loyalty rate. We have increased our repeated customer rate through our quality product and market reputation.



- fair pricing
- robust safety monitoring
- collaborative R&D
- faster regulatory approvals
- premium pricing power
- resilient supply chain

Input > Value chain activities > Output

SDG Goal 03: Continuous innovation and introduction of quality medication ensuring Good Health & Well-Beings.

SDG Goal 08: The company has ensured Decent Work & Economic Growth by continuous development and expansion of production facilities.

SDG Goal 16: Beacon has achieved Peace, Justice and Strong Institutions by encouraging ethical leadership and following standard policies to ensure corruption.

SDG Goal 17: By facilitating knowledge sharing among important stakeholders and building relationship beyond country border, Beacon has achieved Partnerships of the Goals.

Natural Capital

Input

Resource Material

Ecosystem

Large volumes of clean water is used for chemical synthesis, fermentation, cooling, and cleaning processes. In addition, Fossil fuels (gas, oil) and electricity (from the grid) to power labs, manufacturing plants, and climate control systems are all part of the manufacturing process. A stable climate and clean air for operational continuity and employee health is available.

Outcome

Resource Management

Emission & Pollution

SDG Served

Through effective planning & management, we were able to reduce water intensity by around 20% and increasing rainwater reserve by around 50%. Besides, we aim to recycle 100% of our wasted water and we have already achieved that. For other kind of wastage, we have installed separate waste treatment plant. Beacon's factory is designed by world's renowned pharmaceutical designer Telester S.A., Spain. The whole factory area is full of green nature and pure air with the cleanest pathways for movement.



Key Points

- Finite resources
- Environment Capacity
- Reduced environmental footprint
- Enhanced resilience

Input > Value chain activities > Output

SDG Goal 06: Beacon has installed high performing technology to recycle water to ensure Clean Water & Sanitation.

SDG Goal 07: Beacon Pharmaceuticals PLC has accomplished Affordable & Clean Energy through installing private electric station at factory.

SDG Goal 09: Large scale production facilities, warehouse with advanced technologies and increasing R&D spendings have ensured Industry, Innovation and Infrastructure goal.

SDG Goal 12: With advanced machineries and automation system, chemical & waste management process, Beacon ensured Responsible Consumption & Production

SDG Goal 13: Through installation of ecofriendly private energy system and advanced water recycling system, Beacon ensured Climate Action.

SDG Goal 15: To improve Life on Land, Beacon has created a green ecofriendly and clean environment at factory area.

Guiding Principles and Content Elements:


Our Integrated Report has been prepared in full alignment with the International Integrated Reporting Council (IIRC) Framework, which serves as the global benchmark for transparent, comprehensive, and value-focused corporate reporting. This framework establishes seven Guiding Principles that form the foundation for both the preparation and presentation of the report, ensuring that the information disclosed is relevant, consistent, and reflective of Beacon Pharmaceuticals PLC's approach to long-term value creation.

These Guiding Principles—strategic focus and future orientation, connectivity of information, stakeholder relationships, materiality, conciseness, reliability and completeness, and consistency and comparability—collectively shape the structure, tone, and analytical depth of the report. They guide how the company communicates its strategy, governance, performance, and prospects in a way that demonstrates the interdependencies between financial and non-financial factors influencing value creation.

In addition, the report incorporates the eight interrelated Content Elements defined by the IIRC Framework. Organizational overview and external environment, Governance, Business model, Risks and opportunities, Strategy and resource allocation, Performance, Outlook, and Basis of preparation and presentation. These elements are fundamentally interconnected and not mutually exclusive, reflecting the integrated nature of Beacon's operations and the dynamic ecosystem in which it operates.

Together, these principles and content elements enable Beacon Pharmaceuticals to present a holistic, balanced, and forward-looking narrative that captures how the company creates, preserves, and delivers sustainable value across multiple capitals—financial, manufactured, intellectual, human, social, and natural.

Capital Integration with Guiding Principles and Content Elements:




Guiding Principles:

From the perspective of Beacon Pharmaceuticals PLC these statements are not just boilerplate text; they are a declaration of our commitment to modern, transparent, and responsible corporate reporting. They form the philosophical and practical backbone of our Integrated Report.

Here is a detailed explanation of what each of these contents means for us at Beacon Pharmaceuticals PLC:

- **Strategic Focus and Future Orientation:** This principle positions our Integrated Report as the central narrative of our business, moving beyond a simple financial summary. It is the story of our strategy in action.
  - **Alignment with Value Creation:** Our strategy is not separate from sustainability; it is driven by it. For example, our strategic goal to "develop novel oncology therapies" is directly linked to our ability to create value. The report explains how this goal creates value for:
    - Short-term: Revenue from new drug launches, shareholder returns.
    - Medium-term: A robust R&D pipeline, market share growth, and a strengthened brand reputation as an innovator.
    - Long-term: Addressing a major global health challenge, contributing to longer, healthier lives (social value), and ensuring the company's longevity and license to operate.
  - **Impact on Capitals:** We don't just use financial capital. Our strategy actively uses and impacts multiple forms of capital:
    - Intellectual Capital: We invest heavily in R&D to build our patent portfolio and drug pipeline.



- Human Capital: We attract and retain top scientific talent to execute our strategy.
- Social & Relationship Capital: We build trust with regulators (like the FDA/EMA), healthcare professionals, and patient communities.
- Natural Capital: We manage the environmental footprint of our manufacturing processes.
- Manufactured Capital: We invest in state-of-the-art production facilities and laboratories.

In essence, this section tells our stakeholders: "Here is our plan for the future, and here is precisely how it will make us a resilient and valuable company for years to come, using all the resources at our disposal."

- **Connectivity of Information:** Our business is a complex, interconnected system. This principle ensures our report reflects that reality, breaking down the "silos" between departments like R&D, manufacturing, and marketing.
  - **Holistic View:** We don't present our R&D success in isolation. We connect it to:
    - Financials: How R&D expenditure is an investment, not just a cost.
    - Manufacturing: How a new drug requires scaling up production capacity.
    - Stakeholders: How engaging with patient groups during clinical trials leads to better drug design and stronger market acceptance.
  - **Risk:** How a regulatory setback in one region impacts our global launch strategy and financial projections.
  - **Example:** A decision to invest in a "green" manufacturing facility (impact on Natural Capital) isn't just a CSR story. It is connected to reduced long-term energy costs (Financial Capital), enhanced brand reputation (Social Capital), and alignment with our purpose of responsible healthcare.

This tells our stakeholders: "We understand that a decision in the lab affects the factory, the balance sheet, and our reputation. Our report shows you these critical connections."

- **Stakeholder Relationships:** Our success is entirely dependent on the relationships we maintain. This section moves beyond listing our stakeholders to demonstrating how we engage with them in a meaningful, strategic dialogue.
  - **Nature and Quality of Relationships:** We don't just communicate to our stakeholders; we engage with them. For example:
    - Patients & Healthcare Professionals: We conduct advisory boards to understand unmet medical needs, shaping our R&D priorities.
    - Regulators: We maintain transparent and proactive communication to ensure compliance and facilitate timely drug approvals.
    - Employees: We use regular surveys and development programs to foster engagement and innovation.
    - Suppliers: We partner with them to ensure ethical and sustainable supply chains.
  - **Recognizing and Responding:** We systematically identify stakeholder concerns (e.g., drug pricing, access to medicine) and show how we are responding. This could be through our patient access programs, tiered pricing in developing countries, or transparent pricing policies.

This tells our stakeholders: "We listen to you, we value your input, and we are strategically integrating your legitimate needs and interests into our business decisions."

- **Materiality & Conciseness:** In an age of information overload, we focus on what truly matters. This principle ensures our report is relevant and accessible, not a lengthy compliance document.
  - **Materiality:** We have a rigorous process to identify "material matters"—the issues that truly affect our ability to create value. For Beacon Pharmaceuticals, this includes:
    - R&D Pipeline Strength and Clinical Trial Outcomes
    - Regulatory Compliance and Drug Safety
    - Intellectual Property Protection
    - Talent Attraction and Retention
    - Ethical Marketing Practices
    - Environmental Impact of Manufacturing
    - Access to Medicines and Affordability
  - **Conciseness:** We present this material information clearly and succinctly. We avoid immaterial details that do not influence stakeholder assessments or decision-making. The report is a strategic tool, not an encyclopedia.

This tells our stakeholders: "We have done the work to identify what is most important. This report cuts through the noise

and gives you the essential information you need to judge our performance and prospects."

- **Reliability and Completeness:** Our credibility is our most valuable asset. This principle is our pledge of integrity and transparency.
  - **Fair and Balanced:** We report the full picture. This means we disclose:
    - Favorable: Successful drug launches, positive clinical trial results, awards for sustainability.
    - Unfavorable: Clinical trial failures, regulatory warnings, manufacturing setbacks, and environmental incidents.
  - **Accuracy and Reliability:** The data in our report is subject to robust internal controls and, where appropriate, external assurance. Stakeholders can have confidence that the figures and narratives are accurate and trustworthy.

This tells our stakeholders: "You can trust this report. We are being honest and transparent about our performance, both our successes and our challenges, because we are accountable to you."

- **Consistency and Comparability:** Value creation is a journey, not a snapshot. This principle allows stakeholders to track our progress and benchmark us against our peers.
  - **Consistency Over Time:** We use the same reporting frameworks (e.g., International Integrated Reporting Council <IR> Framework, IFRS, GRI) and metrics each year. This allows you to see a trend: Is our R&D productivity improving? Is our carbon footprint decreasing? Is employee engagement rising?
  - **Comparability with Peers:** By aligning with global standards, we enable you to compare our performance—on factors like R&D spend as a percentage of revenue, drug approval times, or environmental efficiency—with other leading pharmaceutical companies. This context is crucial for understanding our competitive position and our unique approach to value creation.

This tells our stakeholders: "We make it easy for you to see our trajectory and to understand how we stack up against the competition, providing you with a meaningful basis for your decisions."

Conclusion for Beacon Pharmaceuticals Plc

Collectively, these principles transform our Integrated Report from a static document into a dynamic reflection of our corporate character. It demonstrates that we are a forward-looking, strategically coherent, transparent, and stakeholder-responsive organization. It is the primary vehicle through we build trust and show that our mission to "improve lives through innovation" is integrated into everything we do, ensuring our long-term success and societal legitimacy.

Content Elements:

The elements form the essential narrative structure of our Integrated Report tell our stakeholders a coherent story about who we are, where we are going, and how we are performing in a complex and critical industry.

Here is a detailed explanation of what each of these contents means for us:

- **Organizational Overview and External Environment**

  What we do: This is our "elevator pitch." We clearly state our core purpose to discover, develop, and deliver innovative, high-quality, and affordable medicines that address significant unmet medical needs, particularly in focus therapeutic areas like oncology, cardiometabolic diseases, and rare diseases. We explain that we are not just a manufacturer; we are a research-driven organization dedicated to improving patient lives from discovery through to patient access.

  Under what circumstances we are operating our business: This is a candid analysis of our operating landscape. We describe the macro-environmental forces that shape our business:
  - **Regulatory:** The stringent, evolving oversight from bodies like the FDA, EMA, and others globally. Drug approval pathways, pharmacovigilance requirements, and pricing regulations are central to this.
  - **Competitive:** The intense competition from both large pharma conglomerates and agile biotech firms. The "patent cliff" phenomenon, where blockbuster drugs lose patent protection, is a constant consideration.
  - **Technological:** The rapid advancement of new modalities (e.g., gene therapies, mRNA technology, AI in drug discovery) which present both disruptive threats and immense opportunities.
  - **Socio-Economic:** Global pressures on healthcare budgets, growing demand for drug pricing transparency and access in low-income countries, and shifting demographics (e.g., aging populations).

- **Geopolitical:** Supply chain vulnerabilities, trade policies, and geopolitical tensions that can impact the global flow of APIs (Active Pharmaceutical Ingredients) and finished products.

- **Governance**

  How our governance structure supports our ability to create value: This section demonstrates that our strategy is underpinned by robust oversight. We explain:

  - **Board Composition:** How our Board of Directors possesses a mix of expertise (science, finance, ethics, international markets) to provide effective challenge and guidance.
  - **Committee Structure:** The role of key committees—the R&D Committee that oversees pipeline progress, the Risk Committee that manages everything from clinical trial risks to cyber threats, and the ESG Committee that ensures we meet our social and environmental responsibilities.
  - **Ethics and Culture:** How a "tone from the top" promoting quality, patient safety, and ethical conduct is non-negotiable. This is critical for maintaining our license to operate and avoiding reputational disasters.

- **Business Model**

  Our business model is the engine of our value creation. We present it as a transformation process:

  - **Inputs:** Our financial capital, intellectual capital (scientific knowledge, patents), human capital (researchers, staff), and natural capital (energy, water).
  - **Key Activities:** Our core activities: Research (discovery), Development (clinical trials), Regulatory Approval, Manufacturing (to strict Good Manufacturing Practices), Commercialization & Marketing, and Pharmacovigilance (monitoring drug safety).
  - **Outputs:** The tangible and intangible results: Approved and marketed drugs, scientific publications, and a strengthened brand.
  - **Outcomes:** The value we create: Patient Health Outcomes (social), Revenue & Profit (financial), Medical Advancement (intellectual), and Economic Contribution (jobs, taxes).

- **Risks and Opportunities**

  What are the specific risks and opportunities that may affect our organization's ability to create value: We provide a balanced and honest assessment.


  - **Risks:**
    - **Clinical Trial Failure:** The high probability that a drug candidate will fail in late-stage trials, resulting in significant financial loss.
    - **Regulatory Rejection:** A drug may not receive approval or may have its label restricted.
    - **Patent Expiration & Generic Competition:** The sharp decline in revenue when a drug loses patent protection.
    - **Supply Chain Disruption:** Reliance on specific regions for APIs creates vulnerability.
    - **Pricing & Market Access Pressures:** Governments and payers increasingly negotiating lower prices.
  - **Opportunities:**
    - **Breakthrough Therapies:** The potential for a new drug to become a standard of care and generate substantial value.
    - **Digital Health Integration:** Using AI and big data to improve R&D efficiency and develop companion diagnostics.
    - **Expansion into Emerging Markets:** Tapping into growing demand in Asia, Latin America, and Africa.
    - **Strategic Partnerships & Acquisitions:** In-licensing promising compounds or acquiring innovative biotech to bolster the pipeline.



- **Strategy and Resource Allocation**

  Our Strategic Intent: "To be a top-tier, innovation-driven pharmaceutical company recognized globally for leadership in oncology and for our commitment to sustainable healthcare."

- **Our Strategic Plan & Resource Allocation:** This is our roadmap. We outline our strategic pillars and, crucially, how we fund them:
  - **Pillar 1:** Lead in Oncology: Allocate >40% of R&D budget to oncology, built a dedicated oncology commercial team.
  - **Pillar 2:** Enhance Digital Capabilities: Invest in new AI-powered drug discovery platforms.
  - **Pillar 3:** Ensure Operational Excellence: Capital expenditure allocated to modernize our primary manufacturing facility for greater efficiency and lower environmental impact.
  - **Pillar 4:** Expand Globally: Resource allocation for building commercial infrastructure in key emerging markets.
- **Performance:** We measure and report on our progress against the strategy outlined above.



Strategic Objective: Providing innovative and complex generic products, oncology, and biotech medications.

Performance: "Introduced and commercially marketed around 130 oncology products and 54 biotech products"

Strategic Objective: "Reduce our carbon footprint by 10%." Performance: "Reduced emissions by 8% through energy efficiency projects at our main plant."

Outcomes in terms of effect on the capitals: We show the consequence of our performance on our resources.

- **Financial Capital:** Revenue growth from the new launch; increased R&D expenditure.
- **Intellectual Capital:** New patent grants; growth in our clinical pipeline.
- **Human Capital:** Improved employee engagement scores; key talent retention rates.
- **Social & Relationship Capital:** Improved patient advocacy group ratings; successful regulatory inspections.
- **Natural Capital:** Reduction in water usage and waste generation.

- **Outlook**

  What challenges we may encounter in pursuing our strategy: This is our forward-looking risk assessment. We are transparent about the hurdles ahead, such as anticipated intensified pricing pressure in Europe, potential for clinical delays due to patient recruitment challenges, or rising costs of raw materials.

  What are the potential implications for our business model: We explain how we might need to adapt. For example, pricing pressures might force us to accelerate our efforts in developing more cost-effective manufacturing processes. A challenge in patient recruitment might lead us to invest more heavily in decentralized clinical trial models.

- **Basis of Presentation**

  This is the "fine print" that ensures credibility. We state the reporting frameworks we have adopted (e.g., International Integrated Reporting Council <IR> Framework, IFRS, GRI Standards), the reporting boundary, and the period covered. We also disclose what has been subject to external assurance. This section assures stakeholders that the information in the preceding sections is prepared on a consistent, comparable, and reliable basis.

By structuring our report this way, we provide a holistic, connected, and strategic story. It demonstrates that we have a clear understanding of our environment, a robust plan for the future, a realistic view of the challenges, and a transparent system for measuring our progress and holding ourselves accountable. This builds the trust necessary for investors, employees, and partners to support us on our journey.

US-FDA Approved ARB to Control BP & to Reduce CVD Risk

1. STRONG BP REDUCTION
2. STRONG ORGAN PROTECTION
3. BETTER TREATMENT ADHERENCE

Teslar

Telmisartan



❑ **Teslar** is manufactured with **EP grade API** imported from **Moehs Iberica, Spain.** which makes Teslar a better brand of Telmisartan.

BEACON
Chronic Care

GOVERNANCE AND STATUTORY REPORTS

Directors' Report

This report has been prepared in compliance with Section 184 of the Companies Act 1994 and Corporate Governance Code 2018 of the Bangladesh Securities and Exchange Commission (BSEC) notification no. BSEC/CMRRCD/2006-158/207/Admin/80 dated 03 June 2018.

The Board of Directors of Beacon Pharmaceuticals PLC is pleased to present the Directors' Report on the overall performance of the company along with the Audited Financial Statements for the year ended 30 June 2025.

Pharmaceutical Industry Outlook and Prospects in Bangladesh

• Economic Challenges During FY 2024-2025

During the financial year 2024-2025, businesses across Bangladesh have faced considerable challenges in delivering value to investors. The economic environment has been characterized by declining GDP growth, rising inflation, increasing capital costs, fluctuating foreign exchange rates, and escalating power and energy expenses. These factors collectively contributed to a reduction in purchasing power among consumers and customers, affecting overall business performance across various sectors.

• Resilience of the Pharmaceutical Industry

Despite these macroeconomic headwinds, the pharmaceutical industry has continued to demonstrate resilience and strategic focus. The sector remains committed to expanding its presence in the domestic market, supported by the ongoing improvement of healthcare infrastructure and greater accessibility to medical services nationwide. These developments are driving higher consumption of pharmaceutical products within Bangladesh.

• Bangladesh's Global Position in Generic Pharmaceuticals

Bangladesh has also solidified its position as a major global player in the generic pharmaceuticals market. The industry's ability to produce high-quality, cost-effective generic drugs continues to be a cornerstone of its sustainable growth. Maintaining strict compliance with international regulatory standards-including those set by the U.S. Food and Drug Administration (USFDA) and the European Medicines Agency (EMA)-remains a top priority for manufacturers. Adherence to such rigorous quality and safety benchmarks is essential for sustaining access to international markets and enhancing the global reputation of Bangladesh's pharmaceutical sector.

• Export Performance and Domestic Market Coverage

Currently, Bangladesh exports pharmaceutical products to approximately 166 countries, while catering to nearly 98% of the nation's domestic demand. In FY 2024-2025, pharmaceutical exports reached USD 213 million, compared to USD 205 million in FY 2023-2024, marking a 4% year-on-year increase.

• Future Market Outlook

Looking ahead, the outlook for the pharmaceutical market in Bangladesh remains highly promising. Market projections indicate that revenue is expected to surpass USD 6 billion by 2025, reflecting a strong upward trajectory. Furthermore, the market is anticipated to grow at a compound annual growth rate (CAGR) of 6.28% from 2025-2029.

• Global Market Comparison

In comparison, the global pharmaceutical market is led by the United States, which is projected to generate USD 662.48 billion in 2025, underscoring its dominant position worldwide. In Bangladesh, per capita revenue in the pharmaceutical market is estimated to reach USD 26.58 in 2025, representing the sector's growing contribution to the economy.

• Strategic Importance and Long-Term Viability

Overall, the pharmaceutical industry in Bangladesh continues to exhibit robust growth potential, driven by rising domestic demand, expanding export opportunities, and a steady shift toward the production of affordable and accessible generic medicines. The sector's sustained performance amid economic challenges underscores its strategic importance and long-term viability within both national and global contexts.

Risk Factors and Management

The Board of Beacon Pharmaceuticals PLC continuously monitors and evaluates potential risks that may affect the Company's sustainability, profitability, and long-term growth. Risk management is firmly embedded within the Company's strategic and operational framework, guided by the belief that resilience to risk is essential to achieving strategic objectives and maintaining stakeholder confidence.

The pharmaceutical industry in Bangladesh operates within a complex and evolving environment influenced by macroeconomic volatility, regulatory requirements, and global market dynamics. Rising production costs, exchange rate fluctuations, and inflationary pressures continue to pose significant financial challenges, while the Company's dependence on imported raw materials exposes it to supply chain disruptions and cost variability.

Regulatory compliance remains a critical area of focus, as stringent local and international quality standards govern the sector. Beacon mitigates these risks through strict adherence to current Good Manufacturing Practices (cGMP), continuous process improvements, and regular compliance audits aligned with the USFDA and EMA frameworks.

Technological advancement and innovation are vital to sustaining competitiveness in the pharmaceutical sector. The risk of technological obsolescence is effectively managed through ongoing investments in research and development, automation, and digital transformation initiatives aimed at improving productivity, product quality, and process efficiency.

Environmental and sustainability risks are addressed through responsible manufacturing practices, efficient energy use, waste reduction, and adherence to environmental regulations. The Company's commitment to sustainable operations reinforces its long-term business viability and alignment with global best practices.

The Board remains confident that Beacon's proactive and structured risk management framework will continue to safeguard its assets, ensure operational continuity, and strengthen the Company's resilience in an increasingly competitive and dynamic pharmaceutical landscape.

During the financial year 2024-2025, the Company achieved a robust revenue growth of 17.20%, primarily driven by increased domestic sales, product diversification, and improved market penetration. Gross profit rose by 18%, reflecting better production efficiency and effective cost control measures.

Despite rising operating expenses associated with business expansion and inflationary pressure, net profit before tax increased by 36.47%, underscoring strong operational performance. Furthermore, a reduction in income tax expenses contributed to a significant 81.67% rise in net profit after tax, demonstrating the Company's enhanced profitability and improved financial health.

Overall, the financial results highlight the Company's resilience, strategic efficiency, and sustainable growth momentum, even amid challenging economic conditions.

Financial Results at a Glance


The company's financial results for the year ended June 30, 2025, as compared to the previous year, are summarized below:

Particulars	2024-2025 (BDT in million)	2023-2024 (BDT in million)	%	↓ ↑
Revenue	12,543	10,702	17.20	↑
Cost of Goods Sold	6,015	5,169	16.36	↑
Gross Profit	6,528	5,533	17.99	↑
Operating Expenses	4,129	3,671	12.48	↑
Net Profit Before Tax	1,301	953	36.47	↑
Income Tax Expenses	355	432	17.99	↓
Net Profit After Tax	947	521	81.67	↑

Segment-Wise Revenue Performance

The overall revenue of the Company is derived from several operating segments, each contributing to the business's diversified growth. The performance of these segments during the financial year 2024-2025 is summarized below:

Figures are in Million (BDT)



General	Oncology	Biotech	Palliative	Chronic Care	Institution
Growth: 31.07%	Growth: 2.92%	Growth: 25.38%	Growth: 19.88%	Growth: 49.96%	Growth: - 27.57%

Contribution to the National Exchequer

The Company remains committed to fulfilling its fiscal responsibilities and contributing to the national economy through regular payments to the Government exchequer in various forms, including income tax, customs duty, and value-added tax (VAT).


During the financial year ended June 30, 2025, Beacon Pharmaceuticals PLC contributed a total of Tk. 2,071,368,819 to the National Exchequer. This contribution represents 16.16% of the Company's net sales revenue for the year, underscoring Beacon's continued dedication to national development and economic growth.

Dividend

The Board of Directors has recommended a cash dividend of 21% (i.e., Taka 2.10 per share) for general and institutional shareholders, excluding the sponsors and directors, for the financial year ended 30 June 2025.

The dividend will be paid to shareholders whose names appear in the register maintained by CDBL up to the cut-off date, Sunday, 16 November 2025, which has been fixed as the Record Date for dividend entitlement. No interim dividend was declared during the year.

The dividend payment for the past three years are summarized below (Dividend Payout in Million):



Product Development

In the reporting year, 57 new products were added to the Company's portfolio, each receiving strong endorsement from medical professionals and positive acceptance from consumers. Furthermore, 26 new generic formulations were launched. These strategic introductions reflect the Company's unwavering commitment to innovation, expansion of therapeutic coverage, and strengthening of its leadership position within the pharmaceutical industry.




Discussion on Cost of Goods Sold, Gross Profit Margin and Net Profit Margin

The Cost of Goods Sold (COGS) for FY 2024-2025 amounted to BDT 6,014,611,260, compared to BDT 5,168,915,584 in the previous year, reflecting an increase of 16.36%. Although the total COGS rose in line with higher sales volumes, the COGS as a percentage of sales remained stable, as material costs and other direct expenses were largely unchanged.

The Gross Profit for the year stood at BDT 6,528,105,954, reflecting an 18% growth over the prior year. This was primarily driven by higher revenue and an improved product mix, supported by effective cost management and operational efficiency.

The Net Profit for FY 2024-2025 reached BDT 946,511,761, marking a substantial 81.67% increase compared to the previous year. This strong performance was fueled by robust revenue growth, stable production costs, and effective tax management, which optimized after-tax profitability and enhanced overall financial strength.



Extraordinary Activities

The Board wishes to note that during the financial year ended June 30, 2025, the Company did not engage in any extraordinary activities that resulted in significant gains or losses. All income and expenses recorded in the year pertain to the ordinary course of business operations, including revenue from product sales, operating expenses, and statutory obligations.

Related Party Transaction

The Company engaged in certain related party transactions during the year, all of which have been duly reflected in the Financial Statements. These transactions were conducted in the ordinary course of business and have been structured to ensure that they do not conflict with the interests of the Company or its shareholders. Details of these transactions, along with the rationale for each, are disclosed in Note 35.2 of the Financial Statements, in accordance with IAS 24 - Related Party Disclosures, and are summarized below:

Name of the related parties	Nature of the relationship	Nature of transaction	30 June 2025
Beacon Medicare Ltd.	Sister concern	Sale/Loan and advances	2,464,226,709
Ereba Capsules Ltd.	Sister concern	Purchase/Loan and advances	363,701,594
Beacon Business Solutions Ltd.	Sister concern	Purchase/Loan and advances	(31,617,528)
Beacon Nutraceuticals Ltd.	Sister concern	Loan and advances	43,749,090
MEK Pharmatech Ltd.	Sister concern	Loan and advances	69,616,958
MEK Auto Bricks Ltd.	Sister concern	Loan and advances	5,366,735
Beacon Cephalosporin Ltd.	Sister concern	Purchase/Loan and advances	467,799,874
Beacon Oncology Ltd.	Sister concern	Loan and advances	53,544,296
Beacon Developments Ltd	Sister concern	Service received/Loan and advances	794,105,824
Beacon Power Systems Ltd.	Sister concern	Loan and advances	70,000
UB Nutraceuticals Ltd.	Sister concern	Loan and advances	139,477,191
Total			**4,370,040,744**

Variance within the Financial Year

There were no significant variances between the quarterly financial performances during the year under review. The Company delivered strong results through the first three quarters, demonstrating resilience despite various operational challenges. However, heightened political activities in the fourth quarter disrupted business operations, making it a more challenging period. As a result, the Company was unable to fully achieve its targeted performance for the final quarter.

Remuneration to Directors

Details of transactions with key management personnel are disclosed in Note 35.1 of the Financial Statements. This includes the remuneration of the Managing Director and fees paid to other Directors for their attendance at Board and Committee meetings, in accordance with applicable governance and disclosure requirements.

Internal Controls

The Company maintains a sound system of internal controls, which is well-designed, effectively implemented, and regularly monitored. The Board ensures that the control framework is commensurate with the size, scale, and complexity of the business.

The Audit Committee, comprising professionally qualified Directors, interacts closely with statutory auditors, internal auditors, and management to address matters within its terms of reference. The signatory matrix, approved by the Board in line with the Segregation of Duties principle, ensures that all transactions are properly authorized. In addition, operational and fraud risk controls cover the full spectrum of internal financial processes.

An extensive program of internal audits and management reviews supports the internal control framework. Documented policies, guidelines, and procedures exist for all critical business processes, and the internal audit function continuously monitors and evaluates their effectiveness, adequacy, and compliance with established operating systems, accounting procedures, and policies. Based on internal audit reports, process owners undertake corrective actions in their respective areas, thereby further strengthening controls. Significant audit observations and proposed corrective measures are presented to the Audit Committee of the Board.

The Company has also identified and documented key risks and controls for each process relevant to financial operations and reporting. These key controls are tested periodically by the internal audit function. A robust compliance management framework ensures adherence to all legal and regulatory requirements and is regularly assessed for adequacy and effectiveness to mitigate compliance risks.

Minority Shareholder Protection

The Company ensures that minority shareholders are protected from any abusive actions, whether direct or indirect, by controlling shareholders, and provides effective means of redress. The Company maintains strong investor relations and shareholder management processes, through which management-including the Company Secretary, Chief Financial Officer, and Managing Director-continuously engages with shareholders via multiple channels.

The Company has formulated a dividend policy, approved by the Board and published on the Company's website, to ensure transparent access for all shareholders. This policy, presented in this report in accordance with the BSEC directive dated 14 January 2021, helps shareholders understand the internal and external factors considered in dividend declaration and payout decisions.

To maintain transparency, the Company ensures that critical information is available to all shareholders by disseminating disclosures, sharing price-sensitive information, and uploading such updates to the Company's website under the Investors section. Detailed disclosures on material decisions and related party transactions are presented in this report for review and approval by shareholders at the Annual General Meeting.

Code of Conduct

The Company's Code of Conduct (CoC) has been reviewed by the Nomination & Remuneration Committee and adopted by the Board, which applies to all members of the company, including the Board of Directors and Key Management Personnel.

Statutory Auditors

i. Habib Sarwar Bhuiyan & Co. Chartered Accountants will be completing their second term of Audit for the Company at the 24th Annual General Meeting (AGM). In this context, based on the suggestions of the Audit Committee, the Board has recommended re-appointment of Selected firm name as statutory auditors in accordance with Section 210 of the Companies Act 1994 to hold office until the conclusion of the 25th AGM at a consolidated fee of BDT 3,91,304 (including AIT).

ii. As required under the BSEC CG Code, the Compliance Auditor will be appointed at the 24th Annual General Meeting.

Directors' Statement on Financial Reporting and Other Disclosures

The Directors, in accordance with the Corporate Governance Code 2018, confirm the following to the best of their knowledge:

a) The financial statements prepared by the management of the Company present fairly its state of affairs, the results of its operations, cash flows and changes in equity.

b) Proper books of account of the issuer company have been maintained.

c) Appropriate accounting policies have been consistently applied in the preparation of the financial statements and that the accounting estimates are based on reasonable and prudent judgment.

d) International Accounting Standards (IAS) or International Financial Reporting Standards (IFRS), as applicable in Bangladesh, have been followed in the preparation of the financial statements, and any departure therefrom has been adequately disclosed.

e) There is no significant doubt about the issuer company's ability to continue as a going concern.

f) All significant deviations from the previous year in the Company's operating results have been highlighted and the reasons thereof have been explained.

g) The key operating and financial data for the last five years have been disclosed in this report.

h) Beacon Pharmaceuticals PLC went for an initial public offering in the year 2010 and the funds raised thereby have already been utilized accordingly, as reported to the regulators. No other equity instrument has been issued since then.

i) Beacon Pharmaceuticals PLC has recommended the final dividend for the year 2025. The company has not declared a Bonus Share or Stock Dividend as an Interim Dividend in 2025.

j) The declaration by the Chief Executive Officer (CEO) and the Chief Financial Officer (CFO) on Financial Statements 2025 to the Board as prescribed, is annexed to this report as **Annexure-A.**

k) The report and certificate regarding compliance with the Corporate Governance Code as prescribed are annexed to this report as **Annexure-B** and **Annexure-C**, respectively.

l) Number of Board Meetings and Attendance of Directors has been presented in **Annexure-D.**

m) Pattern of Shareholding has been presented in **Annexure-E.**

n) Management discussion and analysis has been duly signed by the Managing Director of the Company and is presented in this Annual Report in **Annexure-F**.

Acknowledgement

The Board takes this opportunity to express its heartfelt thanks to all stakeholders, including its shareholders, investors, employees, customers, business partners, banks and financial institutions, regulatory bodies and auditors, for their immense support and contribution towards the success of the Company.

On behalf of the Board

Nurun Nahar Karim

Nurun Nahar Karim
Chairman, Board of Directors

Annexure-A

DECLARATION BY

MANAGING DIRECTOR (MD) AND CHIEF FINANCIAL OFFICER (CFO)

October 22, 2025
The Board of Directors
Beacon Pharmaceuticals PLC

Subject: Declaration on Financial Statements for the year ended on 30 June, 2025

Dear Sir,

Pursuant to the condition No. 1(5)(xxvi) imposed vide the Commission's Notification No. BSEC/CMRRCD/2016-158/207/Admin/80, Dated June 03, 2018 & under section 2CC of the Securities and Exchange Ordinance, 1969, we do hereby declare that:

(1) The Financial Statements of Beacon Pharmaceuticals PLC for the year ended on 30 June, 2025 have been prepared in compliance with International Accounting Standards (IAS) or International Financial Reporting Standards (IFRS), as applicable in the Bangladesh and any departure there from has been adequately disclosed;

(2) The estimates and judgments related to the financial statements were made on a prudent and reasonable basis, in order for the financial statements to reveal a true and fair view;

(3) The form and substance of transactions and the Company's state of affairs have been reasonably and fairly presented in its financial statements;

(4) To ensure above, the Company has taken proper and adequate care in installing a system of internal control and maintenance of accounting records;

(5) Our internal auditors have conducted periodic audits to provide reasonable assurance that the established policies and procedures of the Company were consistently followed; and

(6) The management's use of the going concern basis of accounting in preparing the financial statements is appropriate and there exists no material uncertainty related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern.

In this regard, we also certify that:-

(i) We have reviewed the financial statements for the year ended on 30 June, 2025 and that to the best of our knowledge and belief:

   (a) These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading;

   (b) These statements collectively present true and fair view of the Company's affairs and are in compliance with existing accounting standards and applicable laws.

(ii) There are, to the best of knowledge and belief, no transactions entered into by the Company during the year which are fraudulent, illegal or in violation of the code of conduct for the company's Board of Directors or its members.

Sincerely yours,

Mohammad Ebadul Karim
Managing Director

Md. Jalal Uddin FCA
Chief Financial Officer

CORPORATE GOVERNANCE

CERTIFICATE

Annexure-B

MNA ASSOCIATES
Chartered Secretaries

ANNEXURE-B
[(Certificate as per condition No. 1(5)(xxvii)]

Report to the Shareholders of BEACON Pharmaceuticals PLC. on Compliance to the Corporate Governance Code 2018;

We have examined the compliance status to the Corporate Governance Code by Beacon Pharmaceuticals PLC. for the year ended on 30 June 2025. This Code relates to the Notification No. BSEC/CMRRCD/2006 -158/207/ Admin/80, dated 03 June 2018 of the Bangladesh Securities and Exchange Commission.

Such compliance with the Corporate Governance Code is the responsibility of the Company. Our examination was limited to the procedures and implementation thereof as adopted by the Management in ensuring compliance to the conditions of the Corporate Governance Code.

This is a scrutiny and verification and an independent audit on compliance of the conditions of the Corporate Governance Code as well as the provisions of relevant Bangladesh Secretarial Standards (BSS) as adopted by Institute of Chartered Secretaries of Bangladesh (ICSB) in so far as those standards are not inconsistent with any conditions of this Corporate Governance Code.

We state that we have obtained all the information and explanations, which we have required, and after due scrutiny and verification thereof, we report that, in our opinion:

a) The Company has complied with the conditions of the Corporate Governance Code as stipulated in the above-mentioned Corporate Governance Code issued by the Commission except those mentioned in the statement of compliance status;

b) The Company has complied with the provisions of the relevant Bangladesh Secretarial Standards (BSS) as adopted by the Institute of Chartered Secretaries of Bangladesh (ICSB) as required by this Code;

c) Proper books and records have been kept by the company as required under the Companies Act, 1994, the Securities Laws and other relevant laws; and

d) The governance of the company is satisfactory.

MNA Associates
Chartered Secretaries

M Nurul Alam FCS
Chief Executive Officer
Enrollment No. 015

Place: Dhaka
Dated: November 6, 2025

MNA ASSOCIATES

MNA Associates
Tropical Molla Tower 4th Floor| Sha-15/1-4 Pragati Sarani (Gulshan Link Road Badda end) | Middle Badda, Dhaka-1212

COMPLIANCE WITH THE

Annexure-C

Corporate Governance Code (CGC)

As Per condition no.1(5) (xxvii). Status of Compliance with the conditions imposed by the Commission's Notification No. BSEC/CMRRCD/2006- 158/207/Admin/80, dated 3 June 2018 issued under section 2CC of the Securities and Exchange Ordinance, 1969:

Condition No.	Title	Compliance Status		Remarks (if any)
		Complied	Not Complied	
1	**Board of Directors**			
1(1)	**Size of the Board of Directors**			
	Board's Size: Board members shall not be less than 5 (Five) and more than 20 (Twenty)	√	–	The Board is comprised of 8 (Eight) members
1(2)	**Independent Directors: Representation of ID in Board**			
1(2)(a)	Number of Independent Director: At least 2(two) directors or one-fifth (1/5) of the total number of directors in the company's Board, whichever is higher, shall be independent directors; any fraction shall be considered to the next integer or whole number for calculating number of independent director(s): Provided that the Board shall appoint at least 1(one) female independent director in the Board of Directors of the company;	√		There are 4 (Four) Independent Directors in the Board including one female Independent Director
1(2)(b)	Without contravention of any provision of any other laws, for the purpose of this clause, an "Independent Director" means a director–	√	–	The Independent Directors have declared their compliance
1(2)(b)(i)	Who do not hold any share or less than 1% (one) percent share of total paid-up shares of the company	√	–	
1(2)(b)(iii)	Who has not been an executive of the company in immediately preceding 2 (two) financial years	√		
1(2)(b)(iv)	Who do not have any other relationship, whether pecuniary or otherwise, with the company or its subsidiary/associated company	√		
1(2)(b)(v)	Who are not the members or TREC holder, directors or officers of any stock exchange	√		
1(2)(b)(vi)	Who is not the shareholder, directors excepting independent director or officer of any member or TREC holder of stock exchange or an intermediary of the capital market	√		

Condition No.	Title	Compliance Status		Remarks (if any)
		Complied	Not Complied	
1(2)(b)(vii)	Who are/were not the partners or executives during preceding three years of any statutory audit firm	√		
1(2)(b)(viii)	Who are not the independent directors in more than 5 (five) listed companies	√		
1(2)(b)(ix)	Who has not been reported as a defaulter in the latest Credit Information Bureau (CIB) report of Bangladesh Bank for nonpayment of any loan or advance or obligation to a bank or a financial institution;	√		
1(2)(b)(x)	Who is not been convicted for a criminal offence involving moral turpitude	√		
1(2)(c)	The Independent Directors shall be appointed by the board of directors and approved by the shareholders in the Annual General Meeting: Provided that the Board shall appoint the Independent Director, subject to prior consent of the Commission, after due consideration of recommendation of the Nomination and Remuneration Committee (NRC) of the company;	√		
1(2)(d)	The post of Independent Directors cannot remain vacant for more than 90 days	√		
1(2)(e)	The tenure of office of an Independent Directors shall be for a period of three years which may be extended for one term only & Independent Director shall not be subject to retirement by rotation as per companies Act, 1994. After completing two terms e.g., six (6) years, a time gap of one (1) tenure e.g., three (3) years independent director may be considered for reappointment.	√		
1(3)	**Qualification of Independent Director (ID)**			
1(2)(e)	Independent Director shall be knowledgeable individual with integrity	√		
1(3)(a)	**Independent Director shall have the following qualification**			
1(3)(b)(i)	Business Leader who is or was a promoter or director of an unlisted company having minimum paid-up capital of Tk.100.00 million or any listed company or a member of any national or international chamber of commerce or registered business association; or			Not applicable

Condition No.	Title	Compliance Status		Remarks (if any)
		Complied	Not Complied	
1(3)(b)(ii)	Corporate leader who is or was a top-level executive not lower than CEO or MD or DMD or CFO or Head of Finance or Accounts or company secretary or head of internal audit and compliance or head of legal service or a candidate with equivalent position of an unlisted company having minimum paid up capital of 100 million or of a listed company.	√	–	The Independent Director MR. REZANUR CHOWDHURY FCA and Mohammed Ariful Hoque FCA, ACA (Eng & Wales) possesses requisite qualification.
1(3)(b)(iii)	Former or existing official of government or statutory or autonomous or regulatory body in the position not below 5th Grade of the national pay scale, who has at least educational background of bachelor degree in economics or commerce or business or Law: Provided that in case of appointment of existing official as independent director, it requires clearance from the organization where he or she is in service; or	√		Not applicable
1(3)(b)(iv)	University teacher who has an educational background in economics or commerce or business studies or law.	√	–	The Independent Director Prof. ABM Faroque and Prof. Dr. Shamem Ara Mili possesses requisite qualification.
1(3)(b)(v)	Professional or who is or was an advocate practicing at least in the high court division of supreme court or a CA or CMA or CFA or CCA or CPA or CMA or CS or equivalent position.	√		The Independent Director MR. REZANUR CHOWDHURY FCA and Mohammed Ariful Hoque FCA, ACA possesses requisite qualification.
1(3)(c)	The Independent Director shall have at least 10 years of experience in any field mentioned in clause (b)	√		
1(3)(d)	In special cases, the above qualifications or experiences may be relaxed subject to prior approval of the commission	√		Not applicable
1.4	**Duality of Chairperson of the Board of Directors and Managing Director or Chief Executive Officer**			
1(4)(a)	The Chairman of the Board and the Managing Director (MD) and /or Chief Executive Officer (CEO) shall be different individuals.	√		Ms. Nurun Nahar Karim is the Chairman of the Board and Mr. Mohammad Ebadul Karim is the Managing Director of the company.

Condition No.	Title	Compliance Status		Remarks (if any)
		Complied	Not Complied	
1(4)(b)	The MD and/or CEO of a listed company shall not hold the same in another listed company	√		
1(4)(c)	The Chairman of the board shall be elected from among the non-executive Directors of the company	√		Ms. Nurun Nahar Karim is the Chairman of the Board.
1(4)(d)	The board shall clearly define respective roles & responsibilities of chairperson and MD and/or CEO	√		
1(4)(e)	In the absence of chairperson of the board, remaining members may elect one of themselves from non-executive directors as chairperson & the reason of absence shall be duly recorded in the minutes	√		
1.5	**The Directors' Report to Shareholders**			
1.5 (i)	Industry outlook and possible future developments in the industry	√		
1.5 (ii)	Segment-wise or product-wise performance	√		
1.5 (iii)	Risk and Concern including external & internal risk factors threat to sustainability & negative impact on environment, if any	√		
1.5 (iv)	A discussion on cost of goods sold, gross profit margin and net profit margin, where applicable;	√		
1.5 (v)	A Discussion on continuity of an Extra-ordinary activities and their implications (gain or loss)	√		No such extra ordinary gain or loss occurred
1.5 (vi)	A detailed discussion on related party transactions along with a statement showing amount, nature of related party, nature of transactions and basis of transactions of all related party transactions;	√		
1.5 (vii)	A statement of utilization of proceeds raised through public issues, rights issues and/or any other instruments;	√		
1.5 (viii)	An explanation if the financial results deteriorate after the company goes for Initial Public Offering (IPO), Repeat Public Offering (RPO), Rights Share Offer, Direct Listing etc.;	√		
1.5 (ix)	An Explanation on significant variance occurs between quarterly financial performance and Annual Financial Statements	√		
1.5 (x)	A statement of Remuneration to Directors including independent director	√		

Condition No.	Title	Compliance Status		Remarks (if any)
		Complied	Not Complied	
1.5 (xi)	The financial statements prepared by the management of the issuer company present fairly state its affairs, the result of its operation, cash flows and changes in equity	√		
1.5 (xii)	Proper books of account of the issuer company have been maintained	√		
1.5 (xiii)	Appropriate accounting policies have been consistently applied in preparation of the financial statements and that the accounting estimates are based on reasonable and prudent judgment	√		
1.5 (xiv)	A statement that International Accounting Standards (IAS)/ Bangladesh Accounting Standards (BAS)/International Financial Reporting Standards (IFRS)/Bangladesh Financial Reporting Standards (BFRS), as applicable in Bangladesh, have been followed in preparation of the financial statements and any departure there-from has been adequately disclosed.	√		
1.5 (xv)	The system of internal control is sound in design and has been effectively implemented and monitored	√		
1.5 (xvi)	A statement that minority shareholders have been protected from abusive actions by, or in the interest of, controlling shareholders acting either directly or indirectly and have effective means of redress;	√		
1.5 (xvii)	There are no significant doubts upon the issuer company's ability to continue as a going concern. If the issuer company is not considered to be a going concern, the fact along with the reasons thereof should be disclosed.	√		
1.5 (xviii)	Significant deviations from the last year's operating results of the issuer company shall be highlighted and the reason thereof should be explained	√		
1.5 (xix)	Key operating and financial data of at least preceding five years shall be summarized	√		
1.5 (xx)	If the issuer company has not declared dividend (cash or stock) for the year, the reasons thereof shall be given	√		21% Cash Dividend only for General Shareholders
1.5 (xxi)	No bonus share or stock dividend has been or shall be declared as interim dividend	√		
1.5 (xxii)	The number of Board meetings held during the year and attendance by each director shall be disclosed.	√		

Condition No.	Title	Compliance Status		Remarks (if any)
		Complied	Not Complied	
1.5 (xxiii)	**Report on the pattern of shareholding disclosing the aggregate number of shares held by-**			
1.5(xxiii)(a)	Parents/Subsidiary/Associated companies and other related parties (name wise details)	√		
1.5 (xxiii)b	Directors, Chief Executive Officer, Company secretary, Chief Financial Officer, Head of Internal Audit and their spouses and minor children (name wise details)	√		
1.5 (xxiii) c	Executives	√		
1.5 (xxiii)d	Shareholders holding ten percent or more voting interest in the company (name wise details)	√		
1.5 (xxiv)	**Disclosure on the appointment /reappointment of directors-**			
1.5 (xxiv)a	A brief resume of the director	√		
1.5 (xxiv)b	Nature of his/her expertise in specific functional areas	√		
1.5 (xxiv)c	Names of companies in which the person also holds directorship and the membership of committees of the board than this company	√		
1.5 (xxv)	A management discussion and analysis signed by CEO or MD presenting detailed analysis of the company's position and operations along with a brief discussion of changes in the financial statement, among others focusing on:	√		
1.5(xxv)(a)	Accounting policies & estimation for preparation of financial statements	√		
1.5(xxv)(b)	Changes in accounting policies & estimation, if any clearly describing the effect on financial performance or results and financial position as well as cash flows in the absolute figures	√		
1.5(xxv)(c)	Comparative analysis (including effect of inflation) of financial performance or results and financial position as well as cash flows in the absolute figures	√		
1.5(xxv)(d)	Compare such financial performance or results and financial position as well as cash flows with the peer industry scenario	√		
1.5(xxv)(d)	Compare such financial performance or results and financial position as well as cash flows with the peer industry scenario	√		

Condition No.	Title	Compliance Status		Remarks (if any)
		Complied	Not Complied	
1.5(xxv)(e)	Briefly explain the financial and economic scenario of the country and the globe	√		
1.5(xxv)(f)	Risks & concerns issued related to the financial statements, explaining such risk and concerns mitigation plan of the company	√		
1.5(xxv)(g)	Future plan or projection or forecast for company's operation, performance and financial position, with jurisdiction thereof, i.e., actual position shall be explained to the shareholders in the next AGM	√		
1.5(xxvi)	Declaration or certification by the CEO and the CFO to the board as required under condition No:.3(3) shall be disclosed as per Annexure-A;	√		
1.5(xxvii)	The report as well as certificate regarding compliance of conditions of the code as required under condition No.9 shall be disclosed as per Annexure-B & Annexure-C;	√		
1.5 (xxviii)	The Directors' report to the shareholders does not require to include the business strategy or technical specification related to products or services, which have business confidentiality.	√		
1(6)	The company shall conduct its Board meetings and record the minutes of the meetings as well as keep required books and records in line with BSS as adopted by the Institute of Chartered Secretaries of Bangladesh	√		
1(7)	**Code of Conduct for the Chairperson, other Board members and Chief Executive Officer**			
1(7)(a)	The board shall lay down a code of conduct based on the recommendation of the NRC at condition No.6 for the chairperson of the board, other board members & CEO of the company	√		
1(7)(b)	The code of conduct as determined by the NRC shall be posted in the website of the company among others prudent conduct & behavior; confidentiality; conflict of interest; compliance with laws, rules & regulations; prohibition of insider trading; relationship with environment, employees, customers and suppliers; and independency	√		
2.00	**Governance of Board of Directors of Subsidiary Company**			
2 (a)	Provisions relating to the composition of board of holding company shall be made applicable to the composition of the board of subsidiary company	√		

Condition No.	Title	Compliance Status		Remarks (if any)
		Complied	Not Complied	
2 (b)	At least one (1) independent director of the board of the holding company shall be a director in the board of subsidiary company	√		
2 (c)	The minutes of the subsidiary company shall be placed for review at the following board meeting of the holding company	√		
2 (d)	The minutes of the respective board meeting of the holding company shall state that they have reviewed the affairs of the subsidiary company also	√		
2 (e)	The audit committee of the holding company shall also review the financial statements, in particular the investments made by the subsidiary company	√		
3.	**Managing Director (MD) or Chief Executive Officer (CEO), Chief Financial Officer (CFO), Head of Internal Audit and Compliance (HIAC) and Company Secretary (CS)**			
3 (1)	**Appointment**			
3(1)(a)	The Board shall appoint a Managing Director (MD) or Chief Executive Officer (CEO), a Company Secretary (CS), a Chief Financial Officer (CFO) and a Head of Internal Audit and Compliance (HIAC);	√		
3(1)(b)	Position of MD, CFO, HIAC and CS shall be filled by different individuals The positions of the Managing Director (MD) or Chief Executive Officer (CEO), Company Secretary (CS), Chief Financial Officer (CFO) and Head of Internal Audit and Compliance (HIAC) shall be filled by different individuals;	√		
3(1)(c)	The MD or CEO, CFO, HIAC and CS shall not hold any executive position in any other company at the same time: Provided that CFO or CS of any listed company may be appointed for the same position in any other listed or non-listed company under the same group for reduction of cost or for technical expertise, with prior approval of the Commission: Provided further that the remuneration and perquisites of the said CFO or CS shall be shared by appointing companies proportionately;	√		
3(1)(d)	The Board shall clearly define their respective roles, responsibilities and duties of CFO, HIAC & CS	√		
3(1)(e)	The MD or CEO, CFO, HIAC and CS shall not be removed from their position without approval of Board as well as immediate dissemination to the commission & stock exchange(s).	√		

Condition No.	Title	Compliance Status		Remarks (if any)
		Complied	Not Complied	
3(2)	Requirements to attend BOD's Meetings-The MD or CEO, CFO, HIAC and CS shall attend Board of Directors meeting The MD or CEO, CS, CFO and HIAC of the company shall attend the meetings of the Board: Provided that the CS, CFO and/or the HIAC shall not attend such part of a meeting of the Board which involves consideration of an agenda item relating to their personal matters.	√		
3(3)	**Duties of Managing Director (MD) or Chief Executive Officer (CEO) and Chief Financial Officer (CFO)**			
3(3)(a)	The MD or CEO and CFO shall certify to the board that they have reviewed financial statements for the year and that to the best of their knowledge and belief:	√		
3(3)(a) (i)	These statements do not contain any materially untrue statement or omit any material fact or contain statements that might be misleading; and	√		
3(3)(b)	These statements together present a true and fair view of the company's affairs and are in compliance with existing accounting standards and applicable laws	√		
3(3)(c)	The certification of the MD or CEO and CFO shall be disclosed in the annual report	√		Included in the Annual Report
4				
4(i)	Audit Committee	√		
4 (ii)	Nomination and Remuneration Committee	√		
5	**Audit Committee**			
5(1)	**Responsibility to the Board of Directors**			
5 (1)(a)	Audit Committee shall be the sub-committee of the Board of Directors	√		
5 (1)(b)	The committee shall assist the Board of Directors in ensuring that the financial statements reflect true and fair view of the state of affairs of the company and in ensuring a good monitoring system within the business	√		

Condition No.	Title	Compliance Status		Remarks (if any)
		Complied	Not Complied	
5 (1)(c)	The Audit Committee shall be responsible to the Board of Directors. The duties of the Audit Committee shall be clearly set forth in writing	√		
5 (1)(c)	**Constitution of the Audit Committee**			
5 (2)(a)	The Audit Committee shall be composed of at least three (3) members	√		Audit committee comprised with the Five members including Four Independent Directors.
5 (2)(b)	The Board shall appoint members of the Audit Committee who shall be non-executive directors of the company excepting Chairperson of the Board and shall include at least 1 (one) independent director;	√		Audit committee comprised by the Five Non-executive Directors including four Independent
5 (2)(c)	All members of the audit committee should be financially literate and at least one member shall have accounting or related financial management experience and 10 (ten) years of such experience.	√		
5 (2)(d)	When the term of service of any Committee member expires or there is any circumstance causing any Committee member to be unable to hold office before expiration of the term of service, thus making the number of the Committee members to be lower than the prescribed number of 3 (three) persons, the Board shall appoint the new Committee member to fill up the vacancy immediately or not later than 60 (sixty) days from the date of vacancy in the Committee to ensure continuity of the performance of work of the Audit Committee;	√		
5 (2)(e)	The company secretary shall act as the secretary of the committee	√		
5 (2)(f)	The quorum of the Audit Committee meeting shall not constitute without at least 1 (one) Independent Director.	√		
5(3)	**Chairperson of the Audit Committee**			
5 (3)(a)	The Board shall select 1 (one) member of the Audit Committee to be Chairperson of the Audit Committee, who shall be an independent director;	√		Independent Director Mohammed Ariful Hoque FCA, ACA is the Chairperson

Condition No.	Title	Compliance Status		Remarks (if any)
		Complied	Not Complied	
5 (3)(b)	In the absence of the Chairperson of the Audit Committee, the remaining members may elect one of themselves as Chairperson for that particular meeting, in that case there shall be no problem of constituting a quorum as required under condition No. 5(4)(b) and the reason of absence of the regular Chairperson shall be duly recorded in the minutes.	√		
5 (3)(c)	Presence of Chairman of the Audit Committee in the Annual General Meeting	√		
5 (4)	**Meeting of the Audit Committee**			
5 (4) (a)	The Audit Committee shall conduct at least its four meetings in a financial year: Provided that any emergency meeting in addition to regular meeting may be convened at the request of any one of the members of the Committee;	√		Audit Committee held Four meetings during the year
5 (4) (b)	The quorum of the meeting of the Audit Committee shall be constituted in presence of either two members or two-third of the members of the Audit Committee, whichever is higher, where presence of an independent director is a must.	√		
5 (5)	**Role of Audit Committee**			
5 (4) (b)	Oversee the financial reporting process	√		
5 (5) (b)	Monitor choice of accounting policies and principles	√		
5 (5) (c)	Monitor Internal Audit and Compliance process to ensure that it is adequately resourced, including approval of the Internal Audit and Compliance Plan and review of the Internal Audit and Compliance Report;	√		
5 (5) (d)	Oversee hiring and performance of external auditors	√		
5 (5) (e)	Hold meeting with the external or statutory auditors for review of the annual financial statements before submission to the Board for approval or adoption;	√		
5 (5) (f)	Review along with the management, the annual financial statements before submission to the Board for approval;	√		

Condition No.	Title	Compliance Status		Remarks (if any)
		Complied	Not Complied	
5 (5) (g)	Review along with the management, the quarterly and half yearly financial statements before submission to the Board for approval;	√		
5 (5) (h)	Review the adequacy of internal audit function	√		
5 (5) (i)	Review the Management's discussion and analysis before disclosing in the annual report	√		
5 (5) (j)	Review statement of significant related party transactions submitted by the management	√		
5 (5) (k)	Review Management Letters or Letter of Internal Control weakness issued by statutory auditors;	-	-	No such case occurred
5 (5) (l)	Oversee the determination of audit fees based on scope and magnitude, level of expertise deployed and time required for effective audit and evaluate the performance of external	√		
5 (5) (m)	Oversee proceeds raised through initial public offering/ repeat public offering/rights issue the company shall disclose to the audit committee about the uses/applications of funds by major category (capital expenditure, sales and marketing expenses, working capital etc.), on a quarterly basis, as a part of their quarterly declaration of financial results oversee whether the proceeds raised through Initial Public Offering (IPO) or Repeat Public Offering (RPO) or Rights Share Offer have been utilized as per the purposes stated in relevant offer document or prospectus approved by the Commission: Provided that the management shall disclose to the Audit Committee about the uses or applications of the proceeds by major category (capital expenditure, sales and marketing expenses, working capital, etc.), on a quarterly basis, as a part of their quarterly declaration of financial results: Provided further that on an annual basis, the company shall prepare a statement of the proceeds utilized for the purposes other than those stated in the offer document or prospectus for publication in the Annual Report along with the comments of the Audit Committee.	√		
5 (6)	**Reporting of the Audit Committee**			
5 (6)(a)	**Reporting to the Board of Directors**			

Condition No.	Title	Compliance Status		Remarks (if any)
		Complied	Not Complied	
5 (6) (a) (i)	The audit committee shall report on its activities to the board of directors	√		
5 (6)(a) (ii)	**Audit committee immediately report to the Board on the following findings-**			
5 (6) (a) (ii) (a)	Report on conflict of interest	-		No such case occurred
5 (6) (a) (ii)(b)	Suspected or presumed fraud or irregularity or material defect in the internal audit & compliance process or in the financial statement	-		No such case occurred
5 (6) (a) (ii)(c)	suspected infringement of laws, regulatory compliances including securities related laws, rules and regulations; and	-		No such case occurred
5 (6) (a) (ii)(d)	Any other matter which deems necessary shall be disclosed to the board of directors immediately	-		No such case occurred
5 (6) (b)	Reporting to the authorities: If the Audit Committee has reported to the Board about anything which has material impact on the financial condition and results of operation and discussed accordingly with the Board and management but they unnecessarily ignored, then inform to commission regarding the findings, upon reporting of such matters to the Board for 3 times or completion of 6(six) months from the date of first reporting to Board, whichever is earlier.	-		No such case occurred
5 (7)	Report on activities carried out by the Audit Committee, including any report made to the Board under condition No. 5(6)(a)(ii) above during the year, shall be signed by the Chairperson of the Audit Committee and disclosed in the annual report of the issuer company.	√		
6	**Nomination and Remuneration Committee (NRC)-**			
6(1)(a)	Nomination committee is a sub-committee of the Board	√		
6(1)(b)	NRC shall assist the board in formulation of the nomination criteria or policy for determining qualifications, positive attributes, experiences and independence of directors & top-level executives as well as considering remuneration of directors, top level executive	√		

Condition No.	Title	Compliance Status		Remarks (if any)
		Complied	Not Complied	
6(1)(c)	The Terms of Reference (ToR) of the NRC shall be clearly set forth in writing covering the areas stated at the condition No. 6(5)(b).	√		
6 (2)	**Constitution of the NRC**			
6(2)(a)	The committee shall comprise of at least 3 members including an independent director	√		NRC comprised with the five Non-Executive Directors including Four Independent Director.
6(2)(b)	At least 02 (two) members of the Committee shall be non-executive directors;	√		All members of NRC comprised with the Non-Executive Directors
6(2)(c)	Members of the committee shall be nominated and appointed by the board	√		
6(2)(d)	The board shall have authority to remove and appoint any member of the committee	√		
6(2)(e)	In case of death, resignation, disqualification, or removal of any member of the committee or any other cases of vacancies, the board shall fill the vacancy within 180 (one hundred eighty) of occurring such vacancy	√		No such case occurred
6(2)(f)	The Chairperson of the Committee may appoint or co-opt any external expert and/or member(s) of staff to the Committee as advisor who shall be non-voting member, if the Chairperson feels that advice or suggestion from such external expert and/or member(s) of staff shall be required or valuable for the Committee;	√		No such case occurred
6(2)(g)	Company secretary shall act as the secretary of the committee	√		
6(2)(h)	Quorum of the NRC shall not constitute without attendance of at least an independent director	√		
6(2)(i)	No member of the NRC shall receive any remuneration other than Directors' fees or honorarium from the company	√		
6 (3)	**Chairperson of the NRC**			

Condition No.	Title	Compliance Status		Remarks (if any)
		Complied	Not Complied	
6(3)(a)	The board shall select one member of the NRC to be chairperson of the committee who shall be an Independent Director	√		Independent Director Professor ABM Faroque is the NRC Chairperson
6(3)(b)	In the absence of chairperson of NRC, the remaining members may elect one of themselves as chairman of the meeting.	-	-	No such case occurred.
6(3)(c)	The chairperson of NRC shall attend the AGM and in the absence of regular chairperson, any member from the NRC shall be selected to attend in AGM	√		
6 (4)	**Meeting of the NRC**			
6(4)(a)	The NRC shall conduct at least 1 meeting in a financial year	√		The NRC held One meeting during the year.
6(4)(b)	The Chairperson of the NRC may convene any emergency meeting upon request by any member of the NRC;	√		
6(4)(c)	The quorum of the meeting of the NRC shall be constituted in presence of either two members or two third of the members of the Committee, whichever is higher, where presence of an independent director is must as required under condition No. 6(2)(h);	√		
6(4)(d)	The proceedings of each meeting of the NRC shall duly be recorded in the minutes and such minutes shall be confirmed in the next meeting of the NRC.	√		
6(5)	**Role of the NRC**			
6(5)(a)	NRC shall be independent and responsible or accountable to the board and shareholders	√		
6(5)(b)	**NRC shall oversee among others the following matters and make report with recommendation to the Board-**			
6(5)(b)(i)	Formulating the criteria for determining qualifications, positive attributes and independence of director and recommend policy to Board relating to remuneration of the directors, top level executive considering the following-	√		
6(5)(b)(i)(a)	The level and composition of remuneration is reasonable and sufficient to attract, retain and motivate suitable directors to run the company successfully	√		

Condition No.	Title	Compliance Status		Remarks (if any)
		Complied	Not Complied	
6(5)(b)(i)(b)	The relationship of remuneration to performance is clear and meets appropriate performance benchmarks; and	√		
6(5)(b)(i)(c)	Remuneration to directors, top level executive involves a balance between fixed and incentive pay reflecting short and long-term performance objectives appropriate to the working of company and its goals	√		
6(5)(b)(iii)	Identifying persons who are qualified to become directors and top-level executive in accordance with the criteria laid down and recommend their appointment and removal to the board	√		
6(5)(b)(iv)	Formulating the criteria for evaluation of independent directors and the board	√		
6(5)(b)(v)	Identifying the company's needs for employees at different levels and determine their selection, transfer or replacement or promotion criteria; and	√		
6(5)(b)(vi)	Developing, recommending and reviewing annually the company's human resources and training policies	√		
6(5)(b)(c)	The company shall disclose the nomination and remuneration policy and the evaluation criteria and activities of NRC during the year at a glance in its annual report.	√		
7	**External or Statutory Auditors-**			
7(1)	**The Company shall not engage its external or statutory auditors to perform the following services-**			
7(1)(i)	Non-engagement in appraisal or valuation services or fairness opinions	√		
7(1)(ii)	Non-engagement in financial information systems design and implementation	√		
7(1)(iii)	Non-engagement in Book-keeping or other services related to the accounting records or financial statements	√		
7(1)(iv)	Non-engagement in Broker-dealer services	√		
7(1)(v)	Non-engagement in Actuarial services	√		
7(1)(vi)	Non-engagement in Internal audit or special audit services	√		
7(1)(vii)	Non-engagement in any other service that the audit committee determines	√		

Condition No.	Title	Compliance Status		Remarks (if any)
		Complied	Not Complied	
7(1)(viii)	Audit or certification services on compliance of corporate governance as required under condition: 9(1) and	√		
7(1)(ix)	Non-engagement any other service that creates conflict of interest.	√		
7 (2)	No partner or employees and family members of the external audit firms shall possess any share of the company they audit at least during the tenure of their audit assignment of that company.	√		
7 (3)	Representative of external or statutory auditors shall remain present in the shareholders meeting (AGM or EGM) to answer the queries of the shareholders	√		
8	**Maintain a Website by the Company-**			
8.(1)	The company shall have an official website linked with the websites of the stock exchange	√		beaconpharma.com.bd
8.(2)	The company shall keep the website functional from the date of listing	√		
8.(3)	The company shall make available the detailed disclosures on its website as required under the listing regulations of the concerned stock exchange(s)	√		
9	**Reporting and Compliance of Corporate Governance-**			
9.(1)	Obtaining Certificate from a professional accountant/ Secretary regarding compliance of conditions of Corporate Governance Guidelines of the BSEC on a yearly basis and disclose it in the Annual Report	√		
9(2)	The professional who will provide the certificate on compliance of the code shall be appointed by the shareholders in Annual General Meeting	√		
9(3)	The directors of the company shall state, in accordance with the Annexure-C attached, in the directors' report whether the company has complied with these conditions	√		

Annexure-D

NUMBER OF BOARD MEETINGS AND ATTENDANCE OF DIRECTORS

Sl. No	Name of Directors	Meeting Held	Number of Meeting Attended
1	**Ms. Nurun Nahar Karim**, Chairman	4	4
2	**Mr. Mohammad Ebadul Karim**, Managing Director	4	4
3	**Mr. Mohammad Niazul Karim**, Director	4	4
4	**Mr. Ulfat Karim**, Director	4	4
5	**Mr. Rezanur Chowdhury FCA**, Independent Director	4	3
6	**Prof. A B M Faroque**, Independent Director	4	4
7	**Mr. Mohammed Ariful Hoque FCA**, Independent Director	4	3

Annexure-E

PATTERN OF SHAREHOLDING

Sl. No	Name of Shareholders	Designation	No. of Shares Held	% of Shares Held
a)	**Parent/subsidiary/associate companies**			
	N/A	N/A	N/A	
b)	**Directors, company secretary, chief financial officer, head of internal audit, and their spouses and minor children**			
	Mohammad Ebadul Karim	Managing Director	58,228,800	25.21%
	Nurun Nahar Karim	Chairman	4,725,000	2.05%
	Mohammad Niazul Karim	Director	6,354,000	2.75%
	Ulfat Karim	Director	22,776,815	9.86%
	Md. Jalal Uddin FCA	CFO and Head of IT	Nill	Nill
	Ms. Rahamat Ara Huda FCA, FCMA	Head of Internal Audit	Nill	Nill
	Md. Sahabuddin FCS	Company Secretary	Nill	Nill
c)	**Executive**			
	Mohammad Ebadul Karim	Managing Director	5,82,28,800	25.21%
d)	**Shareholders holding ten percent (10%) or more voting interest in the Company**			
	Mohammad Ebadul Karim	Managing Director	5,82,28,800	25.21%

Management

Discussion and Analysis

Annexure-F

As per condition no. 1 (5) (xxv) of the Corporate Governance Code 2018 issued by Bangladesh Securities and Exchange Commission, the Management's Discussion & Analysis are as follows:

Accounting policies and estimation for preparation of financial statements

The Company follows International Financial Reporting Standards (IFRSs) and International Accounting Standards (IASs) as adopted by Financial Reporting Council (FRC) along with the Companies Act 1994, the Securities and Exchange Rules 2020 and other applicable laws and regulations in Bangladesh for preparation of financial statements. Detail description of accounting policies and estimation used for preparation of the financial statements of the Company are disclosed in the notes 1 to 3 to the financial statements.

Changes in accounting policies and estimation

The Company has been following consistent policies and estimation. There are no such changes in accounting policies or estimation which has material impact on financial statements.

Comparative analysis of financial performance and financial position as well as cash flows for current financial year with preceding five years

Major areas of financial performances and financial position as well as cash flows for the financial year 2024-25 along with preceding five years are as follows:

Particulars	FY (BDT in Million)					
	2024-25	2023-24	2022-23	2021-22	2020-21	2019-20
Financial position						
Total assets	19,404	18,932	14,642	10,816	8,536	7,177
Total liabilities	12,737	12,841	8,700	4,872	3,180	2,547
Shareholders' equity	6,667	6,090	5,942	5,944	5,355	4,630
Financial performance						
Revenue	12,543	10,702	8,510	8,023	7,121	5,591
GP	6,528	5,533	4,289	4,147	3,687	2,872
Operating profit	2,675	2,004	1,174	1,682	1,422	343
Net profit after tax	947	521	510	935	863	381
Cash flows						
NOCF per share	6.93	-0.78	2.69	4.68	0.85	1.26
Stock performance						
EPS	4.10	2.26	2.21	4.05	3.74	1.65
NAV per share	28.86	26.37	25.72	25.73	23.18	20.04
Market price per share (closing rate at year end)	105.90	153.80	245	258.30	123.60	60.70
Price earnings ratio (times)	25.82	68.05	110.86	63.78	33.05	36.79

The Company has been enjoying a persistent growth in yearly turnover during the tenure of six years from 2020 to 2025 under analysis. The company has reported a revenue growth of 17.20% and profit growth of 81.67% compared to the previous year. The Company has also reported EPS growth of 81.67% as compared to last year.

Industry scenario

The peer companies within the pharmaceuticals industry includes Square Pharmaceuticals PLC, ACI PLC, Renata PLC, Ibn Sina Pharmaceuticals PLC, among others. All the companies have diversified business conglomerate having several businesses in different sectors. Accordingly, the company has no such peer company to draw a reasonable comparison.

Financial and economic scenario of the country and the globe

The FY 2024-2025 has brought forth considerable economic struggles, largely stemming from global events and political unrest in the country. These were marked by substantial trade disruptions and a surge in inflationary pressures. Bangladesh has experienced a significant devaluation of the BDT but has seen a substantial rise in

foreign exchange reserves, reaching nearly 27 billion USD by June 2025. The world is projected to experience a slowdown in growth due to rising interest rates and the consequences of geopolitical disruptions, which have triggered widespread economic turmoil.

According to IQVIA, the pharmaceutical industry in Bangladesh continues to grow at a double-digit rate of 12.43% with a value of BDT 300 billion. The countries in the Asia-Pacific region will experience substantial volume growth of more than 10% by 2027. While the global pharmaceutical industry's current value stands at around $1.6 trillion, it is forecasted to see a CAGR of 3-6%, ultimately reaching a market size of approximately $1.9 trillion in 2027. The global generic medicines market was valued at approximately $400 billion in 2022 maintaining a stable growth rate of 6.1%, and it is projected to contribute an additional $12 billion in growth by 2027. This can be attributed to the increasing number of ANDA approvals and the launch of generic medications.

Despite facing the challenges, Beacon Pharmaceuticals PLC has managed to maintain a healthy double-digit growth. The ongoing economic instability has had a significant impact on the exchange rate, particularly concerning the US dollar and high inflation leading to a substantial increase in the costs associated with production and operations. Given that Bangladesh's pharmaceutical industry predominantly relies on imported raw materials, the company are now tackling with substantial price hikes across all inputs, thus putting immense pressure on our operational margins. Nevertheless, the company responded to these difficulties with coordinated efforts from every function across the Company. BPPLC engaged in continuous negotiations with our partners and service providers to mitigate the effects of rising prices. Additionally, BPPLC implemented immediate cost control measures, streamlined our processes and resource allocations, and made prudent procurement decisions where applicable.

In conclusion, apart from containing inflation at tolerable levels, keeping import payments manageable and maintaining stability in the foreign exchange markets might be a critical challenge for the economy. Bangladesh expects that the formulation of a contractionary cautious monetary and credit program will support the economic recovery process in the coming days as well as mitigate inflationary and exchange rate pressures. In addition to the government's endeavors to tackle the challenges, the private sector in Bangladesh is also consistently channeling its efforts and enthusiasm to lead the country's progress.

Risk and Concerns

The company has exposure to the credit risk, liquidity risk and market risk arising from its operations as outlined in the financial statements. Financial risks are addressed with secured contracts and buyer financing arrangements as well as foreign exchange hedging policies. Given the devaluation of Bangladeshi currency and ensuing inflation, the Company is putting in additional measures in place in terms of sourcing, inventory management, cash-flow management to protect business performance against the macro-economic shocks. Having strong internal control systems, management has ensured good governance and footprint of BPPLC Business in Bangladesh. The Company has a formalized risk management framework and process under the governance and supervision of the Audit Committee.


BPPLC perceives that proactive management of these risks is of fundamental significance to ensure our business growth. BPPLC regularly identify functional and entity level risks and do extensive reviews to ensure the risks are righty identified and proper mitigation plans are in place for the same.

Future Outlook

The Company has taken all sorts feasible plans, strategy and vision to continue the operations of the Company for foreseeable future. This is relevant to share that the Company maintains a periodic action plans along with mid-term and long-term strategies to maintain the sustainability in its performances and financial position. We have reviewed our annual operating plans to account for the macro-economic environment and are also reviewing our strategy from quarter to quarter to adjust to changes as they materialize.

While liquidity is not a challenge for the business, efficient management of overheads and production costs is going to be a priority for the next year particularly considering the macroeconomic adversities. In terms of portfolio the Company is committed to building its new brands and strengthening category foothold of new launches. The Company has a rigorous focus on its go-to-market strategy to ensure execution excellence in servicing the market with a range of portfolios. Leveraging real time data and analytics and increased automation will be key drivers in unlocking efficiencies in the entire supply chain.

Last but not least we are committed to growing and developing talent, across levels through impactful learning and development interventions. Employee welfare, health, safety and an energizing, safe culture are also critical pillars to achieve our vision. We believe we will be able to stay on a growth path, despite multiple challenges of macro-economic environment, by exhibiting higher degree of agility.



Mohammad Ebadul Karim
Managing Director

AUDIT COMMITTEE REPORT

The Audit Committee ("the Committee") is a sub-committee of the Board of Directors. It plays a vital role in ensuring the company's financial integrity, governance standards, and risk management processes. The primary responsibility of the Committee is to ensure that the financial statements of the company are accurate, fair, and present a true and fair view of the company's financial position.

The Committee oversees the external audit process, internal audit functions, and evaluates the performance of external auditors. Through these functions, the Committee promotes transparency, accountability, and adherence to sound corporate governance practices. By upholding audit quality and fostering a culture of impartiality and objectivity, the Committee contributes significantly to the company's credibility and the trust of its stakeholders.

The inclusion of the Nomination and Remuneration Committee in recommending Audit Committee members reflects a collaborative approach to governance, ensuring that individuals with the requisite expertise, integrity, and independence are appointed to serve effectively.

Terms of Reference

The terms of reference of the Audit Committee have been approved by the Board in accordance with the Code of Corporate Governance, 2018 issued by the Bangladesh Securities and Exchange Commission (BSEC). These terms outline the Committee's authority, responsibilities, and operational framework in overseeing the company's audit and control environment.

Composition of the Audit Committee

In alignment with the Code of Corporate Governance, the Audit Committee of the company comprises three Independent Directors, one Non-Executive Director, and the Board Secretary, with the Chairman being an Independent Director.

The Chief Financial Officer (CFO) and Head of Internal Audit (HIA) attend meetings by invitation, while the Company Secretary serves as the Secretary to the Committee.

Mr. Rezanur Chowdhury, Professor A B M Faroque, and Mr. Mohammad Ariful Hoque, FCA, ACA (England & Wales) have been appointed as members of the Audit Committee.

The inclusion of Mr. Rezanur Chowdhury, with his extensive experience in accounting, finance, and taxation, and Professor A B M Faroque, with his distinguished background in pharmaceutical technology and research, will further strengthen the Committee's oversight capability. Along with Mr. Mohammad Ariful Hoque, a fellow and associate chartered accountant with international credentials, the reconstituted Audit Committee is well-positioned to uphold the highest standards of governance and financial transparency.

Name	Representation in the Board	Representation in the Committee	Number of Meeting Held During the Period	
			Held	Attended
Mr. Mohammed Ariful Hoque FCA	Independent Director	Chairman	4	3
Mr. Rezanur Chowdhury	Independent Director	Member	4	3
Prof. ABM Faroque	Independent Director	Member	4	4
Mr. Mohammad Niazul Karim	Director	Member	4	4

Role and Responsibilities of the Audit Committee

The Audit Committee is entrusted with the crucial responsibility of overseeing the integrity of the Company's financial management and reporting systems. It is empowered to address all matters relating to financial affairs and reviews both internal and external audit activities. This includes evaluating internal control systems, accounting policies, and procedures to ensure they are robust, effective, and compliant with applicable standards.

The primary objective of the Committee is to ensure that the Company maintains a sound, transparent, and well-governed financial reporting framework that provides accurate, timely, and relevant financial information to management, regulators, shareholders, and other stakeholders. By ensuring the accuracy and appropriateness of financial disclosures, the Audit Committee plays a central role in enhancing transparency, regulatory compliance, and stakeholder confidence.

Through its oversight functions, the Committee strengthens the Company's broader governance structure, supports financial stability, and safeguards the interests of shareholders and stakeholders.

Financial Reporting

The Audit Committee's responsibilities in financial

reporting are essential for ensuring accuracy, transparency, and adherence to legal, regulatory, and accounting standards. Key duties include:

1. Review of Quarterly, Half-Yearly, and Interim Financial Statements

The Committee reviews all interim financial statements to ensure they present a fair and accurate reflection of the Company's financial position. It also verifies that all disclosures made to the Stock Exchanges are aligned with the financial statements and comply with regulatory requirements.

2. Review of Annual Financial Statements

Before submission to the Board of Directors, the Committee conducts a comprehensive review of the Annual Financial Statements to ensure full compliance with:

- **Securities Laws** – Adherence to relevant securities regulations
- **Companies Act, 1994** – Compliance with applicable statutory provisions
- **International Financial Reporting Standards (IFRS)**
- **International Accounting Standards (IAS)**
- **Conflict of Interest Requirements** – Ensuring disclosures are free from any conflict
- **Other Relevant Regulatory Requirements**

Through this rigorous review process, the Committee ensures that the Company's financial statements are accurate, reliable, and fully aligned with the highest standards of governance—thereby maintaining credibility and strengthening stakeholder trust.

Internal Audit

The Audit Committee plays a vital role in overseeing the internal audit function to ensure the effectiveness of internal controls and operational processes.

1. Review of Internal Audit Reports

The Committee regularly reviews internal audit reports containing observations, recommendations, and management's responses. It ensures that appropriate corrective actions are being taken and engages in discussions with management on areas relating to internal controls, system improvements, and operational efficiency.

2. Follow-up on Implementation of Recommendations

To ensure timely implementation of internal audit recommendations, the Committee reviews follow-up reports that track progress and the adequacy of corrective actions taken.

3. Suggesting Additional Improvements

The Committee may recommend further enhancements to strengthen internal controls, update procedures, and introduce improved systems or technologies that reduce risk and enhance operational performance.

Through these activities, the Committee supports strong internal governance, ensures continuous improvement, and enhances the Company's ability to manage risks effectively.

External Audit

The Audit Committee is responsible for overseeing the external audit process to ensure that the Company's financial statements are audited independently and in accordance with applicable standards.

1. Meeting with External Auditors After the Annual Audit

Following the annual audit, the Committee meets with external auditors to review findings, discuss the presentation of financial statements, and address any significant issues.

2. Review of Audit Scope, Strategy, Plans, and Fees

The Committee reviews the external auditors' scope, audit strategy, and annual plan to ensure they are comprehensive. It also reviews and approves statutory audit fees, ensuring the audit remains both thorough and cost-effective.

3. Review of External Auditors' Performance

The Committee evaluates the external auditors' independence, objectivity, and overall performance. Based on this assessment, it recommends to the Board the appointment or reappointment of auditors and approval of their fees.

These oversight activities reinforce audit quality, ensure independence, and strengthen the reliability of the Company's financial reporting.

Internal Control Framework

The Audit Committee evaluates the Company's internal control environment across the following key components:

- **Control Environment:** Reinforcing ethical standards, governance tone, and compliance culture.
- **Risk Assessment:** Identifying and evaluating potential risks and ensuring appropriate mitigation strategies.
- **Control Activities:** Reviewing key control mechanisms, including approvals, segregation of duties, access controls, and authorization procedures.
- **Information & Communication:** Ensuring effective communication and reporting of internal control processes throughout the organization.
- **Monitoring:** Continuously assessing and testing the effectiveness of internal controls through internal audits, compliance reviews, and management oversight.

Audit Review Highlights

During the financial year, the Audit Committee undertook the following major review activities:

- Assessed compliance of capitalization policies with **IAS 16**, ensuring consistency and accuracy.
- Evaluated assumptions regarding the useful lives of assets under **IAS 16 – Property, Plant and Equipment.**
- Reviewed inventory control systems and operational practices.
- Examined historical trends of inventory provisioning and write-offs.
- Conducted analytical reviews to identify unusual or one-off material revenue transactions.

Recommendations

The Committee made the following recommendations to the Board for the financial year ending June 30, 2026, subject to approval at the 24th Annual General Meeting (AGM):

1. **Reappointment of Statutory Auditors:** Reappointment of **M/s. Habib Sarwar Bhuiyan & Co., Chartered Accountants** as Statutory Auditors at an audit fee of BDT 3,91,304 (including AIT).
2. **Reappointment of Corporate Governance Compliance Auditors:** Appointment of **MNA Associates, Chartered Secretaries and Consultants** as Corporate Governance Compliance Auditors and Scrutinizer at a proposed fee of Tk. 100,000.

These recommendations reflect the Company's sustained commitment to maintaining high standards of transparency, accountability, and governance.

Appreciation

The Audit Committee expresses its sincere appreciation to the Board of Directors, management team, statutory auditors, and the internal audit department for their continued cooperation and support. Their dedication has enabled the Committee to effectively discharge its duties in ensuring financial integrity, strengthening internal controls, and promoting sound corporate governance.

The Committee acknowledges that this collaborative effort is essential to maintaining the Company's reputation for transparency, accountability, and strong stakeholder confidence.

Chairman
Audit Committee

NOMINATION AND REMUNERATION COMMITTEE REPORT

The Nomination and Remuneration Committee (NRC) is a key sub-committee of the Board of Directors and plays a vital role in strengthening the Company's governance framework. The Committee ensures that leadership appointments, succession planning, and remuneration practices are consistent with the Company's values, long-term strategic objectives, and applicable regulatory requirements. Through its oversight, the NRC supports the development of a capable and ethical leadership team that contributes to the sustainable growth of the Company.

The Committee operates independently but remains accountable to the Board of Directors and, ultimately, to the shareholders. Its functions are guided by the Corporate Governance Code 2018 issued by the Bangladesh Securities and Exchange Commission (BSEC) on June 3, 2018, which provides the operating framework for the NRC, particularly regarding appointments, evaluations, and the determination of remuneration.

In accordance with the Code, the NRC Report for the year ended June 30, 2025, is presented below. This report outlines the Committee's responsibilities, activities undertaken during the year, and the measures implemented to ensure that nomination and remuneration practices reflect the highest standards of corporate governance. It also provides transparency to stakeholders regarding the Committee's role in shaping the Company's leadership and organizational structure.

Terms of Reference

The terms of reference of the Nomination and Remuneration Committee have been approved by the Board of Directors in compliance with the Corporate Governance Code 2018 of the Bangladesh Securities and Exchange Commission (BSEC). These terms define the authority, responsibilities, and operating procedures of the Committee.

Composition of the Nomination and Remuneration Committee

The Nomination and Remuneration Committee (NRC) of Beacon Pharmaceuticals Limited has been constituted in accordance with the BSEC Corporate Governance Code. The Committee consists of the following members:

1. **Prof. A B M Faroque (Independent Director)** – Chairman
2. **Mr. Rezanur Chowdhury FCA (Independent Director)** – Member
3. **Mr. Mohammed Ariful Hoque FCA** (Independent Director) – Member
4. **Mr. Md. Niazul Karim (Director)** – Member

Key Roles and Responsibilities

The NRC assists the Board in several important governance areas, including:

- **Formulating Nomination Criteria**

  The NRC develops and recommends policies for the appointment of Directors and top-level executives. This includes setting criteria relating to qualifications, integrity, experience, independence, and leadership attributes.

- **Determining Remuneration Policies**

  The Committee supports the Board in establishing fair, competitive, and transparent remuneration and honorarium policies for Directors and top-level executives. These policies are designed to attract and retain qualified leadership while ensuring alignment with the Company's strategic goals and governance standards.

- **Advising on Staffing and Leadership Needs**

  The NRC provides guidance to management regarding staffing requirements across the organization. It plays a meaningful role in the selection, transfer, promotion, and replacement of employees to ensure that the Company's human resources are aligned with its operational and strategic priorities.

The work of the NRC is instrumental in upholding strong corporate governance practices. Through its oversight of leadership development, succession planning, and remuneration frameworks, the Committee ensures fairness, transparency, and alignment with the Company's long-term objectives—thereby safeguarding shareholder interests and supporting organizational excellence.

Meetings held of the NRC

In the year 2024-25, one meeting was held of the Nomination and Remuneration Committee during the year where a detailed discussion was made relating to the nomination and remuneration policy and the evaluation criteria and activities of NRC.

Name	Representation in the Board	Representation in the Committee	Number of Meeting Held During the Period	
			Held	Attended
Prof. ABM Faroque	Independent Director	Chairman	1	1
Mr. Rezanur Chowdhury FCA	Independent Director	Member	1	1
Mr. Mohammed Ariful Hoque FCA	Independent Director	Member	1	1
Mr. Mohammad Niazul Karim	Director	Member	1	1

Role and Responsibilities of the Nomination and Remuneration Committee

The Nomination and Remuneration Committee (NRC) supports the Board of Directors in ensuring that the Company's policies and practices relating to Board composition, diversity, performance evaluation, and executive remuneration are consistent with good corporate governance principles and regulatory requirements.

The purpose, authority, composition, roles, and responsibilities of the NRC are outlined in its Charter, which has been approved by the Board in accordance with the Corporate Governance Code 2018 issued by the Bangladesh Securities and Exchange Commission (BSEC).

The major responsibilities of the NRC include:

- Recommending a policy on Board diversity, taking into account factors such as age, gender, experience, education, and nationality.
- Formulating criteria for determining the qualifications and independence of Directors.
- Identifying individuals qualified to serve as Directors or Top-Level Executives and recommending their appointment or removal.
- Developing criteria for evaluating the performance of Independent Directors and the Board as a whole.
- Recommending a remuneration policy for Directors and Top-Level Executives.
- Ensuring that the level and structure of remuneration are sufficient to attract, retain, and motivate capable Directors and Executives.
- Ensuring that remuneration balances fixed and variable elements, linking incentives with short- and long-term performance objectives aligned with the Company's strategic goals.
- Identifying human resource requirements and determining criteria for selection, transfer, replacement, and promotion.
- Recommending and annually reviewing the Company's HR and training policies.
- Putting forward the Company's yearly increment policy and related remuneration practices.
- Recommending the Code of Conduct for the Chair of the Board, other Board Members, and the Chief Executive Officer.

Activities of the NRC During the Reporting Period

During the reporting period, the NRC undertook the following key activities:

- Proposed the names of Directors for retirement by rotation and re-election in accordance with applicable laws and regulations.
- Recommended the appointment of Independent Directors in compliance with the BSEC Corporate Governance Code.
- Conducted performance evaluations of the Board, individual Board Members, and Top-Level Executives.
- Prepared the NRC Report for inclusion in the Annual Report 2024–2025.

Nomination, Election, and Selection of Directors

The NRC ensures that the procedures for appointing Directors are transparent, objective, and compliant with regulatory guidelines. The Board places significant emphasis on diversity in age, gender, experience, educational background, nationality, and other relevant attributes to ensure a balanced and effective decision-making environment.

The recruitment and selection process focuses on identifying candidates with appropriate skills, expertise, integrity, and leadership capabilities. Qualifications and selection criteria are defined clearly within the Company's corporate governance framework to promote fairness, equity, and transparency in the appointment process.

Evaluation of the Board

The NRC is responsible for ensuring the effectiveness and efficiency of the Board's performance. In line with good governance practices, the Board conducts an annual self-evaluation to assess its functions, effectiveness, and oversight of internal controls relating to financial reporting and asset protection.

The evaluation process is led by the Chair of the Board with support from the Company Secretary. Each Director completes a confidential assessment covering:

- The functioning of the Board and its Committees;
- The adequacy, quality, and timeliness of reports and information; and
- The effectiveness of the Board's interaction with

Management.

The NRC reviews the results and provides recommendations to support continuous improvement.

Top-Level Executive Selection and Remuneration Policy

The Company's long-term success depends heavily on the competence and commitment of its Directors and Top-Level Executives. The NRC ensures that the recruitment process for Top-Level Executives is transparent, merit-based, non-discriminatory, and consistent with the Company's Code of Conduct.

The remuneration policy aims to:

- Attract and retain high-caliber professionals;
- Reward performance that contributes to sustainable value creation;
- Align the interests of management with those of the Company and its stakeholders.

Remuneration consists of both fixed and variable components based on individual performance, Company results, and strategic objectives. Recruitment and retention practices reinforce Beacon's reputation as a fair, competitive, and ethical employer.

Remuneration for the Board of Directors

Directors are entitled to receive reasonable remuneration for attending Board and Committee meetings, in addition to reimbursement of travel expenses to and from their usual place of residence.

A daily allowance is also provided for the time required to attend and travel for meetings.

The specific amounts of remuneration and allowances are determined by shareholders at the Annual General Meeting (AGM).

Conclusion

The Nomination and Remuneration Committee remains committed to upholding transparency, fairness, and meritocracy in all matters relating to Board appointments, performance evaluation, and executive remuneration. By adhering to these principles, the NRC supports the Board in maintaining an effective leadership structure aligned with the long-term objectives and sustainability commitments of Beacon Pharmaceuticals PLC.

For and on behalf of the Nomination and Remuneration Committee

Beacon Pharmaceuticals PLC



Chairman

NRC Committee

CORPORATE
GOVERNANCE STRUCTURE

Corporate Governance

Beacon Pharmaceuticals PLC is committed to adopting the best practices of Corporate Governance, ensuring transparency, accountability, and ethical conduct in all its activities. The Company's governance framework is designed to protect stakeholder interests, safeguard shareholder assets, and uphold the highest standards of integrity. Corporate Governance at Beacon ensures that the Company's activities are strategically aligned with its long-term goals through sound decision-making, prudent policies, and responsible management practices. The Board of Directors ensures that the activities undertaken by the Company adhere to the highest ethical and professional standards and serve the best interests of all stakeholders.

The Board

The Board of Directors of Beacon Pharmaceuticals PLC consists of eight members, including both executive and non-executive Directors, representing diverse professional backgrounds and expertise.

The non-executive Directors come from different business sectors, bringing valuable experience and perspectives that contribute to strategic planning, policy formulation, and overall governance. The Chairman leads the Board, ensuring effective governance and strategic oversight. The Company Secretary, acting as the compliance officer, prepares meeting agendas in consultation with the Chairman, Managing Director, and Chairmen of various Committees. The Chairman ensures that all Board members are properly briefed on matters raised at Board meetings, and that non-executive Directors receive timely and accurate information to enable them to discharge their responsibilities effectively.

Board Meetings

The Board of Directors, empowered by the shareholders, holds the ultimate authority for setting the Company's strategic direction, formulating policies, and overseeing management performance.

The Board meets regularly to review operational and financial performance, assess risk management practices, and make key decisions essential for the Company's sustainable growth and development.

During the financial year 2024-2025, the Board met several times, ensuring the timely and effective discharge of its duties and responsibilities.

Board Independence

In compliance with the Corporate Governance Code 2018 issued by the Bangladesh Securities and Exchange Commission (BSEC), the Board has appointed the following Independent Directors:

- Mr. Rezanur Chowdhury FCA
- Professor A B M Faroque
- Mr. Mohammed Ariful Hoque FCA
- Prof. Dr. Shamem Ara Mili

These Directors are independent of the Company's management and operations and are free from any business or other relationships that could interfere with their independent judgment. The Board firmly believes that their professional experience, expertise, and integrity significantly enhance the effectiveness of the Board and contribute constructively to its deliberations and decision-making.

Board Committees

To ensure sound governance and effective oversight, the Board of Directors has established several sub-committees that assist in the execution of its responsibilities and in monitoring performance in key areas.

Audit Committee

The Audit Committee plays a vital role in ensuring financial integrity, internal control effectiveness, and compliance with statutory and regulatory requirements. During the financial year 2024–2025, the Committee met four (4) times to review and consider the Annual Financial Statements for the year ended 30 June 2025 and the Quarterly Financial Reports within the same period.

Composition of the Audit Committee:

- Professor A B M Faroque
- Mr. Rezanur Chowdhury FCA
- Mr. Mohammed Ariful Hoque FCA
- Prof. Dr. Shamem Ara Mili
- Mr. Mohammad Niazul Karim

The Audit Committee continues to uphold the highest standards of transparency and accountability in all financial and audit-related matters.

Nomination and Remuneration Committee (NRC)

The Nomination and Remuneration Committee (NRC) assists the Board in formulating policies related to the nomination, evaluation, and remuneration of Directors and Top-Level Executives.

During the financial year 2024–2025, the NRC met once

to develop, recommend, and review the Company's Human Resources and Training Policies, ensuring they remain aligned with corporate governance best practices and the Company's strategic goals.

Composition of the NRC:

- Professor A B M Faroque
- Mr. Rezanur Chowdhury FCA
- Mr. Mohammed Ariful Hoque FCA
- Prof. Dr. Shamem Ara Mili
- Mr. Mohammad Niazul Karim

The Committee also reviews succession planning and ensures that the Company attracts, develops, and retains qualified and competent professionals at all levels.

Internal Control

The Board of Directors bears ultimate responsibility for establishing and maintaining an effective system of internal control within Beacon Pharmaceuticals PLC. The internal control framework is designed to manage risks, safeguard the Company's assets, and ensure that business operations are conducted efficiently, ethically, and in compliance with applicable laws and regulations.

The system provides reasonable assurance that:

- The Company's assets are protected against unauthorized use or material loss;
- Transactions are properly authorized, recorded, and reported; and
- Operational, financial, and compliance risks are effectively identified and managed.

The Board periodically reviews the adequacy and effectiveness of the internal control system, ensuring it remains robust and responsive to evolving business and regulatory environments.

Commitment to Good Governance

Beacon Pharmaceuticals PLC remains committed to maintaining the highest standards of Corporate Governance through ethical leadership, transparency, and accountability. The Board believes that these principles are fundamental to achieving long-term sustainable growth, building investor confidence, and protecting the interests of all stakeholders.

BAPLC

CERTIFICATE



BANGLADESH ASSOCIATION OF PUBLICLY LISTED COMPANIES

Renewed Certificate

This is to certify that

BEACON PHARMACEUTICALS PLC

is an Ordinary Member of Bangladesh Association of Publicly Listed Companies and is entitled to all the rights and privileges appertaining thereto.

This certificate remains current until 31st December, 2025.

Ref. No: CM-2025/177

Date of issue : March 24, 2025

BAPLC

Secretary General



AUDITOR'S REPORT
&
FINANCIAL STATEMENTS



Independent Auditor's Report

To The Shareholders of Beacon Pharmaceuticals PLC

Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of Beacon Pharmaceuticals PLC ("the Company") which comprise the statement of financial position as at 30 June 2025 and the statement of profit or loss and other comprehensive income, statement of changes in equity and statement of cash flows for the year ended 30 June 2025 and notes to the financial statements, including a summary of significant accounting policies and other explanatory notes.

In our opinion, the accompanying financial statements of the Company give a true and fair view of the financial position of the Company as at 30 June 2025 and of its financial performance and its cash flows for the year then ended in accordance with International Financial Reporting Standards (IFRSs), the Companies Act, 1994, the Securities and Exchange Rules 2020, and other applicable laws and regulations.

Basis for Opinion

We conducted our audit in accordance with International Standards on Auditing (ISAs). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' Code of Ethics for Professional Accountants (IESBA Code), and we have fulfilled our ethical responsibilities in accordance with the IESBA Code and the Institute of Chartered Accountants of Bangladesh (ICAB) Bye Laws. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Key Audit Matters

Key audit matters are those matters that, in our professional judgment, were of most significance in our audit of the financial statements of the current period. These matters were addressed in the context of our audit of the financial statements as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters.

The key audit matters are discussed below together with an explanation of how the risk and our audit response were tailored to address these specific areas.

Property, plant and equipment and capital work in progress

Key audit matter description	How the scope of our audit responded to the key audit matter.
At the reporting date, the carrying value of the Company property, plant and equipment amounting to Taka 5,295,634,773. The valuation of property, plant and equipment was identified as a key audit matter due to the significance of this balance to the financial statements. Expenditures are capitalized if they create new or enhance the existing assets, and expenses if they relate to repairs or maintenance of the assets. Classification of the expenditures involves judgment. The useful lives of PPE items are based on management's estimates regarding the period during which the asset or its significant components will be used. The estimates are based on historical experience. The assets currently under construction or pending installation, not yet ready to use, are properly	Our audit procedures to assess the carrying value of property, plant & equipment and capital work in progress included the following: • We assessed whether the accounting policies in relation to the capitalization of expenditures are in compliance with IAS 16 and found them to be consistent. • We evaluated the assumptions made by management in the determination of useful lives to ensure that these are consistent with the principles of IAS 16-Property, Plant and Equipment and compared each class of asset in the current year to the prior year to determine whether there are any significant changes in the useful life of assets, and considered the reasonableness of changes based on our knowledge of the business and the industry. • We obtained a list of capital expenditures incurred during the year and, on a sample basis, checked whether the items were procured based on internal purchase order that had been properly approved by the responsible individuals.

Property, plant and equipment and Capital work in progress

Key audit matter description	How the scope of our audit responded to the key audit matter.
categorized as capital work in progress (CWIP). An effective system should be established to record all directly identifiable costs that can be capitalized, consolidating them into capital work-in-progress. Meanwhile, any expenses that do not meet the criteria for capitalization should be identified and expensed in the regular course of business. Moreover, a significant balance amounting Taka 640,639,965 has been transferred to property, plant and equipment from Capital work in progress during the year for the company.	• We verified a sample of invoices and LC documents to determine whether the classification between capital and operating expenditure was appropriate. • We evaluated whether the useful lives determined and applied by the management were in line with historical experience and the market practice. • We checked whether the depreciation of PPE items was commenced timely, by comparing the date of the acquisition and disposal. • Reclassification from capital in progress to ready for use, with the date of the act of completion of the work. Our procedures mentioned above did not identify any issues with regard to PPE, CWIP & Depreciation.

Revenue Recognition

Key audit matter description	How the scope of our audit responded to the key audit matter.
The accompanying financial statements of the Company reported revenue for the year ended 30 June 2025 amounting to Taka 12,542,717,214 which is 17% (Taka 1,841,028,635) higher than prior year revenue. The principal activities of the Company is the manufacturing, marketing and distribution of General, Oncology, Biotech & Chronic Care products across a number of geographical areas in Bangladesh & abroad. The sales price is determined considering the effect of rebate, discounts and incentives. With regard to the conformity of IFRS 15 "Revenue from Contract with Customers", the recognition and recording or revenue on the basis of assessing different types of contracts and the accuracy of the accounting policies in light of the industry specific circumstances and understanding of the business.	Our audit procedures included the following to assess the identified risk: • We obtained an understanding of management's revenue recognition process. We tested a sample of transactions to verify whether the revenue was accounted for in accordance with the revenue accounting policy as disclosed in Notes 3.12 and 26 of the financial statements and IFRS 15. • We assessed whether the disclosed revenue accounting policy was in accordance with relevant accounting standards. • We tested the internal control over financial reporting, we also assessed the existence and accuracy of the sales recorded. • We tested a sample of individual sales transactions and traced to dispatch notes and subsequent cash receipt or other supporting documents. • We performed analytical reviews to identify any unusual or one-off material revenue transactions. • We verified management's conclusion from assessing different types of contracts and the accuracy of the accounting Policies considering the industry specific guidelines from NBR (VAT department). Our understanding of the price determination complying with direction from Directorate General of Drug Administration. • We tested the appropriateness of the accounting treatment and finally assessed the appropriateness and presentation of disclosures against relevant accounting standards. Our procedures mentioned above did not identify any issues with regard to revenue recognition.

Valuation of inventory

Key audit matter description	How the scope of our audit responded to the key audit matter.
The balance of inventory at the year-end was Taka 3,323,236,482 which is 17% of the total assets. Inventories are valued at lower of cost and net realizable value. Cost of inventories include expenditure incurred in acquiring the inventories, production or conversion costs and other costs incurred in bringing them to their existing location and condition. Cost of inventories is determined by using the weighted average method. Where necessary, allowance is provided for damage, obsolete and slow-moving items to adjust the carrying amount of inventories to the lower of cost and net realizable value. Net realizable value is based on estimated selling price in the ordinary course of business less the estimated costs of completion and the estimated costs necessary to make the sale.	Our procedures included the following to assess inventory valuation: • Evaluating the design and implementation of key inventory controls operating across the company in respect of inventory management. • To attend the physical inventory counts and reconciling the count results to the inventory listings to test the completeness of data. • To review the inventory costing procedures and methodology. • Comparing the net realizable value, obtained through a detailed review of sales subsequent to the year-end, to the cost price of a sample of inventories and comparison to the associated provision to assess whether inventory provisions are complete. • Reviewing the historical accuracy of inventory provisioning, and the level of inventory write-offs during the year; • Verifying the completeness of inventory provisions through assessing actual and forecast sales of inventory lines to assess whether provisions for slow moving/obsolete stock are valid and complete; and • Finally assessed the appropriateness and presentation of disclosures as per IAS-2. Our procedures mentioned above did not identify any issues with regard to inventory.

Measurement and recognition of deferred tax

Key audit matter description	How the scope of our audit responded to the key audit matter.
The balance of reported deferred tax liability of the Company was Taka 169,369,374 as on June 30, 2025. Deferred Tax is recognized on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. Significant judgment is required in relation to deferred tax liability as their liability is dependent on forecasts of future profitability over a number of years. The risk for the financial statements is that where provisions are properly measured for all types of temporary difference as per IAS 12: Income Tax.	We obtained an understanding of the Company's key controls over the recognition and measurement of deferred tax assets and liabilities and the assumptions used in estimating the future taxable expense of the Company. Our audit included the following procedure: • We evaluated the reasonableness of key assumptions, timing of reversal of temporary differences and expiration of tax loss carry forwards, recognition and measurement of deferred tax liability; • We assessed the adequacy of the Company's disclosures setting out the basis of deferred tax liability balances and the level of estimation involved; • Performed the mathematical accuracy of the deferred tax computation; • We also evaluated the potential tax implications as per ITA-2023, the reasonableness of estimates and calculations determined by management; and • Finally assessed the appropriateness and presentation of disclosures as per IAS-12: Income Taxes. Our procedures mentioned above did not identify any issues with regard to deferred tax.

ERP (SAP) system for financial reporting

Key audit matter description	How the scope of our audit responded to the key audit matter.
The IT systems within the Company form a vital component of the financial reporting activities. Our audit procedures have been focused on IT systems ERP-SAP and controls due to the pervasive nature and complexity of the IT environment. We identified the IT systems as a key audit matter due to the following reasons: • Pervasive reliance on complex technology that is integral to the operation of key business processes and financial reporting; Reliance on technology which continues to increase in line with the business strategy, such as the increase in the use of automation across the company; • IT control is important for effective control environment. A key interdependency exists between the ability to rely on IT controls and the ability to rely on financial data, system configured automated controls and system reports; • Continued remediation of IT controls supporting the application systems relevant to the company's financial reporting activities.	Our IT audit scope is driven by the level of reliance placed on technology to obtain sufficient audit evidence within a business process. The technology deemed relevant to the audit is based on the financial data, system configured automated controls and/or key financial reports that reside within it. Testing over the technology deemed relevant to the audit included the following areas: • General IT controls, including user access and change management controls; • Key financial reports and system configured automated controls; Our procedures mentioned above did not identify any issues with regard to ERP (SAP) system.

Related party transactions

Key audit matter description	How the scope of our audit responded to the key audit matter.
The Company has entered into transactions with related parties, as disclosed in Note No. 35 of the Financial Statements. We focused on the identification of related parties and the accuracy, completeness, and disclosure of related party transactions in accordance with applicable accounting standards.	Our audit procedures to address this key audit matter included, among others, the following: • Evaluated the design and tested the operating effectiveness of internal controls over the identification and disclosure of related party transactions. • Reviewed and tested transactions between related parties and verified the accuracy of material account balances affected by these transactions. • Assessed the adequacy and completeness of disclosures related to related party transactions in the financial statements, ensuring compliance with IAS 24 – Related Party Disclosures. Our procedures mentioned above did not identify any issues with regard to related party transactions.

Other Information

The other information comprises all of the information in the Annual Report other than the financial statements and our auditor's report thereon. We have not been provided the Directors' report and other information contained within the annual report, except for the financial statements to the date of our auditor's report. We expect to obtain the remaining reports of the Annual Report after the date of our auditor's report. Management is responsible for the other information.

In connection with our audit of the financial statements, our responsibility is to read the other information identified in the Annual Report as and when it becomes available and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated.

Our opinion on the financial statements does not cover the other information, and we do not express any observation to that effect.

Responsibilities of Management and Those Charged with Governance for the Financial Statements

Management is responsible for the preparation and fair presentation of these financial statements in accordance with International Financial Reporting Standards (IFRSs), the Companies Act, 1994, the Securities and Exchange Rules 2020 and other applicable laws and regulations and for such internal control as management determines is necessary to enable the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error; selecting and applying appropriate accounting policies, and making accounting estimates that are reasonable in the circumstances.

In preparing the financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Those charged with governance are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of financial statements.

As part of an audit in accordance with ISAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit. However, documentation process need be strengthened further.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

From the matters communicated with those charged with governance, we determine those matters that were of most significance in the audit of the financial statements of the current period and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest/benefits of such communication.

Report on other Legal and Regulatory Requirements

In accordance with the Companies Act, 1994 and the Securities and Exchange Rules, 2020 and relevant notifications issued by Bangladesh Securities and Exchange Commission, we also report the following:

a) we have obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purpose of our audit and made due verification thereof;

b) in our opinion, proper books of accounts as required by law have been kept by the Company and so far as it appeared from our examination of these books;

c) the statement of financial position and statement of profit or loss and other comprehensive income dealt with by the report are in agreement with the books of account; and

d) the expenditure incurred was for the purposes of the Company's business.

Habib Sarwar Bhuiyan & Co.
Chartered Accountants
Registration no: CAF-001-010
Signed By:



Md. Shah Alam Mridha FCA
Partner
Enrolment No. - 0733
FRC No. CA-001-014

Dhaka, October 23, 2025
DVC: 2510230733AS590123

Beacon Pharmaceuticals PLC

Statement of Financial Position

As at 30 June 2025

Particular	Notes	Amount in BDT	
		30 June 2025	30 June 2024
Assets			
Non-current assets		**6,535,809,800**	**6,214,724,580**
Property, plant and equipment	4	5,295,634,773	5,056,802,410
Capital work in progress	5	1,093,644,548	1,129,942,489
Intangible assets	6	16,526,379	27,979,681
Right-of-use assets	7	130,004,100	-
Current assets		**12,867,986,688**	**12,716,951,803**
Inventories	9	3,323,236,482	2,887,636,492
Trade and other receivables	10	3,033,235,963	2,982,715,008
Short term investment and loans	11	2,119,186,773	2,627,490,587
Advance income tax	12	189,476,757	159,037,647
Advance, deposits and prepayments	13	3,959,240,991	3,738,157,643
Other financial assets	14	15,743,684	14,962,375
Cash and cash equivalents	15	227,866,038	306,952,051
Total assets		**19,403,796,488**	**18,931,676,383**
Equity & liabilities			
Shareholders' equity		**6,667,081,042**	**6,090,395,149**
Share capital	16	2,310,000,000	2,310,000,000
Capital reserve	17	719,128,532	890,880,677
Other reserve	18	(2,188,523)	(2,278,039)
Retained earnings		3,640,141,033	2,891,792,511
Non-current liabilities		**4,390,337,379**	**3,579,241,053**
Long term loans	19	3,193,098,790	2,728,926,258
Lease liabilities	20	110,588,537	-
Employee benefits	21	917,280,678	673,741,681
Deferred tax liabilities	8	169,369,374	176,573,114
Current liabilities		**8,346,378,067**	**9,262,040,181**
Trade and other payables	22	1,008,652,002	1,397,592,387
Long term loan-current portion	19.1	911,116,476	891,429,545
Lease liabilities-current portion	20	19,415,563	-
Short term loans	23	5,973,224,034	6,698,878,806
Income tax payable	24	383,148,842	246,126,476
Unclaimed dividend	25	50,821,150	28,012,967
Total equity & liabilities		**19,403,796,488**	**18,931,676,383**
Net asset value per share	37.5	**28.86**	**26.37**

The annexed notes 1 to 41 form an integral part of these financial statements.

Company Secretary	Chief Financial Officer	Managing Director	Chairman

Signed as per report of even date

Habib Sarwar Bhuiyan & Co.
Chartered Accountants
Registration no: CAF-001-010
Signed By:

Md. Shah Alam Mridha FCA
Partner
Enrolment No. - 0733
FRC No. CA-001-014

Dhaka, October 23, 2025
DVC: 2510230733AS590123

Beacon Pharmaceuticals PLC

Statement of Profit or Loss and Other Comprehensive Income

For the year ended 30 June 2025

Particular	Notes	Amount in BDT	
		2024-2025	2023-2024
Revenue	26	12,542,717,214	10,701,688,579
Cost of goods sold	27	(6,014,611,260)	(5,168,915,584)
Gross profit		**6,528,105,954**	**5,532,772,995**
Operating expenses		**(4,128,889,053)**	**(3,670,616,567)**
Administrative expenses	28	(758,270,400)	(794,461,875)
Marketing, selling & distribution expenses	29	(3,370,618,653)	(2,876,154,692)
Operating profit		**2,399,216,901**	**1,862,156,428**
Other income	30	275,322,855	141,530,602
Profit before financing and income tax		**2,674,539,756**	**2,003,687,030**
Finance expenses	31	(1,308,447,530)	(1,002,701,103)
Profit before contribution to workers' profit participation fund		**1,366,092,226**	**1,000,985,927**
Contribution to workers' profit participation fund	32	(65,052,012)	(47,665,997)
Net profit before tax		**1,301,040,214**	**953,319,930**
Current income tax	33	(361,732,193)	(369,177,948)
Deferred tax (expense)/income	33.1	7,203,740	(63,136,378)
Net profit after tax for the year		**946,511,761**	**521,005,604**
Other comprehensive income/(loss)	34	89,516	(661,860)
Total comprehensive income for the year		**946,601,277**	**520,343,744**
No. of shares	16	**231,000,000**	**231,000,000**
Earnings per share	37.4	**4.10**	**2.26**

The annexed notes 1 to 41 form an integral part of these financial statements.

Company Secretary	Chief Financial Officer	Managing Director	Chairman

Signed as per report of even date

Habib Sarwar Bhuiyan & Co.
Chartered Accountants
Registration no: CAF-001-010
Signed By:

Md. Shah Alam Mridha FCA
Partner
Enrolment No. - 0733
FRC No. CA-001-014

Dhaka, October 23, 2025
DVC: 2510230733AS590123

Beacon Pharmaceuticals PLC

Statement of Changes in Equity

For the year ended 30 June 2025

Amount in BDT

Particulars	Share capital	Capital reserve	Other reserve	Retained earning	Total
Balance as at 01 July 2024	**2,310,000,000**	**890,880,677**	**(2,278,039)**	**2,891,792,511**	**6,090,395,149**
Total comprehensive income for the year					
Profit/(loss) for the year	-	-	-	946,511,761	946,511,761
Other comprehensive income	-	-	89,516		89,516
Total comprehensive income for the year	**-**	**-**	**89,516**	**946,511,761**	**946,601,277**
Transactions with owners of the company					
Dividend during the year	-	-	-	(369,915,385)	(369,915,385)
Total contributions and distributions	**-**	**-**	**-**	**(369,915,385)**	**(369,915,385)**
Transfer of depreciation on revaluation surplus	-	(221,615,671)	-	221,615,671	-
Adjustment of deferred tax arising from revaluation	-	49,863,526	-	(49,863,526)	-
Total adjustment	**-**	**(171,752,145)**	**-**	**171,752,145**	**-**
Balance as at 30 June 2025	**2,310,000,000**	**719,128,532**	**(2,188,523)**	**3,640,141,033**	**6,667,081,042**
Balance as at 01 July 2023	**2,310,000,000**	**1,068,173,214**	**(1,616,179)**	**2,565,467,021**	**5,942,024,056**
Total comprehensive income for the year					
Profit for the year				521,005,604	521,005,604
Other comprehensive income			(661,860)		(661,860)
Total comprehensive income for the year	**-**	**-**	**(661,860)**	**521,005,604**	**520,343,744**
Transactions with owners of the company					
Dividend during the year				(371,972,651)	(371,972,651)
Total contributions and distributions	**-**	**-**	**-**	**(371,972,651)**	**(371,972,651)**
Transfer of depreciation on revaluation surplus		(221,615,671)		221,615,671	-
Adjustment of deferred tax arising from revaluation		44,323,134		(44,323,134)	-
Total adjustment	**-**	**(177,292,537)**	**-**	**177,292,537**	**-**
Balance as at 30 June 2024	**2,310,000,000**	**890,880,677**	**(2,278,039)**	**2,891,792,511**	**6,090,395,149**

The annexed notes 1 to 41 form an integral part of these financial statements.

Company Secretary | **Chief Financial Officer** | **Managing Director** | **Chairman**

Signed as per report of even date

Habib Sarwar Bhuiyan & Co.
Chartered Accountants
Registration no: CAF-001-010
Signed By:

Md. Shah Alam Mridha FCA
Partner
Enrolment No. - 0733
FRC No. CA-001-014

Dhaka, October 23, 2025
DVC: 2510230733AS590123

Beacon Pharmaceuticals PLC

Statement of Cash Flows

For the year ended 30 June 2025

Particular		Notes	Amount in BDT 2024-2025	Amount in BDT 2023-2024
A)	**Cash flows from operating activities**			
	Receipts from customers and others		12,840,766,511	10,175,819,174
	Payments to suppliers, employees and others		(9,658,353,462)	(9,113,981,676)
	Cash generated from operations		**3,182,413,049**	**1,061,837,498**
	Interest paid		(1,327,236,245)	(983,912,388)
	Income tax paid		(255,148,937)	(257,557,745)
	Net cash generated from/(used in) operations	37.7	**1,600,027,867**	**(179,632,635)**
B)	**Cash flows from investing activities**			
	Acquisition of property, plant and equipment		(217,189,696)	(449,346,655)
	Acquisition of intangible assets		(1,195,950)	(25,221,934)
	Addition in capital work in progress		(604,342,024)	(645,685,286)
	Received from/(payments to) the investments, loans advances		(193,699,874)	(1,282,165,095)
	Receipts from sale of property, plant and equipment		237,070	30,148,200
	Receipts/(payment) from investment in quoted share and other financial assets		(781,573)	5,983,162
	Net cash from/(used in) investing activities		**(1,016,972,047)**	**(2,366,287,609)**
C)	**Cash flows from financing activities**			
	Net receipts/(payments) of loans		(241,795,309)	2,863,927,964
	Dividend paid		(347,107,202)	(369,556,547)
	Net cash from/(used in) financing activities		**(588,902,511)**	**2,494,371,417**
D)	**Net increase/(decrease) in cash and cash equivalents (A+B+C)**		**(5,846,691)**	**(51,548,827)**
E)	Opening cash and cash equivalents		306,952,051	452,188,479
F)	Effect of exchange rate fluctuations on cash and cash equivalents		(73,239,322)	(93,687,601)
G)	**Closing cash and cash equivalents (D+E+F)**	15	**227,866,038**	**306,952,051**
	Net operating cash flows per share	37.6	**6.93**	**(0.78)**

The annexed notes 1 to 41 form an integral part of these financial statements.

Company Secretary	Chief Financial Officer	Managing Director	Chairman

Signed as per report of even date

Habib Sarwar Bhuiyan & Co.
Chartered Accountants
Registration no: CAF-001-010
Signed By:

Md. Shah Alam Mridha FCA
Partner
Enrolment No. - 0733
FRC No. CA-001-014

Dhaka, October 23, 2025
DVC: 2510230733AS590123

Notes to the Financial Statements

As at and for the year ended 30 June 2025

1.0 Background and activities of the Company

1.1 Company profile

Beacon Pharmaceuticals PLC (""the Company"") was incorporated as a private limited company on September 12, 2001, under the Companies Act, 1994 vide registration no. C-43991(531)/2001 dated September 12, 2001 and subsequently converted into a public limited company on February 25, 2008. The Company went for an Initial Public Offering (IPO) in 2010. The Company is a publicly-traded company listed with Dhaka Stock Exchange Limited and Chittagong Stock Exchange Limited since the year 2010. The company has changed its name from Beacon Pharmaceuticals Limited to Beacon Pharmaceuticals PLC dated 22 February 2023.

The registered office of the Company is located at its factory premises at Kathali, Bhaluka, Mymensingh and corporate office is located at 9/B/2, Toyenbee Circular Road, Motijheel C/A, Dhaka-1223."

1.2 Nature of business

The Company specializes in producing and promoting pharmaceutical finished formulations, life-saving intravenous (I.V) fluids, active pharmaceutical ingredients (APIs), as well as bio-tech and genetic engineering products. These products are distributed in both domestic and international markets, and the company additionally offers contract and toll manufacturing services.

1.3 Production facility

Production facility of the Company is located at Kathali, Bhaluka, Mymensingh.

2 Basis of preparation and presentation of the financial statements

2.1 Statement of compliance

"The financial statements have been prepared in accordance with the international Financial Reporting Standards (IFRS) as adopted by the Financial Reporting Council (FRC), the Companies Act 1994, the Securities and Exchange Rules 2020 and other applicable laws and regulations in Bangladesh. Cash Flows from operating activities are prepared under direct method prescribed by the Securities and Exchange Rules 2020.

The financial statements have been prepared on a historical cost basis, except for financial assets and contingent considerations that have been measured at fair value where applicable. The financial statements provide comparative information in respect of the previous period and have been prepared on a going concern basis."

2.2 Reporting period

The financial period of the Company covers one year from 1 July to 30 June and is followed consistently.

2.3 Comparative and reclassification

Comparative information has been disclosed for all numerical, narrative and descriptive information where it is relevant for understanding of the current year financial statements. Comparative figures have been rearranged or reclassified wherever considered necessary, to ensure better comparability with the current year financial statements and to comply with relevant IFRSs.

2.4 Functional and presentation currency

These financial statements have been presented in Bangladeshi Taka (Taka/TK/BDT) which is the Company's functional and presentation currency. All amounts have been rounded off to the nearest integer.

2.5 Use of estimates and judgements

In preparing these financial statements, management has made judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, income and expenses. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Revision to estimates are recognized prospectively.

2.6 Going concern

The Company has adequate resources to continue in operation for foreseeable future and hence, these financial statements have been prepared on going concern basis. As per management assessment there are no material uncertainties related to events or conditions which may cast significant doubt upon the Company's ability to continue as a going concern.

2.7 Date of authorization

The financial statements were authorized for issue by the Board of Directors on 22 October 2025 for publication.

2.8 Standards, amendments and interpretations that are issued but not effective as at 30 June 2025

a) IFRS-18, Presentation and disclosure in financial statements

"The IASB has issued IFRS 18, the new standard on presentation and disclosure in financial statements, with a focus on updates to the statement of profit or loss. The key new concepts introduced in IFRS 18 relate to:

• The structure of the statement of profit or loss;

• Required disclosures in the financial statements for certain profit or loss performance measures that are reported outside an entity's financial statements (that is, management-defined performance measures); and

• Enhanced principles on aggregation and disaggregation which apply to the primary financial statements and notes in general.

IFRS 18 will replace IAS 1; many of the other existing principles in IAS 1 are retained, with limited changes. IFRS 18 will not impact the recognition or measurement of items in the financial statements, but it might change what an entity reports as its 'operating profit or loss'.

IFRS 18 will apply for reporting periods beginning on or after 1 January 2027 and also applies to comparative information. "

b) IFRS-S1,General requirements for the disclosure of sustainability-related financial information

IFRS S1 establishes general requirements with the objective of requiring an entity to disclose information about its sustainability-related risks and opportunities. IFRS S1 prescribes how an entity should prepare and present its sustainability-related financial information. It sets out general requirements for the content and presentation of these disclosures so that the information disclosed is useful to primary users of financial reporting in making decisions about the provision of resources to the entity.

C) IFRS-S2, climate-related disclosures

"The objective of IFRS S2 is to require an entity to disclose information about its climate-related risks and opportunities that is useful to users of general purpose financial reports in making decisions relating to providing resources to the entity. These are climate-related risks and opportunities that could reasonably be expected to affect the entity's cash flows, its access to finance or cost of capital over the short, medium or long term.

3 Significant accounting policies

Accounting policies set out below have been applied consistently to all years presented in these financial statements.

3.1 Current versus non-current classification

The Company presents assets and liabilities in the statement of financial position based on current/non-current classification.

An asset is current when it is:

• Expected to be realized or intended to be sold or consumed in the normal operating cycle, or

• Expected to be realized within twelve months after the reporting period, or

• Held primarily for the purpose of trading, or

• Cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period.

All other assets are classified as non-current.

A liability is current when it is:

• Expected to be settled in normal operating cycle, or

• Due to be settled within twelve months after the reporting period, or

• Held primarily for the purpose of trading, or

• There is no unconditional right to defer the settlement of the liability for at least twelve months after the reporting period.

All other liabilities are classified as non-current.

3.2 Property, plant and equipment

a) Recognition and measurement

Items of property, plant and equipment are measured at cost less accumulated depreciation and accumulated impairment losses, if any. Cost includes expenditure that is directly attributable to the acquisition of the asset and any other costs directly attributable to bringing the asset to working condition for its intended use and the costs of dismantling and removing the items and restoring the site on which they are located.

b) Subsequent costs

Subsequent to initial recognition, cost of replacing part of an item of property, plant and equipment is recognized in the carrying amount of the item if it is probable that the future economic benefits embodied within the part will flow to the Company and its cost can be measured reliably. All other repair and maintenance expenses are charged in the statement of profit or loss and other comprehensive income as they are incurred.

c) Depreciation

All items of property, plant and equipment have been depreciated on straight line basis. Depreciation on additions are charged from the month of acquisition. On disposal of an asset, depreciation is charged up to the date of disposal. No depreciation is charged for land and assets under construction. The Company is following this policy consistently from past years. The estimated useful lives and the rates of residual value of property, plant and equipment for the current and comparative years are as follows:

Categories of property plant and equipment	Rate of depreciation(%)	
	FY 2024-2025	FY 2023-2024
Land & land development	0	0
Building	5	5
Vehicles	20	20
Utility equipment and Installation	5-25	10
Office equipment	10-25	10
Production machinery & equipment	5-25	15
Furniture & fixtures	10	10

d) Impairment

The carrying amount of the Company's non-financial assets, other than inventories and deferred tax assets (considered as disclosed separately under respective accounting standards), are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, the asset's recoverable amount is estimated. However, no such conditions that might be suggestive of a heightened risk of impairment of assets existed at the reporting date.

e) Derecognition

An item of property, plant and equipment is derecognized upon disposal or when no future economic benefits are expected from its use or disposal. Any gain or loss on derecognition of an item of property, plant and equipment is determined as the difference between the net disposal proceeds and the carrying amount of the asset and is recognized in profit or loss.

f) Capital work in progress

Capital work-in-progress represents the cost incurred for acquisition and/or construction of items of property, plant and equipment that were not ready for use at the end of the year and these are stated at cost.

g) Capitalization of borrowing costs

As per the requirements of IAS 23 Borrowing Costs, directly attributable borrowing costs are capitalized during construction period for all qualifying assets. A qualifying asset is an asset that necessarily takes a substantial period of time to get ready for its intended use or sale. The borrowing costs that are directly attributable to the acquisition, construction or production of a qualifying asset are those borrowing costs that would have been avoided if the expenditure on the qualifying asset had not been made. All other borrowing costs are recognized in profit or loss in the period in which they are incurred.

3.3 Intangible assets

a) Recognition and measurement

Intangible assets that are acquired by the Company and have finite useful lives are measured at cost less accumulated amortization and accumulated impairment loss, if any. Intangible assets are recognized when all the conditions for recognition as per IAS 38 Intangible Assets are met. The cost of an intangible asset comprises its purchase price, import duties and non-refundable taxes and any directly attributable cost of preparing the asset for its intended use.

b) Subsequent costs

Subsequent costs are capitalized only when they increase the future economic benefits embodied in the specific asset to which they relate. All other costs are recognized in profit or loss as incurred.

c) Amortization

Amortization is recognized in profit or loss on a straight line basis over the estimated useful lives of intangible assets. The estimated useful lives are three years for the software.

d) Derecognition

An intangible asset is derecognized on disposal, or when no future economic benefits are expected from use or dsposal. Gains or losses arising from derecognition of intangible assets, measured as the difference between the net disposal proceeds and the carrying amount of the assets, are recognized in profit or loss.

3.4 Lease

The Company assesses whether a contract is, or contains, a lease at its inception. That is, if the contract conveys the right to control the use of an identified asset for a period in exchange for consideration.

Company as a leasee

The Company applies a single recognition and measurement approach for all leases, except for short-term leases and leases of low-value assets. The Company recognizes lease liabilities to make lease payments and right-of use assets representing the right to use the underlying assets.

a) Right of use assets

"The Company recognizes right-of-use assets at the commencement date of the lease (i.e., the date the underlying asset is available for use). Right-of-use assets are measured at cost, less any accumulated depreciation and impairment losses, and adjusted for any remeasurement of lease liabilities. The cost of right-of-use assets includes the amount of lease liabilities recognized and lease payments made at or before the commencement date less any lease incentives received.

For its head office rental, the Company has recognized a right-of-use asset as of 30 June 2025. Depreciation of the ROU asset is scheduled to commence from 1 July 2025."

b) Lease liabilities

"At the commencement date of the lease, the Company recognizes lease liabilities measured at the present value of lease payments to be made over the lease term. The lease payments include fixed payments (including in-substance fixed payments) less any lease incentives receivable, variable lease payments that depend on an index or a rate, and amounts expected to be paid under residual value guarantees. The lease payments also include the exercise price of a purchase option reasonably certain to be exercised by the Company and payments of penalties for terminating the lease, if the lease term reflects the Company exercising the option to terminate.

c) Short-term leases and leases of low-value assets

The Company is not applying the recognition and measurement requirements of IFRS 16 to short-term leases (leases of less than 12 months maximum duration). It is also not applying the recognition and measurement requirements of IFRS 16 to leases for which the underlying asset is of low value. Lease payments on short-term leases and leases of low-value assets are recognized as expense on a straight-line basis over the lease term.

3.5 Financial instruments

A financial instrument is any contract that gives rise to a financial asset of one entity and a financial liability or equity instrument of another entity. Non-derivative financial instruments comprise deposits, trade and other receivables, cash and cash equivalents, trade and other payables, intercompany payables, share capital and interest-bearing borrowings.

a) Financial assets

The Company initially recognizes receivables and deposits on the date that they are originated. All other financial assets are recognized initially on the date at which the Company becomes a party to the contractual provisions of the transaction. The Company derecognizes a financial asset when the contractual rights to the cash flows from the asset expire, or it transfers the rights to receive the contractual cash flows in a transaction in which substantially all the risks and rewards of ownership of the financial asset are transferred, or it neither transfers nor retains substantially all of the risks and rewards of ownership and does not retain control over the transferred asset. The Company's financial assets comprise trade and other receivables, financial investment assets, deposits and cash and cash equivalents.

b) Financial liabilities

"The Company initially recognizes financial liabilities in its statement of financial position when the Company becomes a party to the contractual provisions of the liability. The Company recognizes such financial liability when its contractual obligations arising from past events are certain and the settlement of which is expected to result in an outflow from the entity of resources embodying economic benefits. The Company derecognizes a financial liability when its contractual obligations are discharged or cancelled, or expired."

c) Offsetting a financial asset and a financial liability

Financial assets and financial liabilities are offset and the net amount presented in the statement of financial position when, and only when, the Company has a legal right to offset the amounts and intends either to settle them on a net basis or to realize the asset and settle the liability simultaneously.

3.6 Impairment

a) Recognition

Financial assets not carried at fair value through profit or loss and receivables are assessed at each reporting date to determine whether there is objective evidence that any particular asset is impaired. A financial asset is impaired if objective evidence indicates that a loss event has occurred after the initial recognition of the asset, and that the loss event had a negative effect on the estimated future cash flows of that asset that can be estimated reliably. The carrying value of the non-financial assets, other than inventories, are reviewed at each reporting date to determine whether there is any indication of impairment. If any such indication exists, the assets' recoverable amount is estimated. An impairment loss is recognized whenever the carrying amount of the assets or its cash generating unit exceeds its recoverable amount. Impairment losses, if any, are recognized in the statement of profit or loss and other comprehensive income.

b) Calculation of recoverable amount

The recoverable amount of asset is the greater of its net selling price or its value in use. The latter is determined by discounting the estimated future cash flows to a present value using a discount rate which reflects the current market assessment of the time value of money and risk specific to the asset. For an asset that does not generate significantly independent cash inflows, the recoverable amount is determined for the cash generating unit to which the asset belongs.

3.7 Inventories

Inventories are carried at the lower of cost and net realizable value as prescribed by IAS 2: Inventories. Cost is determined on a weighted average basis. The cost of inventories comprises expenditure incurred in the normal course of business in bringing the inventories to their present location and condition. Net realizable value is based on the estimated selling price less any further costs expected to be incurred to make the sale.

3.8 Share capital

Ordinary shares are classified as equity. Incremental costs directly attributable to the issue of ordinary shares are recognized as a deduction from equity, net of any tax effects. Paid up capital represents total amount contributed by the shareholders and bonus shares, if any, issued by the Company to the ordinary shareholders. Holders of ordinary shares are entitled to receive dividends as declared from time to time and are entitled to vote at shareholders' meetings. In the event of a winding up of the Company, ordinary shareholders rank after all other shareholders and creditors and are fully entitled to any residual proceeds of liquidation.

3.9 Employee benefits

The Company maintains both defined contribution plan and defined benefit plan for its eligible permanent employees. The eligibility is determined according to the terms and conditions set forth in the respective trust deeds and rules. Both of the plans are funded and are recognized/approved by NBR.

a) Short-term benefits

Short-term employee benefit obligations are measured on an undiscounted basis and are expensed as the related services are provided. A liability is recognized for the amount expected to be paid under short-term cash bonus or profit-sharing plans if the Company has a present legal or constructive obligation to pay this amount as a result of past service provided by the employee, and the obligation can be estimated reliably.

b) Defined benefits plans(gratuity scheme)

The Company operates a funded gratuity scheme for its permanent employees, under which an employee is entitled to the benefits depending on the length of services and last drawn basic salary.

c) Defined contribution plan (provident fund)

Defined contribution plan is a post employment benefit plan under which the Company provides benefits for all of its permanent employees. The recognized Employees' Provident Fund is being considered as defined contribution plan as it meets the recognition criteria specified for this purpose. All permanent employees contribute 10% of their basic salary to the provident fund and the Company also makes equal contribution. This fund is recognized by the National Board of Revenue (NBR), under the Income Tax Act 2023. The Company recognizes contribution to defined contribution plan as an expense when an employee has rendered required services. The legal and constructive obligation is limited to the amount it agrees to contribute to the fund. Obligations are created when they are due.

d) Worker's Profit Participation Fund (WPPF)

The Company provides 5% of its net profit as a contribution to Workers' Profit Participation Fund before tax and charges such expense in accordance with The Bangladesh Labor Act 2006 (as amended in 2018).

e) Leave encashment

The Company operates unfunded leave encashment scheme, i.e. if its employees do not avail leave during his/her service, s/he will be entitled to encash privilege leave at the time of separation from the Company at the rate of one month's basic pay for 30 days of privilege leave.

f) Group insurance

The Company has also a group insurance scheme for its permanent employees, premium for which is being charged to income statement annually as per the insurance policy.

3.10 Accruals, provisions and contingencies

a) Accruals

Accruals are liabilities to pay for goods or services that have been received or supplied but have not been paid, invoiced or formally agreed with the supplier, including amounts due to employees. Accruals are reported as part of trade and other payables.

b) Provisions

Provisions are recognized when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation. When the Company expects some or all of a provision to be reimbursed, the reimbursement is recognized as a separate asset, but only when the reimbursement is virtually certain. The expense relating to a provision is presented in the statement of profit or loss net of any reimbursement. If the effect of the time value of money is material, provisions are discounted using a current pre-tax rate that reflects, when appropriate, the risks specific to the liability. When discounting is used, the increase in the provision due to the passage of time is recognized as a finance cost. Provisions are reviewed at the end of each reporting period and adjusted to reflect the current best estimate. If it is probable that an outflow of resources embodying economic benefits are required to settle the obligation, the provisions are reversed.

c) Contingencies

• Contingent liability

Contingent liability is a possible obligation that arises from past events, the existence of which will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity. The Company discloses contingent liability in the financial statements. A provision is recognized in the period in which the recognition criteria of provision is met.

• Contingent asset

Contingent asset is a possible asset that arises from past events, the existence of which will be confirmed only by the occurrence or non-occurrence of one or more uncertain future events not wholly within the control of the entity. A contingent asset must not be recognized. Only when the realization of the related economic benefits is virtually certain should recognition take place provided that it can be measured reliably because, at that point, the asset is no longer contingent.

3.11 Income tax

Income tax expense comprises current and deferred tax. Current tax and deferred tax are recognized in profit or loss except to the extent that it relates to the items recognized directly in equity or in other comprehensive income.

a) Current tax

Current tax is the expected tax payable or receivable on the taxable income or loss for the year, using tax rates enacted or substantively enacted at the reporting date, and any adjustment to tax payable in respect of previous years. Provision for corporate income tax is made following the rate applicable for companies as per Finance Act 2024 i.e. 22.5%.

b) Deferred tax

Deferred tax is recognized in respect of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for taxation purposes. Deferred tax is measured at the tax rates that are expected to be applied to temporary differences when they reverse, using tax rates enacted or substantively enacted by the reporting date. Deferred tax assets and liabilities are offset if there is a legally enforceable right to offset current tax liabilities and assets, and they relate to taxes levied by the same tax authority on the same taxable entity, or on different tax entities, but they intend to settle current tax liabilities and assets on a net basis or their tax assets and liabilities will be realized simultaneously. A deferred tax asset is recognized for unused tax losses, tax credits and deductible temporary differences, to the extent that it is probable that future taxable profits will be available against which they can be utilized. Deferred tax assets are reviewed at each reporting date and are reduced to the extent that it is no longer probable that the related tax benefit will be realized.

3.12 Revenue from contracts with customers

Revenue from contracts with customers is recognized when control of the goods or services are transferred to the customer at an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods. To achieve that core principle, IFRS 15 establishes a five-step model as follows:

- Identify the contract with a customer;
- Identify the performance obligations in the contract;
- Determine the transaction price;
- Allocate the transaction price to the performance obligations in the contract; and
- Recognize revenue when (or as) the entity satisfies a performance obligation.

Considering the five steps model, the company recognizes revenue when (or as) the company satisfies a performance obligation by transferring a promised good to a customer. Goods are considered as transferred when (or as) the customer obtains control of that goods. Revenue from sale of goods is measured at the fair value of the consideration received or receivable net of returns and allowances, trade discounts, rebates and Value Added Tax (VAT).

3.13 Finance expenses

Finance costs comprise interest expense on overdraft, borrowings from bank and lease interest. Borrowing costs that are not directly attributable to the acquisition, construction or production of a qualifying asset are recognized in profit or loss.

3.14 Other income

Other income includes interest on FDR and other bank accounts, gain on disposal of fixed assets, interest income on loan to related parties, dividend income, gain on foreign currency fluctuation and other miscellaneous income. Other income is recognized on an accrual basis and shown under statement of profit or loss and other comprehensive income.

3.15 Foreign currency transactions

Transactions in foreign currencies are translated to Bangladesh Taka at the exchange rate prevailing on the date of transactions. All monetary assets and liabilities denominated in foreign currencies are translated to the functional currency at the exchange rate prevailing at the date of statement of financial position. Foreign currency differences arising on the settlement of monetary items or on translating monetary items at the end of the reporting period are recognized in the statement of profit or loss and other comprehensive income as per IAS 21: The Effects of Changes in Foreign Exchange Rates. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rate at the date of transactions.

3.16 Dividends

Final dividend distribution to the shareholders are recognized as a liability in the financial statements in the period in which the dividends are approved by the shareholders at the Annual General Meeting.

3.17 Statement of cash flows

Statement of Cash Flows is prepared under direct method in accordance with IAS 7 Statement of Cash Flows as required by the Bangladesh Securities and Exchange Rules 2020.

3.18 Offsetting

The Company reports separately both assets and liabilities, and income and expenses, unless required by an applicable accounting standard or offsetting reflects the substance of the transaction and such offsetting is permitted by applicable accounting standard.

Particular	Notes	Amount in BDT	
		2024-2025	2023-2024
4 Property, plant and equipment			
A) Cost			
Balance as on 01 July		**7,616,489,186**	**5,755,028,265**
Addition during the year		857,829,662	1,899,346,709
Adjustment during the year		(18,845,463)	(37,885,788)
Balance as on 30 June		**8,455,473,385**	**7,616,489,186**
B) Accumulated depreciation			
Balance as on 01 July		**2,559,686,776**	**2,063,726,721**
Charged during the year		618,752,154	519,752,431
Disposal/adjustment during the year		(18,600,318)	(23,792,376)
Balance as on 30 June		**3,159,838,612**	**2,559,686,776**
Detailed schedule of fixed assets are given in Annexure-A.		**5,295,634,773**	**5,056,802,410**
5 Capital work in progress			
Balance as on 01 July		**1,129,942,489**	**1,956,813,116**
Addition during the year		604,342,024	645,685,286
		1,734,284,513	**2,602,498,402**
Capitalized as property plant & equipment	5.1	(640,639,965)	(1,472,555,913)
Balance as on 30 June		**1,093,644,548**	**1,129,942,489**
5.1 Breakdown of capitalized property, plant and equipment			
Building		440,924,401	1,124,615,441
Pant & machinery		77,160,838	106,635,876
Utility equipment & installation		121,345,905	128,465,775
Furniture & fixtures		12,871	112,838,821
Intangible assets		1,195,950	-
Total		**640,639,965**	**1,472,555,913**
6 Intangible assets			
A) Cost			
Balance as on 01 July		**41,409,909**	**16,187,975**
Addition during the year		1,195,950	25,221,934
Balance as on 30 June		**42,605,859**	**41,409,909**
B) Accumulated amortization			
Balance as on 01 July		**13,430,228**	**5,401,324**
Charged during the year		12,649,252	8,028,904
Balance as on 30 June		**26,079,480**	**13,430,228**
Carrying amounts		**16,526,379**	**27,979,681**

	Particular	Notes	Amount in BDT	
			2024-2025	2023-2024
7	**Right-of-use assets**			
	Cost			
	Balance as on 01 July		**-**	**-**
	Addition during the year		130,004,100	-
	Disposal/adjustment during the year		-	-
	Balance as on 30 June		**130,004,100**	**-**
	Accumulated depreciation			
	Balance as on 01 July		**-**	**-**
	Charged during the year		-	-
	Disposal/adjustment during the year		-	-
	Balance as on 30 June		**-**	**-**
	Carrying amounts		**130,004,100**	**-**

* IFRS 16, Lease has been implemented as of 30 June 2025 and depreciation will commence from 1 July 2025.

	Particular	Carrying amount	Tax base	Taxable/(deductible) temporary differences
8	**Deferred tax assets/liabilities**			
	As at 30 June 2025			
	Property, plant and equipment	4,631,828,971	3,863,548,085	768,280,886
	Right-of-use assets	130,004,100	-	130,004,100
	Intangible assets	16,526,380	32,054,491	(15,528,111)
	Lease liabilities	(130,004,100)	-	(130,004,100)
	Net taxable temporary differences	**4,648,355,351**	**3,895,602,576**	**752,752,775**
	Net deferred tax (assets)/liabilities @ 22.50% tax rate			**169,369,374**
	As at 30 June 2024			
	Property, plant and equipment	4,392,996,608	3,503,690,567	889,306,041
	Intangible assets	27,979,681	34,420,151	(6,440,470)
	Net taxable temporary differences	**4,420,976,289**	**3,538,110,718**	**882,865,571**
	Net deferred tax (assets)/liabilities @ 20% tax rate			**176,573,114**
9	**Inventories**			
	Finished goods		801,995,868	664,559,161
	Work in process		191,926,680	321,059,959
	Raw materials		1,426,146,383	1,264,817,451
	Packing materials		296,075,194	268,260,764
	Material in transit		340,444,967	205,111,028
	Spares and other supplies		266,647,390	163,828,129
	Total		**3,323,236,482**	**2,887,636,492**

Particular		Notes	Amount in BDT	
			2024-2025	2023-2024
10	**Trade and other receivables**			
	Trade receivables		2,487,797,841	2,757,923,483
	Other receivables	10.1	545,438,122	224,791,525
	Total		**3,033,235,963**	**2,982,715,008**
	* Ageing of trade receivables is given in note no. 40.1			
10.1	**Other receivables**			
	Interest receivables		545,438,122	224,791,525
	Total		**545,438,122**	**224,791,525**
11	**Short term investment and loans**			
	Investment in quoted shares	11.1	491,336	401,556
	Loan to related parties		2,118,695,437	2,627,089,031
	Total		**2,119,186,773**	**2,627,490,587**
11.1	**Investment in quoted shares**			
	Market value			
	Balance as on 01 July		**401,556**	**1,061,246**
	Add: Purchased during the year		264	2,170
	Add/(Less): Unrealized gain/(loss)		89,516	(661,860)
	Balance as on 30 June		**491,336**	**401,556**
	*Investment in shares have been recorded on the basis of market value.			
12	**Advance income tax**			
	Balance as on 01 July		**159,037,647**	**104,073,822**
	Addition during the year:			
	AIT on import		102,034,620	120,950,515
	AIT on sales		58,311,962	21,709,682
	AIT on export sales		814,299	-
	AIT on vehicle		6,611,000	5,478,000
	AIT on bank interest		1,704,876	899,450
	Advance tax paid		20,000,000	10,000,000
	Adjustment during the year		(159,037,647)	(104,073,822)
	Balance as on 30 June		**189,476,757**	**159,037,647**
13	**Advances, deposits and prepayments**			
	Advance for VAT		126,881,630	152,087,146
	Advance to employees		220,301,881	198,071,802
	Advance on import and L/C margin		354,382,050	348,044,411
	Advance to suppliers		1,191,111,377	1,082,972,905
	Advance to others		1,896,852,808	1,837,032,091
	Security deposit and earnest money		169,711,245	119,949,288
	Total		**3,959,240,991**	**3,738,157,643**

	Particular	Notes	Amount in BDT	
			2024-2025	2023-2024
14	**Other financial assets**			
	ICB Islami Bank		6,916,505	6,728,452
	Rupali Bank		7,425,794	6,919,119
	First Security Islami Bank		1,401,385	1,314,804
	Total		**15,743,684**	**14,962,375**
	*Other financial assets include investment in FDR.			
15	**Cash and cash equivalents**			
	Cash in hand	15.1	12,935,424	23,008,310
	Cash at bank	15.2	166,133,851	245,257,422
	Cash in transit		48,796,763	38,686,319
	Total		**227,866,038**	**306,952,051**
15.1	**Cash in hand**			
	Head office		3,061,477	4,843,410
	Factory office		958,708	2,318,539
	Sales office/Depots		8,915,239	15,846,361
	Total		**12,935,424**	**23,008,310**
15.2	**Cash at bank**			
	First Security Islami Bank		367,895	378,060
	Janata Bank		16,772,520	50,943,733
	Shahjalal Islami Bank		3,781,814	3,995,533
	ICB Islami Bank		473,043	747,193
	Dutch Bangla Bank		50,393,554	148,066,840
	Rupali Bank		6,017	162,582
	Sonali Bank		917,149	970,712
	Eastern Bank		19,909,288	5,224,996
	Commercial Bank of Ceylon		27,735,984	711,657
	Shimanto Bank		3,127,720	1,255,791
	United Commercial Bank		992,029	6,322,680
	One Bank		-	1,348,466
	Prime Bank		3,000	1,806,801
	Standard Chartered Bank		349,033	-
	Standard Bank		2,529,818	2,580,738
	Mutual Trust Bank		33,530,368	2,866,541
	Dhaka Bank		449,775	413,610
	Jamuna Bank		1,159,262	3,910,692
	Premier Bank		3,446,138	3,497,000
	Bank Asia		19,483	-
	POS collection		41,601	10,053,797
	BO A/C		128,360	-
	Total		**166,133,851**	**245,257,422**

Particular	Notes	Amount in BDT	
		2024-2025	2023-2024
16 Share capital			
Authorized capital			
300,000,000 ordinary shares of BDT 10 each		3,000,000,000	3,000,000,000
Issued, subscribed and paid-up Capital			
231,000,000 ordinary shares of BDT 10 each fully paid up		2,310,000,000	2,310,000,000
Breakdown as follows :			
Wholly paid in cash 176,000,000 shares @BDT 10		1,760,000,000	1,760,000,000
Other than cash 55,000,000 shares @ BDT 10		550,000,000	550,000,000
Total		**2,310,000,000**	**2,310,000,000**

16.1 Composition of shareholdings

Category of shareholders	Percentage of shareholdings		Number of shares	
	30-Jun-25	30-Jun-24	30-Jun-25	30-Jun-24
Sponsors/Directors	39.86%	39.86%	92,084,615	92,084,615
Institutions	38.90%	39.07%	89,868,240	90,251,700
Public	21.23%	21.07%	49,047,145	48,663,685
Total	**100.00%**	**100%**	**231,000,000**	**231,000,000**

16.2 Classification of shareholders by holding

Range of holdings	30-Jun-25			30-Jun-24		
	Number of shareholders	Number of shares	% of shareholdings	Number of shareholders	Number of shares	% of shareholdings
Less than 501 shares	5316	908,572	0.39%	5606	955,759	0.41%
501 to 5000 shares	3902	4,583,140	1.99%	4229	5,139,299	2.22%
5001 to 10000 shares	279	2,087,129	0.90%	322	2,401,654	1.04%
10,001 to 20,000 shares	179	2,516,231	1.09%	194	2,754,644	1.19%
20,001 to 30,000 shares	70	1,745,450	0.76%	74	1,829,703	0.79%
30,001 to 40,000 shares	25	881,485	0.38%	34	1,237,028	0.54%
40,001 to 50,000 shares	27	1,227,380	0.53%	24	1,079,127	0.47%
50,001 to 100,000 shares	66	4,548,394	1.97%	60	4,258,180	1.84%
100,001 to 1000,000 shares	69	26,160,409	11.32%	68	24,044,142	10.41%
Above 1000,000 shares	40	186,341,810	80.67%	34	187,300,464	81.08%
Total	**9,973**	**231,000,000**	**100.00%**	**10,645**	**231,000,000**	**100.00%**

Particular	Notes	Amount in BDT	
		2024-2025	2023-2024
17 Capital reserve			
Revaluation reserve		719,128,532	890,880,677
Total		**719,128,532**	**890,880,677**

17.1 The production machinery & equipment of the Company were revalued during the FY 2019-20 by independent professional valuer G.K. Adjusters Ltd.

Carrying value of revalued assets

FY	Particulars	Opening balance	Depreciation adjustment	Deferred tax on depreciation	Closing balance
2024-2025	Land	168,084,972	-	-	168,084,972
	Building	7,578,890	1,072,484	241,309	6,747,715
	Machineries	715,216,814	220,543,187	49,622,217	544,295,844
	Total	**890,880,676**	**221,615,671**	**49,863,526**	**719,128,531**
2023-2024	Land	168,084,972	-	-	168,084,972
	Building	8,436,877	1,072,484	214,497	7,578,890
	Machineries	891,651,364	220,543,187	44,108,637	715,216,814
	Total	**1,068,173,213**	**221,615,671**	**44,323,134**	**890,880,676**

17.2 **Revaluation reserve adjustment**

Particulars	Revaluation Surplus	Useful Life (in year)	Depreciation on Revaluation Surplus
Land	168,084,972	-	-
Building	21,449,683	20	1,072,484
Machineries	1,470,287,911	7	220,543,187
Total	**1,659,822,566**	**-**	**221,615,671**

	Particular	Notes	Amount in BDT 2024-2025	Amount in BDT 2023-2024
18	**Other reserve**			
	Balance as on 01 July		**(2,278,039)**	**(1,616,179)**
	Unrealized gain/(loss) on investment in shares during the period		89,516	(661,860)
	Balance as on 30 June		**(2,188,523)**	**(2,278,039)**
19	**Long term loans**			
	Rupali Bank PLC		232,320,558	321,914,510
	Prime Bank PLC		354,458,262	461,540,882
	Shimanto Bank PLC		31,230,018	37,595,805
	Syndication loan		3,486,206,428	2,799,304,606
			4,104,215,266	**3,620,355,803**
	Less: Current portion	19.1	911,116,476	891,429,545
	Total		**3,193,098,790**	**2,728,926,258**

*Significant portion of loans were taken from different banks for financing BMRE projects. Loans are classified under long term loans and short term loans on the basis of duration of payments. Amount of loans which will be paid within next twelve months are classified under short term loans. All loans were taken against securities given by the Beacon Pharmaceuticals PLC. Details of Loan arrangements with banks is given in note no. 41.

Particular		Notes	Amount in BDT	
			2024-2025	2023-2024
19.1	**Long term loan-current portion**			
	Rupali Bank PLC		232,320,558	232,000,000
	Prime Bank PLC		175,022,848	156,927,600
	Shimanto Bank Ltd.		6,511,860	10,599,300
	Syndication loan		497,261,210	491,902,645
	Total		**911,116,476**	**891,429,545**
20	**Lease liabilities**			
	Opening balance			
	Non-current		-	-
	Current		-	-
			-	-
	Net change during the year			
	Addition/adjustment		130,004,100	-
	Interest accrued		-	-
	Repayment		-	-
			130,004,100	**-**
	Closing balance			
	Non-current		110,588,537	-
	Current		19,415,563	-
	Total		**130,004,100**	**-**
	* IFRS 16, Lease has been implemented as of 30 June 2025, and depreciation will commence from 1 July 2025.			
21	**Employee benefits**			
	Defined benefit plan-gratuit		393,221,547	318,196,955
	Defined contribution plan-provident fund		313,942,341	246,095,239
	Provision for workers' profit participation fund		5,333,243	47,665,997
	Provision for leave encashment		85,446,593	31,047,466
	Provision for employees medical support		49,336,954	30,736,024
	Total		**917,280,678**	**673,741,681**
22	**Trade and other payables**			
	Trade payables			
		22.1	610,952,965	905,699,687
	Other payables	22.2	397,699,037	491,892,700
	Total		**1,008,652,002**	**1,397,592,387**
22.1	**Trade payables**			
	Local		610,952,965	660,154,078
	Foreign		-	245,545,609
	Total		**610,952,965**	**905,699,687**

	Particular	Notes	Amount in BDT	
			2024-2025	2023-2024
22.2	**Other payables**			
	VAT payable		123,094,384	78,705,644
	Interest payable		-	18,788,715
	Provision for expenses		194,485,861	212,696,950
	Sundry payables		65,646,799	119,982,465
	Provisional liability(goods & services)		14,471,993	61,718,926
	Total		**397,699,037**	**491,892,700**
23	**Short term loans**			
	Janata Bank PLC		1,394,252,767	1,475,579,423
	United Commercial Bank PLC		-	213,710,444
	Standard Chartered Bank		35,341,250	19,122,934
	Eastern Bank PLC		593,238,703	739,693,841
	Commercial Bank of Ceylon PLC		479,720,994	386,610,183
	Shahjalal Islami Bank PLC		2,487,277,879	3,036,779,799
	Mutual Trust Bank PLC		398,585,056	149,670,779
	Prime Bank PLC		381,657,385	359,899,820
	Jamuna Bank PLC		-	214,754,916
	Shimanto Bank PLC		203,150,000	103,056,667
	Total		**5,973,224,034**	**6,698,878,806**
24	**Income tax payable**			
	Balance as on 01 July		**246,126,476**	**79,542,448**
	Addition during the year		361,732,193	369,177,948
	Payment during the year		(224,709,827)	(202,593,920)
	Balance as on 30 June		**383,148,842**	**246,126,476**
25	**Unclaimed dividend**			
	Balance as on 01 July		**28,012,967**	**25,596,863**
	Addition during the year		369,915,385	2,416,104
	Payment during the year		(347,107,202)	-
	Balance as on 30 June		**50,821,150**	**28,012,967**
26	**Revenue**			
	Local		12,347,189,124	10,701,688,579
	Export		195,528,090	-
	Net revenue		**12,542,717,214**	**10,701,688,579**

Particular		Notes	Amount in BDT	
			2024-2025	2023-2024
27	**Cost of sales**			
	Opening stock		1,428,645,580	845,230,477
	Purchased during the year		4,204,816,063	3,858,937,897
	Materials available for use		**5,633,461,644**	**4,704,168,374**
	Closing stock		(1,722,221,577)	(1,428,645,580)
	Materials consumption		**3,911,240,067**	**3,275,522,794**
	Factory overheads	27.1	1,581,254,950	1,505,818,759
	Total manufacturing cost		**5,492,495,017**	**4,781,341,553**
	Opening work in process		321,059,959	295,890,973
	Closing work in process		(191,926,680)	(321,059,959)
	Total cost of goods manufactured		**5,621,628,295**	**4,756,172,567**
	Opening finished goods		664,559,161	617,992,247
	Finished goods purchased during the year		530,419,672	459,309,931
	Finished goods available for sale		**6,816,607,128**	**5,833,474,745**
	Closing finished goods		(801,995,868)	(664,559,161)
	Cost of goods sold		**6,014,611,260**	**5,168,915,584**
27.1	**Factory overheads**			
	Salaries and allowances		442,527,633	371,524,433
	Company contribution to provident fund		10,095,214	9,112,872
	Gratuity		17,727,067	41,879,694
	Employee welfare and recreation		9,616,465	6,791,665
	Entertainment		2,592,068	4,212,269
	Employee fooding		60,634,572	57,299,361
	Local travel and conveyance		289,207	518,373
	Foreign traveling expenses		3,195,444	2,644,551
	Employee medical expense		2,016,562	592,261
	Training expenses		1,277,798	2,623,405
	Supplies and consumables		-	5,306,889
	Research and development expense		36,498,284	69,647,770
	Repair and maintenance		85,551,782	80,743,566
	Transportation		22,464,038	23,209,367
	Telephone, fax, courier and internet		3,788,066	5,145,668
	Utilities		369,897,628	369,504,146
	Fees and renewals		6,125,608	3,021,702
	Books, newspaper and periodicals		-	356,216
	Uniform, laundry and cleaning		36,700	1,900,921
	Printing and stationery		20,160,336	28,957,758
	Legal and consultancy fees		793,922	4,320,007
	Insurance premium		8,815,593	5,350,659
	Freight and carriage		2,852,746	1,260,484

Particular	Notes	Amount in BDT	
		2024-2025	2023-2024
Advertisement and publicity		-	146,353
Corporate social responsibility (CSR)		678,000	1,252,444
Depreciation and amortization		471,005,785	403,794,300
Other expenses		2,614,432	4,701,625
Total		**1,581,254,950**	**1,505,818,759**
28 Administrative expenses			
Salaries and allowances		331,715,584	317,371,467
Company contribution to provident fund		7,911,430	7,784,590
Gratuity		10,298,007	35,775,359
Employee welfare and recreation		8,356,854	10,446,379
Entertainment		7,689,867	7,872,192
Employee fooding		34,171,661	39,847,000
Local travel and conveyance		7,665,565	7,102,748
Foreign traveling expenses		32,029,308	30,861,619
Employee medical expense		1,113,644	6,972,469
Training expenses		3,069,113	774,237
Repair and maintenance		31,730,387	28,095,403
Utilities		3,905,976	9,104,100
Office rent		22,552,580	24,908,012
Transportation		34,913,053	37,210,910
Telephone, fax, courier and internet		5,171,145	7,145,188
Fees and renewals		59,066,068	52,531,265
Books, newspaper and periodicals		94,712	103,174
Uniform, laundry and cleaning		362,278	1,232,864
Printing and stationery		17,219,486	17,400,794
Audit fees		812,378	569,600
Legal and consultancy fees		2,697,370	800,383
Insurance premium		2,118,559	5,255,360
Depreciation and amortization		72,178,029	55,794,166
Advertisement and publicity		4,941,764	1,360,384
Bank charge and commission		13,398,529	38,150,638
Regulatory fees and meeting expense		6,401,026	4,882,945
SAP Implementation expenses		-	15,502,977
Corporate social responsibility (CSR)		14,115,777	9,533,621
Other expenses		22,570,250	20,072,030
Total		**758,270,400**	**794,461,875**
29 Marketing, selling, & distribution expenses			
Salaries and allowances		1,444,593,590	1,231,508,901
Company contribution to provident fund		39,463,432	30,206,850
Gratuity		72,107,297	138,820,521
Employee welfare and recreation		22,498,536	17,178,957

Particular	Notes	Amount in BDT	
		2024-2025	2023-2024
Entertainment		15,019,706	11,538,657
Employee fooding		69,975,937	70,420,648
Local travel and conveyance		150,785,376	104,252,764
Foreign traveling expenses		26,640,491	19,361,215
Training expenses		39,406,631	35,025,697
Repair and maintenance		25,543,272	17,906,834
Office rent		42,161,179	36,259,636
Fuel for vehicles		56,179,544	19,030,550
Transportation		6,060,821	5,292,580
Telephone, fax, courier and internet		34,481,229	30,829,086
Utilities		9,943,898	7,986,011
Fees and renewals		7,197,367	5,295,224
Books, newspaper and periodicals		103,047	890,973
Uniform, laundry and cleaning		607,546	407,546
Printing and stationery		34,060,021	32,898,393
Legal and consultancy fees		9,182,049	6,236,440
Insurance premium		14,986,386	10,543,641
Depreciation and amortization		88,217,592	68,192,869
Advertisement and publicity		13,809,675	16,894,506
Field force expenses (TA/DA)		376,945,132	329,328,761
Sales incentive		122,860,661	98,335,809
Market research and planning		7,886,790	1,223,080
Sample expenses		59,954,188	-
Conference, fair and product launching		245,644,478	248,870,286
Promotional expenses		65,222,130	54,150,544
Distribution and collection expenses		233,217,245	201,070,110
Bad debts		391,990	737,715
Corporate social responsibility (CSR)		6,203,301	3,383,011
Other expenses		29,268,117	22,076,877
Total		**3,370,618,653**	**2,876,154,692**
30 Other income			
Interest on FDR		1,238,560	1,650,794
Interest on STD and SND		9,196,718	2,855,365
Gain/(loss) on disposal of fixed assets		(8,075)	(6,501,072)
Income/(loss) from foreign currency fluctuation		(73,239,322)	(93,687,601)
Interest income from loan to related parties		320,340,452	223,357,137
Dividend income		2,551	1,505
Miscellaneous income		17,791,971	13,854,474
Total		**275,322,855**	**141,530,602**

Particular	Notes	Amount in BDT	
		2024-2025	2023-2024
31 Finance expenses			
Interest on short term loan		829,631,263	785,731,274
Interest on long term loan		533,848,636	216,969,829
		1,363,479,899	**1,002,701,103**
Less: Transfer to CWIP as borrowing cost		(55,032,369)	-
Total		**1,308,447,530**	**1,002,701,103**
32 Contribution to workers profit participation Fund			
Profit before contribution to WPPF		1,366,092,225	1,000,985,927
Applicable rate of contribution		5%	5%
Total		**65,052,012**	**47,665,997**

32.1 As per provision of section 234(1)(b) of the Bangladesh Labor Act 2006 (as amended up to 2018), 5% of net profit before tax is contributed to the above fund in the following proportions:

Particulars	Proportion	2024-2025	2023-2024
Contribution to participatory fund	80%	52,041,610	38,132,797
Contribution to welfare fund	10%	6,505,201	4,766,600
Contribution to WWF	10%	6,505,201	4,766,600
Total	**100%**	**65,052,012**	**47,665,997**

The amount is being transferred to the participation fund, two-third has to be distributed in equal proportions to all the members (beneficiary) of the fund and one-third has to be invested in accordance with the manner as stated in section 242 of Labor Act 2006(as amended up to 2018).

33 Current income tax			
Provision made during the period		334,272,900	222,699,832
Under/(over) provision in prior year		27,459,293	146,478,116
Total		**361,732,193**	**369,177,948**
33.1 Net deferred expense/(income)			
Deferred tax liability/(asset) at the opening of the period		176,573,114	113,436,736
Deferred tax liability/(asset) at the closing of the period	8	169,369,374	176,573,114
Deferred tax expense/(income)		**(7,203,740)**	**63,136,378**

33.2 Reconciliation of effective tax rate

Particulars	2024-2025		2023-2024	
	Percentage	BDT	Percentage	BDT
Profit before tax		1,301,040,214		953,319,930
Tax using the company's tax rate	22.50%	292,734,048	20.00%	190,663,986
Provision for non-deductible expenses	3.19%	41,538,853	3.36%	32,035,845
Over/(under) provision during the year	2.11%	27,459,293	15.37%	146,478,116
Adjustment/provision released during the year	0.00%	-	0.00%	-
Deferred tax expense/(income) during the year	-0.55%	(7,203,740)	6.62%	63,136,378
Total	**27.25%**	**354,528,454**	**45.35%**	**432,314,326**

Particular	Notes	Amount in BDT	
		2024-2025	2023-2024
34 Other comprehensive income			
Unrealized gain/(loss) on quoted shares		89,516	(661,860)
Total		**89,516**	**(661,860)**
35 Related party disclosures			
35.1 Transactions with key management personnel			
Key management personnel compensations are comprised the followings:			
Meeting attendance fees		780,000	645,000
Remuneration and bonus		8,600,000	8,600,000
Medical and welfare		7,200,000	7,200,000
Others		9,600,000	9,600,000
Total		**26,180,000**	**26,045,000**

35.2 Transactions with other related parties

Name of the related parties	Nature of transaction	Balance as on 30 June 2025	Balance as on 30 June 2024
Beacon Medicare Ltd.	Sister concernSale/loan and advances	2,464,226,709	3,557,673,669
Ereba Capsule Ltd.	Sister concern Purchase/loan and advances	363,701,594	99,754,707
Beacon Business Solution Ltd.	Sister concern Purchase/loan and advances	(31,617,528)	(30,265,051)
Beacon Nutraceuticals Ltd.	Sister concern Loan and advances	43,749,090	43,691,449
MEK Pharmatech Ltd.	Sister concern Loan and advances	69,616,958	22,613,490
MEK Auto Bricks Ltd.	Sister concern Loan and advances	5,366,735	7,623,040
Beacon Cephalosporin Ltd.	Sister concern Purchase/loan and advances	467,799,874	294,295,725
Beacon Oncology Ltd.	Sister concern Loan and advances	53,544,296	53,582,661
Beacon Development Ltd	Sister concern Service received/loan and advances	794,105,824	713,720,216
Beacon Power Systems Ltd.	Sister concern Loan and advances	70,000	70,000
UB Nutraceuticals Ltd.	Sister concernLoan and advances	139,477,191	-
Total		**4,370,040,744**	**4,762,759,906**

The sales to and purchases from related parties are made on terms equivalent to those that prevail in arm's length transactions.

36 Other disclosures

36.1 Events after reporting period

The Board of Directors has recommended BDT 2.1 cash dividend per share to General Shareholders (excluding Sponsors and Directors) for the year ended 30 June 2025. The dividend is subject to final approval by the shareholders at the forthcoming annual general meeting of the Company. The financial statements for the year ended 30 June 2025 do not include the effect of the cash dividend which will be accounted for in the period when shareholders' right to receive payment is established. There are no other events identified after the date of the statement of financial position which require adjustment or disclosure in the accompanying financial statements.

36.2 Segment information

The Company essentially provides similar products to customers across the country. Business activities in which it engages and the economic environments in which it operates are of similar nature. Its business is not segmented by products or geographical areas and its operating result is viewed as a whole by its management. Hence, segment information is not relevant for the Company.

36.3 Comparatives and rearrangement

Comparative information has been disclosed for all numerical information in the financial statements and also the narrative and descriptive information when it is relevant for understanding of the current financial statements. To facilitate comparison, certain relevant balances pertaining to the previous year have been rearranged and reclassified whenever considered necessary to conform to current year's presentation.

37 Disclosures as per Securities and Exchange Rules

37.1 Capacity utilization

Actual production and utilization for major products groups are as follows:

Capacity and utilization in million (Pcs)

Major product/Unit	Capacity	30 June 2025		30 June 2024	
		Actual production	Percentage of utilization	Actual production	Percentage of utilization
Tablet	831.17	640.5	77.06%	495.71	59.64%
Capsule	664.34	95.17	14.33%	75.06	11.30%
Powder for suspension (PFS)	7.43	0.21	2.83%	0.31	4.17%
Syrup & suspension	30.98	11.76	37.96%	10.01	32.31%
Pediatrics drops	19.82	0.47	2.37%	0.47	2.37%
Injection	13.97	6.21	44.45%	5.73	41.02%
Infusion	1.7	1	58.82%	1.46	85.88%
Cream & ointment	9.91	1.45	14.63%	0.32	3.23%
Total	**1,579.32**	**756.77**	**47.92%**	**589.07**	**37.30%**

37.2 Contingencies

Contingent liabilities of the Company that relate to bank guarantee to third parties and letter of credit as listed below:

	Amount in BDT	
	30 June 2025	30 June 2024
Bank guarantee		
Commercial Bank of Ceylon	9,041,924	8,929,100
Shahjalal Islami Bank PLC	18,086,347	18,086,347
ICB Islamic Bank	4,269,510	-
	31,397,781	**27,015,447**
Letter of credit		
Commercial Bank of Ceylon	94,880,341	11,481,870
Janata Bank PLC	148,400,000	487,000,000
Eastern Bank PLC	-	31,422,973
Mutual Trust Bank PLC	5,137,952	12,284,540
Prime Bank PLC	112,616,188	-
	361,034,481	**542,189,383**
Total	**392,432,262**	**569,204,830**

37.3 Particulars of disposal of property, plant and equipment

The following assets were disposed off during the year:

Amount in BDT

Class of assets	Cost	Accumulated depreciation	Written down value	Sales price	Gain/loss
Vehicles	2,764,463	2,519,318	245,145	237,070	(8,075)
Office equipment	16,081,000	16,081,000	-	-	-
Total	**18,845,463**	**18,600,318**	**245,145**	**237,070**	**(8,075)**

Particular	Notes	Amount in BDT	
		2024-2025	2023-2024
37.4 Earnings per share			
a) Basic earnings per share			
Basic Earnings Per Share (EPS) is calculated in accordance with the International Accounting Standard (IAS) 33: Earnings Per Share.			
Total profit attributable to shareholders		946,511,761	521,005,604
Weighted average number of shares outstanding		231,000,000	231,000,000
Earnings per share		**4.10**	**2.26**
b) Diluted earnings per share			
No diluted earnings per share is required to be calculated for the year as there was no scope for dilution during the year.			
37.5 Calculation of Net Asset Value(NAV) per share			
Net asset value		6,667,081,042	6,090,395,149
Weighted average number of shares outstanding		231,000,000	231,000,000
NAV per share		**28.86**	**26.37**
37.6 Calculation of Net Operating Cash Flows per share(NOCFPS)			
Net cash flow from operating activities		1,600,027,867	(179,632,635)
Weighted average number of shares outstanding		231,000,000	231,000,000
NOCF per share		**6.93**	**(0.78)**
37.7 Reconciliation of net profit with cashflows from operating activities			
Net profit		946,511,761	521,005,604
Add/(deduct) for noncash items			
Depreciation and amortization		631,401,406	527,781,335
Finance expense		1,308,447,530	1,002,701,103
Current income tax		361,732,193	369,177,948
Deferred tax expense/(income)		(7,203,740)	63,136,378
(Gain)/loss on sale of assets		8,075	6,501,072
(Gain)/loss on foreign currency		73,239,322	93,687,601
		3,314,136,547	**2,583,991,041**
(Increase)/decrease of current assets			
Inventories		(435,599,990)	(895,973,919)
Trade and other receivables		(50,520,955)	(767,588,680)
Prepayments and deposits		347,172,026	(889,259,188)
		(138,948,919)	**(2,552,821,787)**
Increase/(decrease) of current liabilities			
Trade and other payables		(236,313,576)	680,873,076
Employee benefits		243,538,997	349,795,169
		7,225,421	**1,030,668,245**

Particular	Notes	Amount in BDT	
		2024-2025	2023-2024
Cash generated from operation		**3,182,413,049**	**1,061,837,499**
Finance expenses paid		(1,327,236,245)	(983,912,388)
Income tax paid		(255,148,937)	(257,557,745)
Net cash generated from/(used) in operations		**1,600,027,867**	**(179,632,635)**

38 Disclosures as per Schedule-11, Companies Act-1994

38.1 Number of employees

The number of employees engaged for the whole year or part thereof who received a total salary of TK 36,000 p.a. or above at reporting date was as follows :

Number of employees	**4,771**	**4,162**

Total 823 employees out of 4,771 are yet to be confirmed as of 30 June 2025.

38.2 Value of imports on Cost, Insurance and Freight (CIF) basis

Raw and packing materials	2,115,637,928	2,592,635,730
Spares and others	40,295,343	7,169,656
Capital goods	522,924,035	467,386,896
Total	**2,678,857,306**	**3,067,192,282**

39 Financial instruments - Fair values and risk management

Accounting classifications and fair values

The following table shows the carrying amounts and fair values, where applicable, of financial assets and financial liabilities. It does not include fair value information for financial assets and financial liabilities not measured at fair value if the carrying amount is a reasonable approximation of fair value.

When measuring the fair value of an asset or a liability, the Company uses market observable data as far as possible. Fair values are categorized into different levels in a fair value hierarchy based on the inputs used in the valuation techniques as follows:

• Level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities.

• Level 2: inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices).

30 June 2025

Particulars	Notes	Carrying amount								Fair value			
		Investment valued at cost	Fair value hedging instruments	Held for trading	At amortized cost	Loan and receivables	FVOCI-equity instruments	Other financial liabilities	Total	Level 1	Level 2	Level 3	Total
Financial assets measured at fair value													
Investment valued at fair value	11.1	-	-	-	-		491,336	-	491,336	491,336	-	-	491,336
Trade and other receivables	10	-	-	-	-	3,033,235,963	-	-	3,033,235,963	-	-	-	-
		-	-	-	-	3,033,235,963	491,336	-	3,033,727,299	491,336	-	-	491,336
Financial assets not measured at fair value													
Short term investment and loans	11	-	-	-	2,119,186,773		-	-	2,119,186,773	-	-	-	-
Security deposit and earnest money	13	-	-	-	169,711,245		-	-	169,711,245	-	-	-	-
Other financial assets	14	-	-	-	15,743,684		-	-	15,743,684	-	-	-	-
Cash and cash equivalents	15	-	-	-	227,866,038		-	-	227,866,038	-	-	-	-
	-	-	-	2,532,507,740		-	-		2,532,507,740	-	-	-	-
Financial liabilities measured at fair value		-	-	-	-		-	-	-	-	-	-	-
Financial liabilities not measured at fair value													
Long term loans	19	-	-	-	-		-	4,104,215,266	4,104,215,266	-	-	-	-
Short term loans	23	-	-	-	-		-	5,973,224,034	5,973,224,034	-	-	-	-
Trade payables	22.1	-	-	-	-		-	610,952,965	610,952,965	-	-	-	-
Other payables	22.2	-	-	-	-		-	397,699,037	397,699,037	-	-	-	-
Unclaimed dividend	25	-	-	-	-		-	50,821,150	50,821,150	-	-	-	-
Lease liabilities	20	-	-	-	-			130,004,100	130,004,100	-	-	-	-
	-	-	-	-		-		11,266,916,552	11,266,916,552	-	-	-	-

30 June 2024

Financial assets measured at fair value													
Investment valued at fair value		-	-	-	-	-	401,556	-	401,556	401,556	-	-	401,556
Trade and other receivables	10	-	-	-	-	2,982,715,008	-	-	2,982,715,008	-	-	-	-
		-	-	-	-	2,982,715,008	401,556	-	2,983,116,564	401,556	-	-	401,556
Financial assets not measured at fair value													
Short term investment and loans	11	-	-	-	2,627,490,587		-	-	2,627,490,587	-	-	-	-
Security deposit and earnest money	13	-	-	-	119,949,288		-	-	119,949,288	-	-	-	-
Other financial assets	14	-	-	-	14,962,375		-	-	14,962,375	-	-	-	-
Cash and cash equivalents	15	-	-	-	306,952,051		-	-	306,952,051	-	-	-	-
		-	-	-	3,069,354,301		-	-	3,069,354,301	-	-	-	-
Financial liabilities measured at fair value		-	-	-	-		-	-	-	-	-	-	-
Financial liabilities not measured at fair value													
Long term loans	19	-	-	-	-		-	3,620,355,803	3,620,355,803	-	-	-	-
Short term loans	23	-	-	-	-		-	6,698,878,806	6,698,878,806	-	-	-	-
Trade payables	22.1	-	-	-	-		-	905,699,687	905,699,687	-	-	-	-
Other payables	22.2	-	-	-	-		-	491,892,699	491,892,699	-	-	-	-
Unclaimed dividend	25	-	-	-	-		-	28,012,967	28,012,967	-	-	-	-
Lease liabilities	20	-	-	-	-			-	-	-	-	-	-
		-	-	-	-		-	11,744,839,962	11,744,839,962	-	-	-	-

40 Financial risk management

The Company has exposure to the following risks arising from financial instruments:

- Credit risk
- Liquidity risk
- Market risk

Risk management framework

The Company management has overall responsibility for the establishment and oversight of the Company risk management framework. The Company risk management policies are established to identify and analyze these risks faced by the Company, to set appropriate risk limits and controls and to monitor risks and adhere to limits. Risk management policies and systems are reviewed regularly to reflect changes in market conditions and the companies activities. The Company, through its training and management standards and procedures, aims to maintain a disciplined and constructive control environment in which all employees understand their roles and obligations.

40.1 Credit risk

Credit risk is the risk of a financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations.

The Company's exposure to credit risk is primarily influenced by the individual characteristics of each customer. However, management also takes into account factors that may affect the overall credit risk of its customer base, including the default risk associated with the industry and country in which the customers operate. The maximum exposure to credit risk is represented by the carrying amount of each financial asset as reported in the statement of financial position.

Exposure to credit risk

The carrying amount of financial assets represents the maximum credit exposure. The maximum exposure to credit risk at the reporting date was:

	Amount in BDT	
	30 June 2025	30 June 2024
Trade receivables	2,487,797,841	2,757,923,483
Other financial assets	15,743,684	14,962,375
Total	**2,503,541,525**	**2,772,885,858**

Ageing of trade receivables

At 30 June the ageing of trade receivables were as follows:		
Past due 30 days or below	520,643,694	402,453,771
Past due 31-90 days	191,873,781	192,657,646
Past due 91-180 days	42,420,117	2,049,830,944
Past due over 180 days	1,732,860,249	112,981,123
Total	**2,487,797,841**	**2,757,923,483**

A major portion of the Company's trade receivables as at 30 June 2025 relates to intercompany balances, which carry minimal credit risk. Other than trade receivables and other financial assets are not subject to credit risk. Any exposure that does exist is considered negligible and does not require separate disclosure.

40.2 Liquidity risk

Liquidity risk is the risk that the Company will encounter difficulty in meeting the obligations associated with its financial liabilities that are settled by delivering cash or another financial asset. The Company's approach to managing liquidity is to ensure, as far as possible, that it maintains sufficient liquidity to meet its liabilities as they fall due, under both normal and stressed conditions, without incurring unacceptable losses or risking damage to the Company's reputation.

The Company aims to maintain its cash and cash equivalents, along with other investments, at levels exceeding the anticipated cash outflows on financial liabilities. It also closely monitors expected cash inflows from trade and other receivables, alongside expected cash outflows for trade and other payables.

Exposure to liquidity risk

The following are the remaining contractual maturities of financial liabilities at the reporting date.

Particular	Notes	30 June 2025		
		Contractual cash flows		
		Carrying amount	Less than 1 Year	More than 1 Year
Non-derivative financial liabilities				
Long term loans	19	4,104,215,266	911,116,476	3,193,098,790
Short terms loans	23	5,973,224,034	5,973,224,034	-
Lease liabilities	20	130,004,100	19,415,563	110,588,537
Trade and others payable	22	1,008,652,002	1,008,652,002	-
Unclamied dividend	25	50,821,150	50,821,150	-
Total		**11,266,916,552**	**7,963,229,225**	**3,303,687,327**
Derivative financial liabilities		-	-	-

		30 June 2024		
Non-derivative financial liabilities				
Long term loans	19	3,620,355,803	891,429,545	2,728,926,258
Short terms loans	23	6,698,878,806	6,698,878,806	-
Lease liabilities	20	-	-	-
Trade and others payable	22	1,397,592,387	1,397,592,387	-
Unclamied dividend	25	28,012,967	28,012,967	-
Total		**11,744,839,963**	**9,015,913,705**	**2,728,926,258**
Derivative financial liabilities		-	-	-

40.3 Market risk

Market risk is the risk that any change in market prices such as foreign exchange rates and interest, will affect the Company's income or the value of its financial instruments. The objective of market risk management is to manage and control market risk exposures within acceptable parameters.

a) Currency risk

The Company is exposed to foreign exchange risk arising from various currency exposures, primarily with respect to the United States Dollar (USD), Euro (EUR) and Great Britain Pound (GBP). Foreign exchange risk arises from future commercial transactions of recognized assets and liabilities. Management complies with the treasury policy to manage foreign exchange risk against their functional currency.

b) Interest rate risk

Interest rate risk is the risk arising from changes in interest rates on borrowings. Currently, the Company has no borrowings exposed to significant interest rate risk, and the exposure remains minimal.

Exposure to interest rate risk

The interest rate profile of the Company's interest-bearing financial instruments as at the statement of financial position date is presented below.

	Notes	30 June 2025	30 June 2024
Financial Assets			
Other financial assets	14	15,743,684	14,962,375
Other receivable	10.1	545,438,122	224,791,525
Total		**561,181,806**	**239,753,900**
Financial liabilities			
Long term loans	19	4,104,215,266	3,620,355,803
Short term loans	23	5,973,224,034	6,698,878,806
Lease liabilities	20	130,004,100	-
Total		**10,207,443,400**	**10,319,234,609**

41. Beacon Pharmaceuticals PLC has following arrangements with banks as at 30 June 2025

SL No.	Bank Name	Loan Type	Facility Limit	Facility Limit	Outsanding as on 30 June 2025	Outsanding as on 30 June 2024
1	Rupali Bank PLC	Funded	Term Loan-Balancing, Modernization, Rehabilitation and Expansion (BMRE)	700,000,000	232,320,558	296,304,908
			Interest During Construction Period (IDCP)	138,300,000	-	25,609,602
		Funded	Term Loan-Balancing, Modernization, Rehabilitation and Expansion (BMRE-II)	477,100,000	472,839,286	397,530,195
				1,315,400,000	**705,159,844**	**719,444,705**
2	Bank Asia PLC	Funded	Term Loan-Balancing, Modernization, Rehabilitation and Expansion (BMRE-II)	572,500,000	592,208,198	606,175,542
				572,500,000	**592,208,198**	**606,175,542**
3	One Bank PLC	Funded	Term Loan-Balancing, Modernization, Rehabilitation and Expansion (BMRE-II)	286,200,000	266,046,801	77,758,875
				286,200,000	**266,046,801**	**77,758,875**
4	Commercial Bank of Ceylon PLC		Letter of Credit	450,000,000	94,880,341	-
		Non-Funded	Bank Guarantee (BG)		9,041,924	-
			Accepted Bill/Usance Payable at Sight		-	53,857,637
		Funded	Loan Against Trust Receipt (LATR)		229,546,311	94,389,580
			Overdraft	100,000,000	100,174,683	88,362,966
			Revolving Short Term Loan (RSTL)	150,000,000	150,000,000	150,000,000
				700,000,000	**583,643,259**	**386,610,183**
5	Janata Bank PLC	Non-Funded	Letter of Credit	600,000,000	148,400,000	
		Non-Funded	Accepted Bill/Usance Payable at Sight			31,003,811
		Funded	Cash Credit (Hypo)	1,400,000,000	1,394,252,767	1,444,575,611
			Term Loan-Balancing, Modernization, Rehabilitation and Expansion (BMRE-II)	715,500,000	547,331,341	542,808,795
				3,135,500,000	**2,089,984,108**	**2,018,388,217**
6	Standard Chartered Bank	Non-Funded	Accepted Bill/Usance Payable at Sight	380,000,000	-	-
		Funded	STL		35,341,250	-
		Funded	Overdraft	20,000,000	-	19,122,934
				400,000,000	**35,341,250**	**19,122,934**
7	United Commercial Bank PLC	Funded	Overdraft	50,000,000		51,378,002
			Time Loan	300,000,000		162,332,442
			Term Loan-Balancing, Modernization, Rehabilitation and Expansion (BMRE-II)	477,100,000	450,365,984	224,580,889
				1,227,100,000	**450,365,984**	**438,291,333**
8	Eastern Bank PLC	Funded	Accepted Bill/Usance Payable at Sight	450,000,000	4,300,000	117,178,585
			Loan Against Trust Receipt (LATR)		134,499,906	
			Demand Loan	200,000,000	204,343,311	212,111,850
			Overrdraft	200,000,000	250,095,486	410,261,182
			Term Loan-Balancing, Modernization, Rehabilitation and Expansion (BMRE-II)	763,300,000	-	580,754,825
			Credit card Balance			103,787
				2,463,300,000	**1,279,696,805**	**1,320,410,229**

SL No.	Bank Name	Loan Type	Facility Limit	Facility Limit	Outsanding as on 30 June 2025	Outsanding as on 30 June 2024
9	Shahjalal Islami Bank PLC	Non-Funded	Accepted Bill/Usance Payable at Sight	-	-	101,738,500
			Bank Guarantee (BG)	-	-	
		Funded	Bai-Muzzal Time Loan Revolving	1,000,000,000	18,086,347	2,935,079,738
			Loan Against Trust Receipt (LATR)	1,600,000,000	2,487,277,879	
				2,600,000,000	**2,505,364,226**	**3,036,818,238**
10	Prime Bank PLC	Non-Funded	Accepted Bill/Usance Payable at Sight	400,000,000	112,616,188	-
		Funded	Loan Against Trust Receipt (LATR)		38,560,938	-
			Time Loan	150,000,000	153,521,250	153,842,931
			Overdraft	20,000,000	189,575,197	206,056,890
			Term loan	448,000,000	354,458,262	461,540,882
				1,018,000,000	**848,731,836**	**821,440,703**
11	Mutual Trust Bank PLC	Non-Funded	Accepted Bill/Usance Payable at Sight	500,000,000	5,137,952	13,116,723
		Funded	Loan Against Trust Receipt (LATR)		36,382,545	23,357,252
			Time Loan	250,000,000	207,073,449	649,660
			Secured Overdraft	150,000,000	155,129,062	112,547,144
				900,000,000	**403,723,008**	**149,670,779**
12	Shimanto Bank PLC	Funded	Revolving Term Loan	200,000,000	203,150,000	103,056,667
			Term Loan for Vehicle	50,000,000	31,230,018	37,595,805
				250,000,000	**234,380,018**	**140,652,472**
13	Jamuna Bank PLC	Funded	Term Loan-Balancing, Modernization, Rehabilitation and Expansion (BMRE-II)	477,100,000	470,956,714	369,695,485
				977,100,000	**470,956,714**	**584,450,401**
14	ICB Islami Bank PLC	Non-Funded	Bank Guarantee (BG)	4,269,510	4,269,510	-
				4,269,510	**4,269,510**	**-**
Total				**15,849,369,510**	**10,469,871,562**	**10,319,234,609**

Beacon Pharmaceuticals PLC

Fixed Assets Schedule

As at 30 June 2025

Annexure-A

Amount in BDT

Asset class	Cost				Depreciation				WDV as on 30 June 2025
	As on 01 July 2024	Addition	Adjustment/ disposal	As on 30 June 2025	As on 01 July 2024	Addition	Adjustment	As on 30 June 2025	
Land and land development	663,805,802	-	-	663,805,802	-	-	-	-	663,805,802
Factory building	2,147,691,799	440,955,991	-	2,588,647,790	542,227,289	107,493,001	-	649,720,290	1,938,927,500
Corporate head office building	60,456,584	-	-	60,456,584	21,175,016	3,023,571	-	24,198,587	36,257,997
Production machinery	2,170,591,029	92,764,660	-	2,263,355,689	880,889,442	211,191,674	-	1,092,081,116	1,171,274,573
Furniture and fixtures	426,383,594	19,861,702	-	446,245,296	192,724,042	41,816,215	-	234,540,257	211,705,039
Office equipment	251,533,898	27,741,210	2,764,463	276,510,645	134,037,113	29,798,290	2,519,318	161,316,085	115,194,560
Vehicles	711,800,858	142,310,519	16,081,000	838,030,377	392,282,787	112,997,373	16,081,000	489,199,160	348,831,217
Utility equipment and installation	1,184,225,623	134,195,580	-	1,318,421,203	396,351,088	112,432,030	-	508,783,118	809,638,085
As at 30 June 2025	**7,616,489,186**	**857,829,662**	**18,845,463**	**8,455,473,385**	**2,559,686,776**	**618,752,154**	**18,600,318**	**3,159,838,612**	**5,295,634,773**
As at 30 June 2024	**5,755,028,265**	**1,899,346,709**	**37,885,788**	**7,616,489,186**	**2,063,726,721**	**519,752,431**	**23,792,376**	**2,559,686,776**	**5,056,802,410**
Intangible assets as at 30 June 2025	**41,409,909**	**1,195,950**	**-**	**42,605,859**	**13,430,228**	**12,649,252**	**-**	**26,079,480**	**16,526,379**
Intangible assets as at 30 June 2024	**16,187,975**	**25,221,934**	**-**	**41,409,909**	**5,401,324**	**8,028,904**	**-**	**13,430,228**	**27,979,681**

Xalcort

Deflazacort INN 6 mg, 18 mg, 24 mg, 30 mg, 36 mg Tablet & 6mg/5ml Suspension

the safer corticosteroid for inflammatory conditions

Preferable for Cardiac Patients

Due to zero mineralocorticoid activity

Suitable for Diabetic Patients

Does not increase hepatic glucose production

Appropriate for Osteoporotic Patients

Does not impair the activity of osteoblast and osteoclast cells

Recommended for Pediatric Patients

Does not cross blood brain barrier & less impact on growth hormone secretion



Deflazacort can be used in children from 1 month of age



BEACON®
Pharmaceuticals PLC

NOTICE OF
24th ANNUAL GENERAL MEETING

Notice is hereby given that the **24th Annual General Meeting** of the Shareholders of **Beacon Pharmaceuticals PLC** will be held on **Tuesday, 23 December 2025** at **11.00 AM** through hybrid system in combination of physical presence of shareholders at the venue **MES Convention Hall, Kochukhet Dhaka Cantonment, Dhaka, 1206** and by using Digital Platform through the link **https://beaconpharma.bdvirtualagm.com** (Pursuant to the Bangladesh Securities and Exchange Commission's Order to transact the following businesses:

AGENDA

Ordinary Business

1. To receive and adopt the Directors' and Auditors' Report and the Audited Financial Statements of the Company for the year ended 30 June 2025.
2. To declare dividend for the year ended 30 June 2025.
3. To elect/re-elect Directors under rotation.
4. To approve the appointment of Independent Director.
5. To appoint Statutory Auditors for the year 2025-2026 and to fix their remuneration.
6. To appoint Corporate Governance Compliance Auditors for the year 2025-2026 and to fix their remuneration.
7. To approve the transactions among Beacon Pharmaceuticals PLC and its sister concerns till 30 June 2025.

   RESOLVED THAT pursuant to the notification of Bangladesh Securities and Exchange Commission (BSEC) vide no. BSEC/CMRRCD/2009-193/10/Admin/118 dated: 22nd March 2021 and order of Securities and Exchange Commission (SEC) vide no. SEC/CMMRRCD/2006-159/Admin/02-10 dated: 10th September 2006, the related party transactions among sister concerns which are directed by common Directors, is hereby considered and approved, as reported in note no: 35.2 of audited report & audited financial statements till 30 June 2025.

By Order of the Board

Md. Sahabuddin FCS
Company Secretary

Notes:

1. The Record date of the Company was the Sunday, November 16, 2025. Members whose names appeared in the Depository/ Members Register on the Record Date will be eligible to join the meeting and will qualify for Dividend.
2. Members entitled to attend and vote at the Annual General Meeting may appoint Proxy to attend and vote on their stead. The Proxy Form must be affixed with the requisite revenue stamp (BDT. 100.00) and must be submitted to the Corporate Office of the company or e-mailed to rubel-share@beaconpharma.com.bd not less than 48 hours before the time fixed for the Annual General Meeting.
3. The soft copy of the Annual Report 2025, Proxy Form and Notice of 24th AGM of the Company will be sent to all the Members' respective e-mail addresses as available in the record of CDS on the Record date. The soft copy of the Annual Report-2025 will also be available at the Company's website at www.beaconpharma.com.bd.
4. The Corporate Shareholders need to send their authorization letter through e-mail: rubel-share@beaconpharma.com.bd or submitted at the Registered Office of the Company to join the meeting by 11.00 a.m. of 23 December 2025.
5. AGM joining procedure will be notified later through e-mail/SMS/website of the Company in due course.
6. Voting line will be opened for members 48 hours ahead of the AGM time and the login ID will be available at the Company Website.
7. There will be no arrangement for gift/entertainment for the participants in compliance with the guideline of Bangladesh Securities and Exchange Commission.

PHOTOS OF

23rd ANNUAL GENERAL MEETING











NOTES

PROXY FORM

BEACON®
Pharmaceuticals PLC
Light for life

Corporate Office

BEACON Business Centre
9/B/2, Toyenbee Circular Road
Motijheel, Dhaka-1223, Bangladesh

24th ANNUAL GENERAL MEETING will be held on Tuesday, December 23, 2025 at 11:00 AM

BO ID															

No. of Shares held								

I/We, _____ of _____ being a shareholder/ shareholders of **Beacon Pharmaceuticals PLC** hereby appoint Mr./ Mrs./ Ms _____ _____ of _____ as my proxy in my/our absence to attend and vote for me/us an on behalf of the **24th ANNUAL GENERAL MEETING** of the company to be held on Monday, December 23, 2025 at 11:00 AM, at **MES Convention Hall, Kochukhet Dhaka Cantonment, Dhaka, 1206,** through a hybrid format (physical and digital platform) (in pursuant to the Bangladesh Securities and Exchange Commission's order no. SEC/SRMIC/94-231/25; dated: 08 July 2020) and at any adjournment thereof.

As witness my hand this _____ Day of December 23, 2025

Signed this ____ / ____ / 2025

Revenue Stamp of Tk. 100/-

Signature of Proxy _____

Signature of Shareholder _____

Corporate Office

BEACON Business Centre
9/B/2, Toyenbee Circular Road
Motijheel, Dhaka-1223, Bangladesh
Phone : +88-02-41054005-10
E-mail : info@beaconpharma.com.bd
Website : www.beaconpharma.com.bd